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Abstract
Duffy-binding-like domains are present in two potential malaria vaccine candidates.
Located on the merozoite surface, MSPDBL1 and MSPDBL2 have been implicated
in erythrocyte invasion and identified as targets of natural immunity. Merozoite DBL
domains have been shown to bind the Fc region of natural IgM. This is characteristic of
several PfEMP1s, and is also well documented in bacteria, viruses and other parasites,
where it is thought to prevent specific binding of the more deadly IgG antibodies.
We have developed a mammalian expression system to produce merozoite DBL
domains as Fc fusion proteins, facilitating investigation into their adhesive properties.
Fc-fusion proteins are composed of the Fc region of IgG fused to a peptide and are a
rapidly expanding field of bio-engineering. They have been successful in drug delivery
due to their ability to increase serum half-life of the fused protein by the interaction of
the IgG Fc with the neonatal Fc receptor (FcRn). Engineering of the Fc scaffold has
shown improved receptor binding, allowing cross-linking of Fc receptors for improved
vaccine design.
The expression of homodimeric DBL-Fc fusions is difficult, evidenced by incorrect
folding and low protein yield. A flexible, extended hinge region was designed to
increase the distance between the Fc and the fused DBL domain, and improved
protein folding and IgM binding. Further work may optimise this hinge region for
the development of malarial vaccines, or therapeutics for IgM-mediated diseases.
The structural analysis of all known IgM-binding DBL domains and residues on
the merozoite DBL surface predict the involvement of helix 2a in IgM binding. This
contradicts a recent homology model of the IgM-binding interaction, and suggests that
the model needs revision. An improved DBL-Fc fusion could be used to identify critical
binding residues located in this helix using the more focused approach of site-directed
mutagenesis.
xvi
Chapter 1
Introduction
1
1 INTRODUCTION
1.1 The Immune System
The human immune system has evolved as a result of powerful selection pressure imposed
by pathogenic microbes (Cooper and Herrin, 2010; Medzhitov and Janeway, 1997). This
complex and intricate system of cells, tissues and molecules is capable of detecting,
neutralising and destroying infectious microorganisms, therefore protecting the host from
infection (Charles A Janeway et al., 2001; Baron and Klimpel, 1996). The immune system
comprises two interconnected and co-acting reactions: (i) innate and (ii) adaptive response
(Alberts et al., 2002). In order to recognise and neutralise pathogens, innate and adaptive
responses are both capable of distinguishing between self and non-self but they differ in
their approaches.
The innate immune system provides a robust and immediate but non-specific response
to pathogens, relying on conserved features essential to pathogen survival. This system is
present in all multicellular organisms and employs two strategies, firstly by preventing the
pathogen from gaining access, and secondly by the destruction of any invading pathogens,
which is mediated by phagocytic cells and antimicrobial proteins.
The adaptive immune system, a distinct feature of vertebrate immune systems, is
designed to recognise and remember specific pathogens (Alberts et al., 2002). Adaptive
immunity involves the process of somatic cell gene rearrangement and relies on an
enormous and diverse repertoire of antigen-specific recognition receptors which it builds
up by exposure to pathogens. Although slower to respond, adaptive immunity is more
effective than innate and is capable of initiating a stronger response every time a pathogen
is encountered, offering long-lasting protection.
1.1.1 Innate immunity
The innate immune system plays a crucial role in early recognition and response to
pathogens. The first line of defence is to use anatomical barriers to prevent it from entering
the body. Epithelial surfaces provide an almost impermeable physical barrier while the
acidic pH of the stomach and perspiration, antimicrobial secretions such as lysozyme,
microbial antagonism by resident flora and surface-deposited antimicrobial lipids further
deter invading microbes and prevent pathogens from colonising (Elias, 2007). However,
should a pathogen pass these barriers and defences, the next strategy is to neutralise and
destroy the invading microorganism (Alberts et al., 2002).
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This line of defence is based on the detection of conserved products of microbial
metabolism known as pathogen-associated molecular patterns (PAMPs) (Medzhitov,
2001). Crucially, these are readily distinguishable from “self” so that the host is not
harmed. This means that pathogens of different biochemical composition and with
entirely different life cycles can be recognised by overlapping mechanisms (Alberts, 2008;
Mogensen, 2009). For example, any peptide of bacterial origin is identifiable by a
formylmethionine at the N terminus which is a product of procaryotic translation and
differs from the regular methionine produced in eukaryotic translation (Alberts, 2008).
PAMPs are detected by pathogen recognition receptors (PRRs) present on innate immune
cells such as macrophages and dendritic cells (Janeway and Medzhitov, 2002; Luster, 2002).
The repertoire of PRRs is extensive and therefore recognises a diverse range of PAMPs.
Moreover, a single pathogen may engage a number of PRRs via various PAMPs, hence
forming a rapid and robust response. When a pathogen binds to the surface of an innate
immune cell through the PAMP-PRR interaction, a neutralising or destructive response
is initiated.
Phagocytosis, a central component of innate immunity, involves the internalisation
and degradation of pathogens by phagocytic cells such as polymorphonuclear neutrophilic
leukocytes and macrophages. This occurs in response to antigen presentation by a
PAMP-PRR interaction. Macrophages amplify the inflammatory response by secreting
cytokines and chemokines in addition to initiating phagocytosis. This attracts and recruits
further phagocytic cells such as neutrophils and monocytes to the site of infection (Janeway
and Medzhitov, 2002). Another method of phagocytosis involves opsonisation, or coating
of a pathogen by antibodies (Abs) or complement proteins. This facilitates the uptake
of the pathogen by a phagocytic cell. Alternative complement pathways may also be
activated to destroy pathogens by lysis, and antibodies may also act to neutralise the
microbe by blocking its target (Alberts, 2008). Further non-phagocytic cells such as
natural killer (NK) cells and eosinophils all play specific roles in innate immunity.
1.1.2 Adaptive immunity
Although the innate immune system provides an immediate response to invading microbes,
many pathogens have evolved strategies to evade complement pathways and prevent
phagocytosis. The long-lasting adaptive immune system is capable of administering a
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secondary, more specific, response to these pathogens. The adaptive immune system is
recruited through the activation of antigen-specific lymphocytes by antigen-presenting cells
(APCs) such as dendritic cells, macrophages and B cells.
Lymphocytes can be classified into two types, B or T cells which have epitope-specific
receptors to recognise a large repertoire of antigen epitopes (Alberts, 2008). Adaptive
immunity has two major branches: humoral and cell-mediated immunity, which are
initiated by recognition of an antigen by B cell receptors (BCRs) and T cell receptors
(TCRs), respectively.
The basis of cell-mediated immunity is the presentation of peptides on the surface of
APCs by major histocompatibility complex (MHC) molecules (Rudolph et al., 2006; Moon
et al., 2007). Foreign peptides are detected by TCRs which then initiate the proliferation
and differentiation of naive T cells into effector T cells. Two main types of effector T
cells develop depending on the class of pMHC presented - cytotoxic T cells (pMHC class
I) and helper T cells (pMHC class II). Cytotoxic T cells directly kill cells expressing the
appropriate antigen through the release of cytotoxins which lead to the caspase cascade
and apoptosis, while helper T cells promote differentiation of cytotoxic T cells, mediate
macrophage activity and promote B cell activation (Rudolph et al., 2006).
Humoral immunity is based on the recognition of antigens by immunoglobulins, also
known as antibodies (Abs) which exist either in plasma or on the surface of B cells as
part of the B cell receptor repertoire. Upon recognition of an antigen by the BCR, the
complex is internalised by the B cell, expressed on the B cell surface as a peptide on a
class II MHC and presented to the T cell receptors. Through binding of the peptide to
the TCR, B cell activation is promoted by helper T cells. Naive B cells, once activated,
proliferate and differentiate into both Ab-secreting plasma cells, which mediate clearance
of pathogens, and memory B cells which provide a long-lasting response by persisting in
the blood until the pathogen is encountered again.
There are five classes of human Abs: IgA, IgD, IgE, IgG and IgM. Before exposure
to antigens naive B cells only express IgM, and express IgD and IgM when they mature
(Edholm et al., 2011). When B cells are activated, isotype switching occurs, a mechanism
enabling the Abs to switch between the five isotypes. Differentiation between the antibody
classes depends on the type of antigen activating the B cell, as well as secondary signals
such as pattern recognition by PRRs. Each Ab class plays its own specific role in humoral
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immunity, and in combination they form a central part of adaptive immunity and are an
important aspect of this report.
1.1.3 The structure and function of antibodies
Antibodies are immunoglobulins which bind to and neutralise the function of pathogens,
while recruiting effector cells such as phagocytes and activating complement to promote
pathogen clearance (Charles A Janeway et al., 2001). These glycoproteins form the basis
of adaptive immunity and have a characteristic ‘Y’ shape, consisting of two light (λ or κ)
and two heavy (α, δ, γ,  or µ) polypeptide chains linked by covalent interchain disulphide
bonds. The five classes of human Abs share the same basic structure and are categorised
depending on which type of heavy chain they possess. Heavy (H) and light (L) chains
both consist of a combination of variable (V) and constant (C) regions. L chains have one
variable (V) and one constant (C) regions while H chains have one V and 3-4 C regions,
depending on the Ab class. Antigen specificity relies on subtle differences in the V region.
Figure 1.1: Schematic representation of an antibody, showing the heavy and light
polypeptide chains which make up the characteristic ‘Y’ shape as well as the interchain
disulphide bond structure. The two antigen-binding sites are at the tips of the arms and
consist of one constant and one variable domain from each heavy and light chain.
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An antibody has two distinct functional regions. The two identical arms of the ‘Y’
are termed the fragment antigen binding (Fab) region because of their ability to bind
antigens. These arms contain variable regions which define the specificity of the antibody
for the target antigen. The other fragment participates in the recruitment of effector
molecules and is termed the fragment crystalisable (Fc) region. A hinge region links the
Fc and Fab portions and allows flexibility within the Ab molecule. The Fc region recruits
effector cells by binding to glycoproteins on the surface called Fc receptors (FcRs). Each
antibody isotype binds to a specific type of FcR which can be found on the surface of
multiple effector cells (Table 1.1). Depending on the effector cell recruited, Abs have a
wide range of functions such as phagocytosis of Ab-coated pathogens, antibody dependent
cell-mediated cytotoxicity (ADCC), mast cell degranulation and complement activation.
Table 1.1: Fc receptors (FcRs) and their corresponding antibody ligands.
Receptor Ab Ligand Cells
FcγRI (CD64) IgG Macrophages, Neutrophils, Eosinophils, Dendritic
cells
FcγRIIA (CD32) IgG Macrophages, Neutrophils, Eosinophils, Platelets,
Langerhans cells
FcγRIIB (CD32) IgG B Cells, Mast cells, Macrophages, Neutrophils,
Eosinophils, Dendritic cells
FcγRIIIA
(CD16a)
IgG NK cells, Macrophages
FcγRIIIB
(CD16b)
IgG Eosinophils, Macrophages, Neutrophils, Mast cells,
Follicular dendritic cells
FcRn IgG Dendritic cells, Epithelial cells, Endothelial cells,
Hepatocytes, Monocytes, Macrophages
FcRL5 IgG B cells
DC-SIGN IgG Macrophages, Dendritic cells
FcμR IgM B cells, T cells, NK cells
Fcα/μR IgA, IgM B cells, Macrophages
pIg IgA, IgM Epithelial cells
FcRL4 IgA B cells
FcαRI (CD89) IgA Monocytes, Macrophages, Neutrophils, Eosinophils
FcεRI IgE Mast cells, Eosinophils, Basophils, Langerhans
cells, Monocytes, Dendritic cells, Platelets
FcεRII IgE Mast cells, Eosinophils, Basophils, Langerhans cells
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Immunoglobulin-M
Immunoglobulin M (IgM) is the first Ab to be produced by B cells and has an important
role in the initial stages of immunity (Klimovich, 2011). The membrane-bound monomeric
form of IgM forms the BCR which controls B cell responses through interactions with
endogenous and exogenous ligands (Ehrenstein and Notley, 2010). It also exists on mucous
membranes in a secreted form and is found in the circulation at concentrations of 1 - 2
mg/ml in blood and, with a half-life of ∼ 5 days, makes up about 15 % of Ig in the blood.
The circulatory form can be divided into natural and immune IgM, both of which are
crucial for Ab-mediated response to pathogens (Czajkowsky and Shao, 2009). The broadly
reactive but low-affinity natural IgM (nIgM), produced by the B1 subset of B cells, occurs
naturally in the blood of mice raised under germ-free conditions (Rapaka et al., 2010).
In contrast, immune IgM is secreted by B-2 cells following exposure to pathogens and
is mostly antigen-specific (Ehrenstein and Notley, 2010) although production levels fall
upon development of IgG and other Abs. Immune IgM has been shown to be crucial for
protection from viruses, bacteria, protozoa, fungi and helminths (Pleass et al., 2015).
IgM molecules have a subunit with the characteristic ‘Y’ shape seen in other Ab
isotypes, formed from two light chains and two heavy chains. Each heavy chain consists of
one variable region (Vμ) and four constant domains (Cμ1 - Cμ4) as well as a tailpiece (tp)
located at the C terminus of the heavy chain (Sørensen et al., 1999). The tailpiece enables
polymerisation and IgM exists both as pentamer with a five-subunit structure (mass ∼970
kDa) and as a hexamer consisting of six subunits (∼1132 kDa). The pentameric form
contains a 15 kDa joining (J)-chain, attached to the tailpiece by disulphide bonds (Figure
1.2). The hexameric form lacks the J chain and is less common than the pentameric form,
making up 20% of the total IgM. Hexameric IgM has increased avidity for both antigen
and receptor, and is 15-20 times more efficient at activating complement than pentameric
IgM (Pleass et al., 2015; Randall et al., 1990; Wiersma et al., 1998). Hexameric IgM
without a J-chain is unable to bind to the polymeric Ig receptor (pIgR) which mediates
transport of secreted pentameric IgM across epithelia, releasing them to mucosal surfaces
(Johansen et al., 2000). This suggests that the role of hexameric IgM is solely in humoral
immunity (Randall et al., 1990; Wiersma et al., 1998).
The unique multimeric structure gives IgM high avidity and diverse function, including
roles in infection, B cell homeostasis, inflammation, atherosclerosis and autoimmunity
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Figure 1.2: Simple schematic representation of a pentameric IgM molecule (five monomeric
IgM molecules) showing the heavy and light polypeptide chains. The Fab domain contains
one variable and one constant domain Cμ1. The Fc region contains three further constant
domains Cμ2 - Cμ4. Disulphide bonds cross-link adjacent Cμ3 and Cμ4 domains of
individual monomeric molecules and are shown in blue. The location of the J chain is
given in red.
(Ehrenstein and Notley, 2010; Panda and Ding, 2015). Integral to the impressive properties
of multimeric IgM is it’s ability to bind C1q and recruit complement. A single pentameric
IgM molecule can activate the complement cascade and lyse a red blood cell, an action that
would take approximately a thousand IgG molecules to accomplish (Cooper, 1985). Due to
it’s size, attempts to obtain a crystal structure of IgM have been so far been unsuccessful
(Mu¨ller et al., 2013). However, the structure has been modelled by Czajkowsky and Shao
(2009) based on the crystal structure of IgE Fc. The model predicted an unexpected,
non-planar, mushroom-shaped complex with the central portion (formed of C terminal
domains) protruding above the plane created by the Fab domains (Czajkowsky and Shao,
2009). Interestingly, this structure was confirmed by cryo-atomic force microscopy and
is thought to leave the C1q binding region fully exposed, explaining the mechanistic first
steps of complement activation by IgM (Czajkowsky and Shao, 2009). IgM is heavily
glycosylated and has five N-linked glycosylation sites present on each heavy chain as well
as a single site on the J-chain (Klimovich, 2011). Glycosylation is thought to be critical
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for structural integrity and stability of the Ab (Sola and Griebenow, 2009; Arnold et al.,
2007).
Natural IgM is a vital part of the early innate immune response and is the first line of
defence for protection against many pathogens. It is also able to recognise self-components.
The multimeric structure gives the molecule poly-reactivity due to the presence of multiple
antigen binding sites. This enables effective recognition of conserved structures on invading
organisms. Although affinity for antigen is low, poly-reactivity also enables nIgM to bind
multiple structures on the same antigen, thereby enhancing neutralisation by promoting
it’s elimination through clearance by phagocytic cells (Ehrenstein and Notley, 2010).
High poly-reactivity also gives nIgM a superior ability to detect transformed cells in
malignancy where many tumour-related epitopes exist as repetitive carbohydrate motifs
(Kaveri et al., 2012). In a study of tumour specific antibodies where thousands of Abs
were isolated from patients, all were found to be IgMs (Bra¨ndlein et al., 2003). Most of
these IgM Abs were nIgM which bound to modified tumour-specific receptors (Bra¨ndlein
et al., 2003). Similarly, nIgM taken from healthy patients was found to have tumour
specificity (Bra¨ndlein et al., 2003). Natural IgM therefore has significant importance in
the immunogenic response to tumours and is routinely used in diagnosis and therapy of
malignancies.
Although an ineffective opsonin by itself, nIgM is highly effective in facilitating
clearance of small apoptotic particles, senescent erythrocytes and mis-folded proteins
through complement-dependent mechanisms (Pleass et al., 2015). This crucial function
is necessary for tissue homeostasis in order to prevent uncontrolled inflammation and
to suppress autoimmunity. An accelerated development of IgG autoantibodies and
autoimmune disease is seen in the absence of nIgM (Boes et al., 2000).
As well as being a vital aspect of the early immune response, nIgM is considered to
provide an essential boost to the adaptive immune response, particularly that of IgG.
In a study of nIgM-deficient mice, production of antigen-specific IgG was lower when
immunised with T-cell dependent antigen and the specificity of this IgG lower than in
control mice (Boes et al., 1998). Natural IgM provides a invaluable immune-surveillance
system capable of preventing dissemination of microbes, cell debris and transformed cells
within the host and is able to prime the more specific response of the adaptive immune
system, particularly that of IgG.
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IgM-Fc receptors
The Fc region of an Ab mediates effector function through binding of host ligands and
Fc receptors (FcRs). There are several known FcRs for IgM, the polymeric Ig receptor
(pIgR), Fcα/μR, FcμR as well as a number of ligands known to bind IgM including
mannose-binding-lectin (MBL), CD22, TRIM21 and Sp alpha (McMullen et al., 2006;
Adachi et al., 2012; Mallery et al., 2010; Tissot et al., 2002). Due to the multimeric
structure discussed previously, affinity for IgM is high. The pIgR binds both secretory
IgM and IgA on epithelia, as discussed previously. Another FcR shared with IgA is the
Fcα/μR expressed on B cells and macrophages which is involved in the priming of helper T
lymphocytes and in defence against bacteria in peripheral organs (Sakamoto et al., 2001).
Recently, the FcμR has been identified and is expressed in humans on B cells, T cells and
NK cells (Kubagawa et al., 2009; Shima et al., 2010). In mice, the FcμR is only expressed
on B cells, and studies of FcμR deficient mice have shown elevated non-immune IgM levels
in serum as well as natural autoantibody levels (Honjo et al., 2012; Ouchida et al., 2012).
This suggests a role for FcμR binding in IgM homeostasis, autoimmune suppression and
regulation of humoral response (Honjo et al., 2012; Ouchida et al., 2012). The function of
the human FcμR receptor remains unclear.
Immunoglobulin-G
Immunoglobulin G (IgG) is an Ab of molecular weight ∼150 kDa consisting of a single ‘Y’
subunit formed from two light and two heavy chains. Each heavy chain consists of one
variable region (Vγ) and three constant domains (Cγ1 - Cγ3). IgG is produced late in the
primary immune response and is the most abundant Ab found in serum and extracellular
fluid (making up 75% of all Ig and found at 10 mg per ml in the circulation). IgG Abs have
a wide range of functions and are involved in neutralisation of bacteria, viruses and toxins,
as well as opsonising pathogens for engulfment by phagocytes and activating complement
through C1q binding.
IgG can be divided into four subclasses by constant region: IgG1, IgG2, IgG3 and
IgG4. The wide range of effector function seen amongst the subclasses comes largely from
variation in the constant region of the Fc, and as a result the different subclasses bind
to different IgG-Fc receptors (FcγR) as well as C1q (See Table 1.1 for FcRs). Structural
variation is also found in the hinge region which links the Fab and Fc regions, thereby
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altering the conformation of the Ab and further influencing effector function. Although
deficiency in a single IgG subclass can lead to susceptibility of an individual to specific
pathogens, an IgG subclass deficiency is not usually detrimental (Vidarsson et al., 2014).
IgG contains a conserved N-linked glycosylation site at Asn-297 which is located
between the Cγ2 and Cγ3 domains and creates an exposed docking site for FcγR binding
(Vidarsson et al., 2014). Fc glycans are known to play a role in Ab stability, and numerous
studies have investigated the impact of glycosylation on structural integrity and effector
function of IgG (Krapp et al., 2003; Zheng et al., 2014).
IgG-Fc receptors
IgGs are the only Abs to be passed from mother to fetus via the placenta by binding to the
neonatal Fc receptor (FcRn) (Koch et al., 1967; Brambell, 1966). Binding to the FcRn also
aids recycling of IgG by preventing lysosomal degradation. FcRn is unrelated to the classic
FcγRs and is more similar in structure to MHC class I (Story et al., 1994; Roopenian et al.,
2003). Binding occurs in the Cγ2 - Cγ3 interface of the IgG Fc domain (Wines et al.,
2000). IgG binds to FcRns on epithelial cells in a variety of tissues, including the placenta
where IgG are transported through vesicles and released by exocytosis into fetal blood
(Alberts, 2008; Junghans and Anderson, 1996). FcRns are also located on white blood
cells where they are important for IgG-mediated phagocytosis (Vidarsson et al., 2006).
The half-life of IgG in the blood is greater compared to other Ab isotypes due to recycling
mediated by the FcRn. The FcRn binds IgG at a slightly acidic pH, which is found in
the intestinal lumen as well as in acidic endosomes. IgG internalised by pinocytosis binds
the FcRn and is recycled to the cell surface and released at the basic pH of blood. This
prevents lysosomal degradation and increases the half-life of IgG (Vidarsson et al., 2006;
Ghetie et al., 1996).
There are six classic human FcγRs, four of which are activating Fc receptors while
two, FcγRIIB and FcγRIIIB (also known as CD16b), are inhibitory Fc receptors. The
inhibitory FcRIIB is a low affinity receptor and although homologous to the activating
FcRs, contains a distinct ITIM sequence in the cytoplasmic domain (Ravetch and
Bolland, 2001). The four activation FcRs (FcγRI, FcγRIIA, FcγRIIC and FcγRIIIA)
are characterised by the presence of an ITAM motif and are found on most effector cells
apart from lymphoid cells (Ravetch and Bolland, 2001). Activating and inhibitory FcγRs
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are co-expressed on the surface of effector cells and the ratio of their expression determines
the effector response.
As well as FcγRIIB, another low-affinity inhibitory FcR is located on the surface
of dendritic cells, the dendritic cell-specific intercellular adhesion molecule-3-grabbing
non-integrin (DC-SIGN) (Geijtenbeek et al., 2000). DC-SIGN is an important receptor
in the efficacy of IVIG in controlling autoimmune disease, and binding to this receptor
requires specific glycosylation patterns (Czajkowsky et al., 2015; Geijtenbeek et al., 2000).
The FcR-like protein FcRL5 expressed by B cells is homologous to FcRγI and has
recently been identified as an IgG receptor. FcRL5 is thought to play a role in the
regulation of the B cell response (Wilson et al., 2012).
Immunoglobulin-E
Immunoglobulin E (IgE) is a monomeric Ab of low abundance (approximately 0.1 μg per
ml in circulation), consisting of two light and two heavy chains. Unlike IgG which has
three, IgE has four constant domains (Cε1 - Cε4) meaning that it is heavier than IgG
at ∼190 kDa. The Cε3 and Cε4 domains of IgE are homologous to the Cγ2 and Cγ3
domains of IgG. The Cε2 domains of IgE are therefore their most distinguishing feature
and these replace the flexible hinge region of IgG. From the crystal structure of the IgE-Fc
it is notable that the Cε2 domains bend back and make extensive contact with the Cε3
domains, causing an acute bend in the IgE molecule (Wan et al., 2002). This gives it a
unique and more rigid structure than IgG.
IgE plays a role in both allergic and anti-parasitic response and is involved in the
activation of mast cells and basophils leading to the consequential release of mediators
such as histamine, which are associated with IgE-dependent allergic reactions (Kinet,
1999). When FcεRs are activated in the lungs, the release of toxic mediators are induced,
causing the symptoms of asthma (Gould and Sutton, 2008).
IgE is highly susceptible to cleavage and inactivation by proteases produced by parasitic
helminths (Quinn et al., 2016). Several splice variants of IgE are known to exist, including
one such variant called IgE-tailpiece (IgE-tp), which has eight novel residues including a
cysteine in place of the two carboxy-terminal amino acids in classical IgE (Quinn et al.,
2016). This variant has been shown to associate with α-1-antitrypsin (A1AT) in plasma
which protects the Ab from proteolysis while enhancing the interaction with FcεRI (Quinn
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et al., 2016).
IgE-Fc receptors
Two IgE-Fc receptors are known, the high affinity FcεRI and the lower affinity FcεRII
which are present on most immune cells. The high affinity FcεRI captures both Cε3
domains of IgE and the subsequent and exceptionally slow rate of dissociation on mast cells
and basophils is responsible for persistent sensitisation of these cells to allergic challenge
(Stone et al., 2010).
Immunoglobulin-A
The highly hydrophilic immunoglobulin A (IgA) is the most abundant Ab in secretions
at mucosal sites (making up 10 % of Ig in total). Consisting of the characteristic ‘Y’
structure common to most Ab molecules, IgA contains two heavy and two light chains. A
molecule of IgA has three constant regions (Cα1 - Cα3) and, like IgM, contains a tailpiece
and J-chain at the heavy chain C terminus (Kerr, 1990). This also gives IgA the ability
to polymerise, and although it is primarily found in monomeric form it can also take a
dimeric form (Atkin et al., 1996). In serum, catabolic rates of IgA are five times faster
than IgG which is synthesised at the same rate of IgA, therefore the concentration of IgA
is about one-fifth the concentration of IgG (Kerr, 1990). In secretions, IgA synthesis rates
are far higher than any other Ab class. IgA is therefore overall the most highly synthesised
Ab isotype with more IgA produced in total than all of the other Ab classes combined
(Kerr, 1990).
IgA does not have the ability to activate complement and it lacks residues in the Fc
region which have been identified in IgG and IgM as critical for C1q binding. Two distinct
subclasses of IgA exist: IgA1 (90%) and IgA2 (10%). IgA1 has an extended hinge region
compared to IgA2 which has an additional 13 amino acid, highly O-glycosylated region.
This extended hinge region makes IgA1 susceptible to cleavage by proteases and therefore
IgA2 dominates at mucosal sites, whereas IgA1 is more common in serum. Like IgM,
IgA is capable of travelling across epithelial boundaries through binding of the J-chain to
the polymeric Ig receptor (pIg). It is thought that the primary function of IgA is in the
neutralisation of pathogens at mucosal sites such as gastrointestinal, genitourinary and
respiratory tracts (Hayes et al., 2014).
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IgA-Fc receptors
Due to it’s ability to polymerise and the presence of the J-chain, secretory IgA binds
the polymeric Ig receptor (pIg) through the Cα3 domain, leading to transport across
epithelial surfaces (Brandtzaeg and Prydz, 1984). Another receptor shared with IgM is
the Fcα/μR expressed on B cells and macrophages. For this receptor interaction, the Cα2
- Cα3 domain interface is critical while the J-chain is not considered essential for binding
(Sakamoto et al., 2001). IgA has a high level of glycosylation although its glycans are not
required for receptor interaction (Mattu et al., 1998).
A receptor unique to IgA, is the FcαRI (CD89), thought to play a role in mucosal
immune defence (Bakema and van Egmond, 2011). FcαRI has homology with FcγRs and
FcεRI, although the binding site at the Cα2 - Cα3 interface is distinct from the homologous
regions in IgG and IgE at the hinge proximal regions of Cγ2 and Cε3 respectively (Woof,
2002).
The FcR-like protein FcRL4 expressed by B cells has recently been identified as an IgA
receptor. FcRL4, like the IgG receptor FcRL5, is thought to play a role in the regulation
of the B cell response (Wilson et al., 2012).
Immunoglobulin-D
Co-expressed with IgM by mature B cells before isotype switching triggers expression of the
other Ab classes, immunoglobulin D (IgD) is a monomeric Ab of relatively low abundance
(approximately 30 μg per ml in circulation). The role of IgD is not fully understood. IgD
exists in both membrane-bound form and in serum and it consists of two light and two
heavy chains. Although IgD has three constant domains (Cδ1 - Cδ3) similar to IgG, it has
a long hinge region which gives it a unique flexible ‘T’ shape compared to the traditional
‘Y’ shape of other Ab isotypes. This makes the molecule highly flexible thus enhancing
antigen binding, although making it susceptible to proteolytic degradation (Chen and
Cerutti, 2011; Vladutiu, 2000).
IgD-Fc receptors
The FcR for IgD remains elusive although there is evidence for the presence of FcδRs on
B cells, basophils and mast cells (Chen and Cerutti, 2011).
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1.2 Fc Fusion Technology
Fc fusion therapeutics are a fast growing field of bio-engineering. Monoclonal antibodies
(mAbs) have dominated the field of therapeutics in recent years mainly due to the
biological and pharmacological properties resulting from the effector function of the Fc
region. A new generation of therapeutics whereby the Fc region of an IgG antibody is
fused to an active protein drug, are proving successful. The IgG Fc allows interaction with
FcRs on immune cells and gives the protein of interest antibody-like properties. The IgG
Fc also binds to the neonatal Fc receptor (FcγRn) an action which facilitates recycling,
thus protecting the active protein from endosomal degradation. The addition of the IgG
Fc therefore increases the serum half-life of the protein of interest, extending exposure
to the target by limiting renal clearance, consequently improving pharmacological effect
and its therapeutic potential. This technology has opened up therapeutic use and drug
delivery of smaller active proteins in particular as clearance of such molecules (< 60 kDa)
is rapid with half-life ranging from between a few minutes to hours. Fc-fusion proteins also
form homodimers which improves avidity of the active protein giving it further therapeutic
advantage (Figure 1.3).
Other fusion proteins which are designed to improve the half-life of the fused protein
include HSA-fusions and Transferrin-fusion proteins. The 66.5 kDa human serum albumin
(HSA) is also known to bind the FcRn, with a slightly lower affinity than IgG and therefore
shorter half-life (456 hours compared to 480 hours for IgG) (Strohl, 2015). HSA-fusion
proteins are also currently in development and are showing some success in clinical trials
with Tanzeum (GlaxoSmithKline) receiving FDA approval in April 2014 (Strohl, 2015).
Novozymes have also shown that an engineered HSA is able to improve half-life by
improving the affinity for FcRn 12-fold (Andersen et al., 2014). This has potential to
improve the half-life of HSA-fusion therapeutics. Further fusion proteins designed to
improve half-life include fusion of Transferrin or CTP although so far none have FDA
approval (Strohl, 2015).
Fc-fusions have additional practical advantages which add to their success over
other fusion proteins. Cost-effective and efficient purification by protein A/G affinity
chromatography streamlines the manufacturing process while the attachment of the IgG
Fc domain improves stability and solubility, further simplifying the manufacturing process.
As a result, Fc-fusion proteins are fast gaining commercial success and there are currently
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Figure 1.3: Schematic representation of a dimeric Fc-fusion protein. The fused
peptide is covalently attached to the Cγ2 via a hinge region which forms a disulphide
bridge and produces a dimeric fusion protein. Adapted from Czajkowsky et al. (2012).
nine approved by the FDA for use in drug delivery (Table 1.2). Like many mAbs, most
of these Fc-fusion proteins target receptor-ligand interactions acting either as antagonists
or as agonists to manipulate immunity by either blocking or stimulating receptor function
(Czajkowsky et al., 2012).
Table 1.2: FDA approved hIgG Fc-fusion proteins currently in the clinic.
Trade Name Base protein Approved use Year of
Approval
Molecular
weight (kDa)
Eloctate
(aloctate)
Antihemophilic
factor
Hemophilia A 2014 220
Alprolix Coagulation
Factor IX
Hemophilia A 2014 98
Nulojix
(belatacept)
CTLA-4 Organ rejection 2011 90
Eylea
(aflibercept)
VEGFR1/
VEGFR2
Age related macular
degeneration
2011 115
Arcalyst
(rilonacept)
IL-1R Cryopyrin-associated
periodic syndromes
2008 251
NPlate
(romiplostim)
Thrombopoietin-
binding peptide
Thrombocytopenia 2008 59
Orencia
(abatecept)
Mutated
CTLA-4
Rheumatoid arthritis 2005 92
Amevive
(alefacept)
LFA-3 Psoriasis and transplant
rejection
2003 73
Enbrel
(etanercept)
TNFR Rheumatoid arthritis 1998 51
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Currently, all FDA-approved Fc-fusion proteins use the Fc region from the IgG1
subclass. This is due to its increased half-life over other subtypes as well as its superior
engagement of FcγRIIA which makes it the preferred subclass for use in delivery of antigen
to APCs (Czajkowsky et al., 2012). It has been suggested that IgG3 could be used to
improve complement activation. However, the increased length of the IgG3 hinge region
means that it is more susceptible to proteolytic cleavage than other subclasses and this
technical difficulty would have to be overcome for its use in Fc-fusion proteins (Czajkowsky
et al., 2012).
The recent success of Fc-fusion proteins has mostly been focussed on drug delivery,
although direct targeting of FcRs by the Fc-fusion protein gives promise for Fc-fusion
based vaccines (Czajkowsky et al., 2012). Once the target FcRs are identified, the
need for receptor cross-linking in enhanced cell signalling highlights the importance of
valency particularly when targeting low-affinity receptors. It has recently been shown that
Fc-fusions can be modified to polymerize into a hexameric form with twelve fused partners
(Mekhaiel et al., 2011). The Hexa-Fc scaffold has thus been developed to oligomerise
monomeric IgG Fc into hexameric oligomers (Czajkowsky et al., 2015). This construct is
able to enhance binding to low-affinity receptors with increased avidity, thus opening up
the use of Fc-fusion proteins as vaccines (Czajkowsky et al., 2015).
Further modifications to the Fc-scaffold may improve the therapeutic potential of an
Fc-fusion protein, including modifications to the hinge region or to the fused protein.
These have been comprehensively reviewed by Czajkowsky et al. (2012).
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1.3 Parasite Fc-Binding Proteins
We have seen that the function of the five Ab classes and the recruitment of effector cells
relies on Ab Fc binding to glycoprotein FcRs which are present on immune cell surfaces.
A successful field of bio-engineering takes advantage of these interactions to develop
successful Fc-fusion based therapeutics and has further potential for the development
of vaccines.
In some cases, an FcR-like pathogen is also able to take advantage of this system;
hijacking the Ab by binding to the Fc portion of a non-immune antibody instead of
the antigen-specific Fab region. This allows the pathogen to evade immunity as the Ab
is prevented from interacting with host FcRs, the effector function is blocked and the
pathogen is masked in host non-specific Ab. Parasites, which rely on remaining undetected
within their host for survival, are particularly proficient in this immune evasion strategy.
A large number of human parasites are able to bind the Fc portion of immunoglobulin
non-specifically and prevent downstream Fc-mediated destruction. This strategy,
mediated by Ig-binding molecules expressed on the surface of the parasite is also well
documented in bacteria and viruses such as Staphylococcus aureus which expresses protein
A, herpes simplex virus which expresses the glycoprotein complex gE-gI, a known Fcγ
receptor, as well as IgA-binding proteins identified in many strains of Streptococcus
(Watkins, 1964; Lubinski et al., 2011; King and Wilkinson, 1981; Pleass et al., 2001; Nezlin
and Ghetie, 2004; Pleass and Woof, 2001). In parasites, Fc-binding proteins which play a
role in evasion of the immune response may also add to the infectivity and persistence of
the parasite in circulation.
IgM Fcμ-binding proteins are less well documented than for IgG and IgA. This may
be due to difficulties in distinguishing between low-affinity natural IgM Fab binding
and Fc-receptor interactions (Czajkowsky et al., 2010). Several protozoa are known
to utilise IgM-binding proteins, including Toxoplasma gondii and pathogenic species of
Trypanosomitidae (Vercammen et al., 1999; Vincendeau and Dae¨ron, 1989; Czajkowsky
et al., 2010). More recently, proteins from the Plasmodium falciparum erythocyte
membrane protein 1 (PfEMP1) family, expressed on the surface of P. falciparum-infected
erythrocytes (IEs) have been shown to bind natural IgM via the Fc. Only certain P.
falciparum strains have been shown to bind IgM, but binding phenotypes are linked to
the most serious clinical effects of malaria. PfEMP1 proteins are known to contribute to
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the pathogenesis of malaria by mediating cytoadhesion (Smith et al., 2013). The role of
IgM-binding in PfEMP1 is discussed further in Section 1.5.3.
Recently, P. falciparum proteins located on the surface of the merozoite, the infective
form of the parasite, have also been shown to bind natural IgM via the Fc (Crosnier et al.,
2016). The role of these merozoite proteins is unclear but interestingly they contain a
Duffy-Binding-Like (DBL) domain which is also present in PfEMP1s and known to be the
FcR for many IgM-binding isolates as well as the binding site for other cytoadherant
phenotypes. These binding domains will be a key focus of this report. In order to
understand why proteins expressed at different stages in parasite development bind to
IgM via the Fc and contain homologous binding regions, it is first necessary to understand
the immune response at various stages of the parasite’s complex lifecycle and the immune
evasion tactics employed by the parasite. This will be discussed in Section 1.4.
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1.4 Immunity and Malaria
With around half of the world’s population at risk, malaria is a major global health
problem. Caused by the highly successful Plasmodium parasite, which is injected into a
human host by the Anopheles mosquito upon taking a blood meal, in 2013 there were
an estimated 198 million clinical cases of malaria worldwide, 584,000 of which resulted in
death (WHO, 2015). Malaria immunity develops slowly and as a result 78% of malaria
deaths occur in children under five years of age. Moreover, 90% of all malaria deaths
occur in Africa where many mothers are unable to afford or access treatment, therefore
prevention is critical (WHO, 2015; Miller et al., 2002). Despite some recent success in
prevention and control measures (Yewhalaw et al., 2011; Greenwood and Targett, 2011),
mosquito-insecticide resistance and drug-parasite resistance threaten to undermine these
efforts. Antibody response is an important aspect in protective immunity to Plasmodium,
particularly in the blood stages of infection where several parasite antigens that are
known to cause clinical symptoms drive strong antibody responses. Antigenic variation
means that immunity to a malarial infection is short-lived and leads only to partial
immunity which is unable to protect an individual against a new infection. Malaria vaccine
development is urgently needed but the complexity of the parasite lifecycle and intricacy
of the host-parasite interaction means that it is a great scientific challenge to develop an
effective vaccine.
There are more than 100 species of Plasmodium, five of which cause malaria in humans
(Plasmodium falciparum, P. vivax, P. malariae, P. knowlesi and P. ovale). While P.
falciparum is the most virulent species and causes the highest rates of complications and
mortality, P. vivax is the most widely distributed species worldwide. In Africa, however,
the risk of infection with P. vivax is low due to the absence of the Duffy gene in many
populations, which is required for infection of red blood cells. Here, where the vast majority
of malaria deaths occur, P. falciparum poses a huge burden on the poorest and most
vulnerable communities.
1.4.1 Lifecycle of Plasmodium falciparum
A human host becomes infected with the malarial parasite P. falciparum when a
parasite-laden Anopheles mosquito takes a blood meal. During the mosquito stage of
infection, gametes reproduce in the midgut to produce diploid zygotes. These develop
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within the midgut into ookinetes which burrow through the midgut wall and form oocysts
on the other side. As oocysts grow and divide, thousands of active haploids called
sporozoites are produced which burst into the body cavity of the mosquito where they
travel to and invade the salivary glands. It is from the saliva of the infected mosquito
that sporozoites are injected into the human host’s skin where they migrate into the blood
stream.
Figure 1.4: Lifecycle of Plasmodium falciparum within the mosquito and human
hosts. Upon taking a blood meal, an anopheles gambiae mosquito injects sporozoites
into the human host. These migrate to and invade liver cells where they differentiate and
multiply, generating merozoites, the invasive form of the parasite. Merozoites subsequently
infect and then multiply inside erythrocytes or differentiate into gametocyes which are
injested by a mosquito upon taking a blood meal. The change of environment in the
mosquito midgut induces gamete formation and the life cycle repeats.
Sporozoites are transported through the blood stream to the liver sinusoids where they
migrate across the sinusoidal wall in order to invade hepatocytes. Invasion occurs rapidly,
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approximately within 60 minutes of inoculation (Baron et al., 1996). A single sporozoite
multiplies and re-differentiates within an infected hepatocyte over the course of 5 - 10
days to generate thousands of merozoites, which are the invasive form of the parasite
(Maier et al., 2009). Subsequently, bulging hepatocytes burst and merozoites are released
into the blood stream where they rapidly begin a cycle of invasion and infection of host
erythrocytes.
Merozoites within an infected erythrocyte consume haemoglobin, giving them energy
to develop into trophozoites. Upon gorging itself on haemoglobin, a trophozoite undergoes
schizogony and develops into a schizont, consequently another round of asexual replication
then produces multiple merozoites per schizont. A bulging schizont ruptures 48 hours after
infection of the erythrocyte, releasing merozoites into the blood stream once again where
they infect further erythrocytes. The cycle of infection, multiplication and bursting of
erythrocytes continues, producing a high parasite burden on the host. The blood stage
parasites are responsible for clinical manifestations of the disease and the cycle of fresh
merozoites bursting into the blood stream responsible for the waves of parasitemia.
A few blood stage merozoites don’t develop into schizonts and multiply, instead they
differentiate into gametocytes. Upon ingestion when a mosquito takes a blood meal from
an infected human host, the change in environment in the mosquito midgut induces gamete
formation and the life cycle repeats (Figure 1.4).
Plasmodium falciparum multiplies rapidly within a human host during cycles of
erythrocyte invasion by merozoites. The host first encounters the parasite during the
symptomless pre-erythrocytic phase and the parasite is exposed to the immune system
again in the form of the infective merozoite. The immune response to malaria is complex
and stage-specific. Individuals exposed to repeat infection do eventually develop immunity,
although as it is slow to develop children are of high risk.
1.4.2 Innate immunity and malaria
A co-ordinated increase is seen in the levels of pro-inflammatory cytokines in malaria-naive
individuals at the time that the parasite emerges from the liver and at the first infection
of erythrocytes (Hermsen et al., 2003). This confirms the in vitro observation that
infected erythrocytes (IEs) induce tumour-necrosis factor (TNF) and the production of
other pro-inflammatory cytokines by peripheral-blood mononuclear cells (PBMCs) of naive
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donors within 10 hours (Stevenson and Riley, 2004; Scragg et al., 1999). Recently, it has
been suggested that innate immunity is triggered when parasite density crosses a threshold
value (Stevenson and Riley, 2004). This means that blood parasite densities oscillate
between a high level (where innate responses are triggered and parasites are partially
cleared) and low level (where innate immune responses are not triggered) (Stevenson and
Riley, 2004). This implies that innate responses are essential during the initial phase of
infection and allow the host time to develop an adaptive response. From an evolutionary
perspective, this is advantageous for the parasite as well as the host. A reduction in
the virulence of the initial infection means a decreased incidence of early host death, the
parasite therefore has more chance of being passed to the next mosquito host (Stevenson
and Riley, 2004).
There have been relatively few investigations into the role of innate immunity in
malaria. It has been suggested that regulatory cytokines produced by innate immune cells
in response to malaria modulate the subsequent adaptive immune response (Stevenson
and Riley, 2004). This may also help provide a first step in downstream T-cell activation
(Stevenson and Riley, 2004). Macrophages, dendritic cells (DCs) and B cells have been
implicated as the antigen-presenting cells (APC) involved in T cell activation in response
to malaria (McCall and Sauerwein, 2010; Stevenson and Riley, 2004).
Macrophages have also been implicated in the phagocytosis of IEs in the absence of
malaria-specific antibody (Stevenson and Riley, 2004). Scavenger receptors including the
class B receptor CD36 may have a role in opsonin-independent phagocytosis of IEs by
monocytes in non-immune individuals (Serghides et al., 2003). Dendritic cells are central
to both innate and adaptive immunity and express toll-like-receptors (TLRs) which play
a role in both activating innate immunity and modulating adaptive immune response
to microbial pathogens, including intracellular protozoan parasites (Stevenson and Riley,
2004). Their exact role in malaria is unclear, however TLR-mediated signals have been
implicated in anti-parasite mechanisms (Stevenson and Riley, 2004). Investigations into
DC activation by P. falciparum have had conflicting conclusions as to whether parasites
interact with DCs to promote inflammatory response (Urban et al., 1999; Ocana-Morgner
et al., 2003; Seixas et al., 2001). It has been suggested that an initial, transient period
of conventional APC/DC activation may be followed by a period of down-regulated or
absent pro-inflammatory signals, the relevance of which is unclear (Stevenson and Riley,
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2004).
γδT cells bridge the responses between the innate and adaptive immune systems and
have been reported to increase in number in response to infection with P falciparum
(Hviid et al., 2001). The clinical relevance of this is unclear, however, they have been
reported to have anti-parasitic properties (Jagannathan et al., 2014; Elloso et al., 1994).
One suggestion is that the role of γδT cells is to activate further cells such as T cells and
NK cells (Stevenson and Riley, 2004).
Natural Killer (NK) cells are often the first cells to respond to in vitro exposure of
PBMCs to IEs with rapid IFN-γ production (Artavanis-Tsakonas and Riley, 2002). They
are also known to be involved in controlling early parasitemia in murine models. The
IFN-γ response is IL-12 dependent which suggests that the source is NK cells. NK cell
activation in response to P. falciparum infection produces IFN-γ 24 - 48 hours before γδT
cells and NKT cells respond, and activation of γδT cells and NKT cells correlates highly
with the NK response suggesting that this response initiates a further cascade of innate
responses (Stevenson and Riley, 2004; Artavanis-Tsakonas and Riley, 2002). However,
high levels of IFN-γ are associated with pathology and clinical immunity is associated
with decreased IFN-γ production (Riley, 1999).
The impact of the innate response on the outcome of infection by P. falciparum is
unclear due to relatively few investigations. A rapid pro-inflammatory response might
be able to control early parasitemia until the adaptive response is initiated. A potent
pro-inflammatory response may also promote the development of severe malaria by
overstimulating the adaptive response. In reality, it is possible that the innate response
has the potential to be both initially beneficial and subsequently harmful unless modulated
by the adaptive immune response (Stevenson and Riley, 2004).
Natural IgM and Plasmodium falciparum
The role of natural IgM in the innate immune response to malaria is unknown. However,
given its exceptional ability to clear small apoptotic particles it has been suggested that
natural IgM could be effective in the clearance of particle remnants produced upon
erythrocyte rupture (Pleass et al., 2015).
In order to survive and establish infection, P. falciparum parasites have evolved highly
effective immune evasion mechanisms and have found ways to use natural IgM to their own
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benefit (Pleass et al., 2015). These will be discussed in Section (1.5) along with numerous
other ingenious tactics.
1.4.3 Adaptive immunity and malaria
In malaria endemic regions, repeated exposure to P. falciparum infection over many years
eventually results in relative immunity or “premunition”. However, because of the slow
development time malaria deaths are highest in children who have not yet developed
immunity. The adaptive response of B cells and antibodies forms the basis of naturally
acquired immunity to malaria.
Antibodies use a variety of mechanisms to protect against malaria both directly and in
collaboration with effector cells. By binding to surface-expressed antigens, protective
antibodies are able to directly block invasion of erythrocytes as well as blocking the
release of merozoites from schizonts. Antibodies are also able to bind phagocytes via
the Fc receptor, limiting parasite growth. Antibodies further promote parasite clearance
by stimulating the splenic removal of IEs as well as initiating opsonisation, therefore
enhancing phagocytic activity and complement-mediated clearance.
Immune responses to pre-erythrocytic stages are thought to have little involvement
in adaptive immunity (McCall and Sauerwein, 2010). When the liver is bypassed
and blood-stage parasites directly injected, immune individuals are still able to reduce
parasitemia and avoid symptoms. In contrast, immunisation with whole irradiated
sporozoites or pre-erythrocytic antigens can induce immunity (Kumar et al., 2006). During
erythrocytic stages, there is more exposure to the parasite and a more extensive immune
response is established. Potential targets of an immune response at this stage are
parasite-encoded surface-expressed proteins revealed by free merozoites in the bloodstream
as well as intra-erythocytic parasites. Protective immunity is thought to be largely
mediated by IgG1 and IgG3 subclasses, as treatment of patients with IgG extracted from
immune individuals reduces parasitemia and improves clinical symptoms. Parasite-specific
IgG molecules target clonally variant surface antigens (VSA) expressed by the parasite in
the blood stages (Hviid, 2005).
Little is known about the role of immune IgM in malaria, and although protective
immunity is mainly associated with IgG, several studies have implicated IgM (Bolad et al.,
2005; Brown et al., 1986; Boudin et al., 1993). Murine studies suggest that parasite-specific
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IgM is a potent adjuvant (Couper et al., 2005; PG et al., 1982) while immune complexes
containing IgM stimulate the development of acquired T-cell-mediated immunity (Pleass
and Holder, 2005).
Transcriptional switching occurs between members of gene families such as the Var
gene family. Var genes code for expression of Plasmodium falciparum erythrocyte
membrane protein 1 (PfEMP1), a family of proteins located on the surface of an infected
erythrocyte. Switching is a tactic employed by the parasite to avoid immune recognition
by parasite-specific antibodies. This process, known as antigenic variation, gives rise
to a wide range of proteins causing parasites with different antigenic and phenotypic
characteristics to appear at different times within a population (Recker et al., 2011). In
order to develop immunity to the parasite, the host has to build a large repertoire of
antibodies recognising the range of antigens expressed by the parasite, a process which
takes years and involves repeat exposure. The immunity developed is also non-sterile and
a state of relative immunity is reached instead, where low levels of parasitemia are unlikely
to cause clinical symptoms.
The parasite lifecycle is complex but the human host has a sophisticated immune
system consisting of the early innate response and the deadly adaptive response. In order
to be successful the parasite must remain undetected in the host and it has developed
ingenious immune evasion mechanisms. Antigenic variation enables the parasite to slow
down immune detection while it multiplies inside infected erythrocytes. The parasite
has evolved further tactics to avoid clearance of the infected erythrocyte should it be
identified. These must be understood in order to develop effective vaccines to tackle the
disease burden.
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1.5 Plasmodium falciparum Immune Evasion
The persistence of an infection by Plasmodium falciparum as well as the ability to cause
recurrent infections is partly due to the parasite’s superior ability to evade the host
immune response. The parasite is vulnerable whilst moving between cells within the
host, however the parasite moves very rapidly within the bloodstream and swiftly infects
cells, removing itself from the bloodstream and out of danger from antibodies. Upon
invasion of erythrocytes, the parasite undergoes developmental changes and consequently
the erythrocyte becomes more rigid, knob-like structures form on the membrane and
parasite-expressed proteins appear on the membrane surface, hence an infected erythrocyte
is readily distinguishable from an uninfected erythrocyte.
The parasite has itself developed mechanisms to avoid recognition by the immune
system. Antigenic variation in P. falciparum infection is one reason that the parasite is
able to proliferate so successfully and has the ability to reinfect time after time before
the host can develop immunity. The wide range of protein variants expressed at critical
stages in the lifecycle keeps the parasite one step ahead of the host immune response.
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a highly-variant
family of proteins encoded by the var genes. The var gene family consists of 60 var genes
per parasite genome which code for PfEMP1. PfEMP1s are expressed on the surface of
infected erythrocytes (IEs) following invasion by the merozoite. Transcriptional switching
of this protein family slows immune recognition of the IE and allows the parasite time
to develop before bursting out and infecting more erythrocytes. Susceptibility to malaria
corresponds with gaps in an individual’s repertoire of PfEMP1-specific Abs (Hviid, 2010).
The long acquisition time of immunity is partly due to the intraclonal and interclonal
variation of PfEMP1 proteins, as well as the parasite’s ability to express multiple PfEMP1s
at one time in a mutually exclusive manner and its ability to quickly switch expression
among the different variants (Barfod et al., 2011). Moreover, a variant of PfEMP1 may
only be expressed for a short period of time before this switching occurs, limiting its
exposure to the immune system.
PfEMP1 are also highly cytoadherent which gives them further advantages over the
immune response. Cytoadherence prevents parasite clearance and PfEMP1, a known
virulence factor, contributes to the severity of the clinical disease. The sequestration of
IEs within host tissues and organs and the coating of an IE with uninfected erythrocytes
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(known as rosetting) prevents clearance of the parasite by the spleen and leads to severe
malaria pathogenesis. These surface proteins also aid the parasite in avoiding further
clearance of the IE by binding to the Fc of natural IgM, preventing specific binding
from more destructive IgG molecules. Protein variants which bind natural IgM are also
present in the Merozoite Surface Protein (MSP) family located on the merozoite surface.
The variant of surface protein expressed therefore determines pathogenesis and clinical
disease. Antigenic variation of cytoadherent surface proteins is a deadly combination and
the reason that the parasite thrives within the human host. Clinical disease depends on
the cytoadherent property of the variant expressed and the pathogenesis that it produces.
1.5.1 Sequestration of parasites
One characteristic of the PfEMP1 protein family is its cytoadhesive property, an attribute
linked to clinical malaria symptoms (Hviid, 2010). PfEMP1 variants act as ligands,
adhering to host receptors such as chondroitin sulphate A (CSA), cluster of differentiation
36 (CD36) and intercellular adhesion molecule-1 ( ICAM-1) thus mediating tissue-specific
sequestration of IEs (Barfod et al., 2011). Sequestration allows the parasite to avoid
immune evasion by avoiding clearance by the spleen and leads to the accumulation of IEs
in various tissues. Consequently, this pathogenesis leads to life-threatening inflammation
and circulatory disturbances (Barfod et al., 2011). For example, the adherence of IEs to
I-CAM1 has been linked to cerebral malaria, while adherence to CSA is associated with
placental malaria.
1.5.2 Rosetting
Another phenotype arising from the adhesive nature of PfEMP1 is rosetting, which is
the coating of P. falciparum-infected erythrocytes with uninfected erythrocytes. This is
a virulent phenotype and has long been associated with the occurrence of severe malaria
due to microvascular obstruction caused by high densities of rosettes (Juillerat et al.,
2011). PfEMP1 has been identified as the rosetting ligand and numerous receptors on the
erythrocyte have been implicated in binding (Chen et al., 1998; Mercereau-Puijalon et al.,
2008).
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1.5.3 Natural IgM Fc-binding
A less characterised adhesive property of P. falciparum is the ability of PfEMP1 proteins
to bind the Fc portion of natural IgM (Czajkowsky et al., 2010). It has been discussed
previously that in order to evade destruction mediated by the Fc region of an Ab, many
pathogens have evolved Fc-binding proteins (Czajkowsky et al., 2010). The Fc portion of
an antibody is implicated in effector functions through binding to Fc receptors on effector
cells. Binding of the protein to the Fc portion interferes with effector functions such as
phagocytosis and cytotoxicity by preventing pathogen-specific Abs from interacting with
host Fc receptors. It has been shown that in the case of P. falciparum, the PfEMP1 protein
VAR2CSA (involved in placental pathogenesis) binds to non-specific IgM through the Fc
portion of the antibody. This masks the infected red blood cell and blocks subsequent
binding of specific human monoclonal IgG, therefore evading the specific immune response.
PfEMP1 proteins are a well-recognised virulence factor for P. falciparum, known
for their cytoadherent properties amongst variants whose expression can be switched to
avoid recognition. Less characterised Fc-binding proteins are DBLMSP1 and DBLMSP2
which are expressed on the surface of the merozoite. These are part of the Merozoite
Surface Protein 3 (MSP3) family of proteins and also have the ability to bind to the
Fc portion of natural IgM (Crosnier et al., 2016). Interestingly, these proteins contain
a Duffy-binding-like (DBL) domain, a highly conserved region which is also present in
PfEMP1. These have been well characterised as binding domains in PfEMP1 and are not
present in any other MSP3 proteins. DBL domains therefore have potential as vaccine
candidates and are the focus of this report.
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1.6 Plasmodium falciparum Vaccine Development
Malaria is the leading cause of mortality and morbidity worldwide and the malaria burden
is particularly heavy in vulnerable communities in subsaharan Africa where P. falciparum
is widespread. A malaria vaccine is urgently needed, however vaccine development is
difficult due to the complexity of the parasite lifecycle which limits immune exposure as
well as effective immune evasion mechanisms. The clinical outcome of malaria depends on
many factors and consequently severe malaria is difficult to predict. However, key targets
of natural immunity provide a starting point for vaccine development.
1.6.1 Current progress in vaccine development
In 2006, the World Health Organisation (WHO) set out a framework for vaccine
development in the Malaria Vaccine Technology Roadmap, which was then updated in
2013 in response to changing epidemiological and control status (Malaria Vaccine Funders
Group, 2013). The current Roadmap consists of a long and a short-term strategic goal.
The long-term objective is to develop a vaccine by 2025 with a protective efficacy of >80%.
The aim is for this vaccine to provide protection against clinical disease for longer than
4 years. A short-term landmark goal required a first-generation vaccine to be developed
and licensed by 2015. In July 2015, following relative success of RTS,S in phase 3 clinical
trial which showed a substantial reduction in clinical malaria over a 3 - 4 year period,
marketing authorisation for RTS,S was submitted (Kaslow and Biernaux, 2015). RTS,S
is a promising pre-erythrocytic vaccine candidate which targets circumsporozoite protein
(CSP) which is expressed on the surface of the sporozoite and is essential for parasite
development as well as invasion of mosquito and human host tissues (Mueller et al., 2010).
This reduces the number of parasites in the blood by blocking invasion and inhibiting
development of the parasite. The overall vaccine efficacy of RTS,S, however, falls short
of the target 50% protective efficacy against severe disease lasting longer than one year
(Kaslow and Biernaux, 2015).
The liver stages are essential in the initial development of the parasite within the human
host, the pre-erythrocytic phase is therefore an excellent target for early intervention in
order to prevent clinical disease and transmission. A sporozoite-based vaccine could also
have the potential to limit infection in both the mosquito vector and the human host.
The relatively short developmental period of 8 - 15 days and the low levels of parasitemia
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mean that targets of natural immunity in the liver stages are limited. However, surface
and secretory proteins expressed by the sporozoite may be essential for either parasite
development or invasion of host tissues and therefore have potential as vaccine candidates.
Efforts to improve on the efficacy of RTS,S include more than twenty vaccine candidates
in clinical trial (Ouattara and Laurens, 2015). The success of recent candidates has
mostly been limited with few progressing past early stages. Recently, immunisation
with radiation-attenuated sporozoites (RAS) has been shown to induce sterile immunity
in patients and has raised hopes for another pre-erythrocytic vaccine candidate PfSPZ
with excellent efficacy (Hoffman et al., 2002; Seder et al., 2013). PfSPZ uses irradiated
sporozoites to invoke a natural immune response without causing clinical disease. One
problem of PfSPZ for mass vaccination is the need to administer intravenously as a clinical
trial given under the skin in 2011 reported disappointing results (Seder et al., 2013). The
lack of infrastructure to support this requirement also poses further problems as the vaccine
must be stored frozen in liquid nitrogen vapour phase. Although the vaccine efficacy of
PfSPZ is promising, work must be done to find a way around the logistical challenges
faced in order to harness the vaccine’s potential.
Transmission blocking vaccines (TBV) where immunity is raised to mosquito stage
antigens, are aimed at preventing the development of the parasite within the mosquito
host. This prevents the parasite from being passed on from an immunised individual
and infecting a further host. TBVs may be used alongside other control and prevention
measures such as drainage and insecticides to reduce transmission rates, as well as to
complement the use of human lifecycle stage vaccines. TBVs based on sexual stage
parasite surface proteins such as Pfs25, Pfs28, Pfs30, Pfs48 have had limited success,
proving difficult to manufacture and in some cases causing serious side effects (reviewed
by Dinglasan et al. (2013)). The current leading TBV is based on the mosquito-stage
antigen anopheline midgut analyl aminopeptidase N1 (AnAPN1), located on the surface
of the mosquito midgut (Atkinson et al., 2015). Vaccination involves immunisation of the
human host, acquired antibodies are then passed to the mosquito along with the parasite.
Some, but not all of these antibodies have been shown to be effective at preventing the
parasite from entering cells of the midgut wall. The antibody response therefore needs to
be focussed and current vaccine development aims to identify the transmission-blocking
region of the protein (Atkinson et al., 2015). Combined use of TBVs as well as human
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lifecycle stage vaccines may be necessary to reach long term vaccine goals. By reducing
transmission within a community, protective efficacy of other vaccine components may be
improved and the spread of parasites resistant to such vectors may also be reduced.
1.6.2 Potential vaccine candidates
Further surface and secreted sporozoite proteins also have potential as vaccine candidates,
such as thrombospondin-related anonymous protein (TRAP) which has a role in sporozoite
motility and the invasion of liver cells (Akhouri et al., 2008).
Pre-erythrocytic stage vaccines have the potential to make a significant public health
impact. In order to meet long-term goals, however, a second-generation vaccine must
be developed in addition to these. Another approach is to target the blood stage of the
infection where parasites become symptomatic and cause clinical disease.
Clinical symptoms correspond with invasion of erythrocytes by merozoites. One tactic
for vaccine development is to block invasion and prevent disease progression and clinical
symptoms. RH5 of the reticulocyte binding protein-like homologue family is a critical
mediator of erythrocyte invasion through its interaction with basigin (Ord et al., 2015).
Antibodies raised against RH5 have shown inhibition of erythrocyte invasion in several
studies (Douglas et al., 2011; Ord et al., 2012; Reddy et al., 2014) showing RH5’s promise
as a vaccine candidate (Ord et al., 2015).
It is during the blood stages, where the parasite is repeatedly exposed to the immune
system, that the main targets of natural immunity have been identified. Proteins exposed
to the immune system on the surface of both the merozoite as well as the merozoite-infected
erythrocyte induce a natural immune response and are therefore ideal vaccine candidates.
The main cause of severe disease is thought to be due to the cytoadherent property
of proteins expressed on the surface of infected erythrocytes. Vaccines blocking
cytoadherence would have a therapeutic effect and significantly reduce severity of disease,
preventing further deterioration in patients exhibiting the first symptoms of clinical
disease. PfEMP1 is exposed on the surface of infected erythrocytes and is a well-known
target of natural immunity. PfEMP1 variants have been identified as a virulence factor,
the pathogenesis of which relies on its cytoadherent property (Miller et al., 2002). A
PfEMP1-based cytoadherence-blocking vaccine may therefore improve clinical symptoms
and reduce disease severity.
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DBL domains are conserved binding domains present in PfEMP1 proteins on the
erythrocyte surface. There is hope that DBL domain fragments may be identified with
immunogenicity for inducing anti-adhesion antibodies. Two fragments from the PfEMP1
variant VAR2CSA which have been found to have high affinity for CSA are expected to
enter clinical studies in the near future (Fried and Duffy, 2015). These fragments show
promise for a vaccine giving protection against placental malaria which is a major cause of
maternal, fetal and infant mortality. However, susceptibility to malaria corresponds with
gaps in an individual’s repertoire of PfEMP1-specific Abs (Hviid, 2010). Due to a large
number of PfEMP1 alleles responsible for a range of cytoadherent properties, targeting
PfEMP1 directly may have limited success as a single vaccine may only be protective
against a single variant. Although polymorphic, DBL domains can be categorised into
groups based on sequence homology blocks. If a common binding region can be identified
across the catalogue of PfEMP1 DBL domains, there may be potential to develop a single
PfEMP1 based vaccine with immunogenicity to all cytoadherent, virulent alleles.
Conserved binding regions in PfEMP1, called DBL domains, are also present in two
merozoite surface proteins from the MSP3 protein family. MSP3 is a multi-gene family
of proteins which have long been associated with clinical immunity. IgG3 antibodies to
the highly conserved C-terminal region have been shown to be associated with reduced
incidence of malaria (Polley et al., 2007). The presence of DBL domains in these
MSP3-family proteins implies functional similarities with PfEMP1 as well as with parasite
invasion ligands such as EBA-175 (Chiu et al., 2015). MSPDBL proteins have recently
been shown to induce a powerful immune response. Antibodies to MSPDBL1 have
been shown to inhibit parasite growth in vitro while antibodies specific to the DBL
domain of MSPDBL2 have been associated with reduced risk of clinical malaria. These
antibodies have also been shown to opsonise merozoites for FcγR-mediated phagocytosis
by monocytes (Chiu et al., 2015). MSPDBL1 and MSPDBL2 have also been found to
bind unknown receptors on the erythrocyte surface through the DBL domain, which
suggests that they may be involved in erythrocyte invasion (Chiu et al., 2015). A target of
protective antibodies, MSPDBL1 and MSPDBL2 have potential for vaccine development
as an MSPDBL-based vaccine may act to prevent erythrocyte invasion.
A further member of the MSP3-family of proteins, MSP3.1 has also been identified as
a target of protective Abs against P. falciparum by screening a genomic expression library
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using a method called Antibody Dependent Cellular Inhibition (ADCI) (Druilhe et al.,
2005). As well as being shown to induce anti-parasitic effects in the presence of monocytes
both in vitro and in vivo, MSP3.1 is associated with protective immunity as well as an
improved prognosis of drug-treated cerebral malaria (Demanga et al., 2010; Druilhe et al.,
2005; Sirima et al., 2011). The MSP3-family also share a NLRNA/NLRNG N-terminal
signature signal sequence. Unlike the PfEMP1 family of proteins, MSP3 proteins are
simultaneously expressed on the merozoite surface. As well as showing sequence homology
between members of the family, they are also highly conserved between different parasite
isolates. MSP3.1 shows sequence conservation in the C-terminal region with many field
isolates from Africa and Asia, and has shown significant promise in clinical trials (Singh
et al., 2009). Moreover, antibodies raised both naturally and by immunisation to a member
of the MSP3-family show cross-reactivity with other members of the family (Singh et al.,
2009; Demanga et al., 2010) further indicating the potential of this protein family in
vaccine development.
MSPDBL1 and MSPDBL2 proteins, from the MSP3 protein family expressed on the
merozoite surface, have recently been identified as candidates for vaccine development.
Thought to be involved in erythrocyte invasion, interestingly they are the only proteins
expressed on the merozoite surface to contain a DBL domain, a structurally conserved
binding region also present in PfEMP1 and known to be responsible for its cytoadherent
property. Due to the difficulties faced by antigenic variation and variant switching in
PfEMP1 proteins, these proteins may be a better candidate in the race to develop an
erythrocytic stage vaccine and meet long-term objectives. A MSPDBL-based vaccine able
to prevent invasion of erythrocytes would limit parasitemia, slowing disease progression
and reducing severity of disease. These proteins require more attention and are a particular
focus of this report.
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1.7 MSPDBL1 and MSPDBL2
The potential of MSPDBL1 and MSPDBL2 as vaccine candidates has only recently been
realised, as it has been suggested that naturally acquired antibodies specific to MSPDBL2
contribute to protective immunity (Tetteh et al., 2013; Chiu et al., 2015). MSPDBL1
and MSPDBL2 are interesting proteins that differ in structure from the rest of the MSP
protein family in that they contain a DBL domain. This domain is responsible for the
cytoadherence of PfEMP1 proteins on the surface of the erythrocyte, is similar to the
Plasmodium vivax Duffy binding protein, and is found in other P. falciparum invasion
ligands such as Erythocyte Binding Antigen-175 (EBA-175), EBA-140 and EBA-181 (Chiu
et al., 2015). MSPDBL1 has been shown to inhibit merozoite invasion into erythrocytes
in vitro (Sakamoto et al., 2012) and more recently, the MSP1 complex has been shown to
act as a platform for the display of MSPDBL1 and MSPDBL2 on the merozoite surface
for binding to erythrocyte receptors (Lin et al., 2014). MSPDBL1 and MSPDBL2 appear
to be involved in the initial attachment of the merozoite to erythrocytes during invasion,
a critical stage in the P. falciparum lifecycle.
MSPDBL1 and MSPDBL2 bind to the Fc of natural IgM via their DBL domains
(Crosnier et al., 2016). This is a binding characteristic seen in many pathogens and
is thought to prevent recognition of the parasite by the more specific IgG antibody.
This mechanism needs to be further understood in order to develop an effective
invasion-blocking vaccine. Furthermore, the IgM binding property could be used to control
IgM-mediated diseases and complement activation. DBL-Fc fusion protein therapeutics
which bind IgM with high affinity could be used as therapeutics to prevent diseases such
as IgM-associated peripheral neuropathies, to reduce systemic deposition of monoclonal
IgM and its associated symptoms, or reduce complement activation in conditions such as
type II cryoglobulinemia.
1.7.1 Duffy-Binding-Like protein domains
Modifications to both the merozoite and erythrocyte membrane surfaces by the MSP and
PfEMP1 protein families are key stages in disease progression, targets for natural immunity
and therefore targets for vaccine development.
Duffy-Binding-Like (DBL) protein domains, named after the Duffy binding proteins in
P. knowlesi and P. vivax which bind the Duffy antigen receptor for chemokines (DARC),
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are conserved domains common to both MSPDBL1, MSPDBL2 and PfEMP1 and are
believed to be essential to their function (Hodder et al., 2012; Wickramarachchi et al.,
2009). DBL domains are cysteine-rich modules, found in var and EBL genes and are
classified into six types (α, β, γ, δ, , and ξ). Although conserved within classes of
homology blocks, DBL domains have a diverse function and there is great variation in the
host receptors with which they interact (Rask et al., 2010; Hodder et al., 2012). MSPDBL1
and MSPDBL2 both have a single, highly polymorphic, DBL domain while multiple DBL
domains are present in PfEMP1 (Wickramarachchi et al., 2009).
Figure 1.5: Ribbon diagram showing the structure of MSPDBL2. Helices are labelled
h1-h9 and regions corresponding to subdomains 1-3 are coloured cyan, blue and green,
respectively. Only electron density corresponding to Cys-177 was observed in the region
between residues Ser-172 and Asn-185 and no electron density was observed for the loop
(Lys-375, Val-387) between helices 5 and 6 (Hodder et al., 2012). These regions were
modelled using SWISS-MODEL, and are coloured in black (Arnold et al., 2006). (Figure
adapted from Hodder et al. (2012))
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Both DBL domains have recently been expressed and shown to be functional as
erythrocyte-binding domains with similar properties to the full-length proteins (Hodder
et al., 2012). Furthermore, the crystal structure of MSPDBL2 has been solved and from
this, the structure of MSPDBL1 modelled. The crystal structure reveals a canonical
DBL fold consisting of a boomerang-shaped α-helical core formed from three subdomains
(Hodder et al., 2012) (Figure 1.5).
Although DBL variants have high sequence diversity, their structural similarity
suggests that structure is critical for cytoadherence. This binding property and their
involvement in erythrocyte invasion makes them of particular interest in understanding
the virulent nature of P. falciparum and in order to develop effective vaccines to reduce
the parasite burden and lower mortality and morbidity rates particularly in sub-saharan
Africa.
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1.8 Summary
Antibodies form a central part of the immune response to a pathogen, identifying the
threat and recruiting effector cells in order to neutralise and destroy the invading organism.
Effector cells are recruited through binding of the antigen-bound Ab to FcRs present on
the cell surface. An antibody consists of two regions, the Fab and Fc. The Fab arms of
the ‘Y’ shaped Ab molecule is antigen specific whereas the constant Fc region binds to
the FcR on effector cells.
Monoclonal antibodies have dominated the field of therapeutics in recent years,
although a relatively new range of therapeutics harnesses the interaction of the IgG Fc
with the neonatal receptor (FcRn) in order to improve the half-life of a fused immunogenic
protein. Fc-fusion proteins are proving to be successful therapeutics, with numerous
Fc-fusions reaching FDA approval in recent years. Recently, engineering of the Fc-scaffold
has opened up the use of Fc-fusions in vaccines where cross-linking of multiple receptors
is important in order to prime the immune response. The Hexa-Fc scaffold is a hexameric
Fc-fusion scaffold which shows improved binding to FcRs and may enable delivery of
twelve fused proteins.
The pressing need for new vaccine development in malaria in order to meet long-term
targets is clear, with limited vaccine candidates progressing past phase two clinical
trials. Of the most promising candidates, RTS,S has showed limited efficacy and the
highly effective PfSPZ has practical limitations for use in the field. Clinical symptoms
correspond with the blood stages of infection and it is anticipated that a new blood
stage vaccine may prove effective in targeting clinical disease. In the blood stages of
infection, immunogenic proteins are present on the surface of both infected erythrocytes
and merozoites. Cytoadherence of infected erythrocytes in various tissues is associated
with virulence, and conserved regions called Duffy-Binding-Like (DBL) domains have a
pivotal role in cytoadherence of the deadly P. falciparum.
Two merozoite surface proteins, MSPDBL1 and MSPDBL2, are the only MSPs to
contain DBL domains. These domains, like those on the surface of erythrocytes, are
cytoadherent and have recently been shown to bind the Fc region of natural IgM. These
are the only DBL domains present on the merozoite surface and identification of binding
sites present in these domains may lead to identification of residues critical to IgM-binding
in DBL domains of the surface of infected erythrocytes. Critical binding regions may
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be used to raise binding-blocking antibodies while the DBL-Fc fusion proteins may be
developed for therapeutic use for treatment of IgM-mediated conditions.
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1.9 Aims
The two merozoite DBL domains will be expressed as Fc-fusion proteins for two reasons:
1. To further investigate their IgM-binding properties.
2. As novel DBL-Fc fusion proteins which can be further developed for vaccine use.
The central aim of this project is to produce Fc-fusion proteins from the P. falciparum
merozoite surface proteins MSPDBL1 and MSPDBL2. Recombinant protein will then be
used to investigate the binding properties of the DBL domains, two blood stage vaccine
candidates, and to determine residues and structural properties critical for binding. This
is important because it would allow us to formulate with improved accuracy the properties
of these DBL domains that are a potential target for vaccination.
In order to achieve these aims, methods will be developed to express the DBL domains
in a mammalian expression system. The DBL domains will be fused to an IgG1-Fc
domain which, while convenient for protein purification, will provide proof-of-concept for
an Fc-fusion protein based on these DBL domains. Such a protein with increased plasma
half-life will have prolonged therapeutic activity.
In order to identify residues critical for binding, a library of DBL mutants from
MSPDBL1 and -2 will be produced and their IgM-binding properties investigated. A
comprehensive analysis of the structural and sequential similarities between MSPDBL1
and MSPDBL2 DBL domains along with eight other known IgM-binding DBL domains
from PfEMP1 in contrast with fifteen non-binding DBL domains will provide further
insight into the IgM-binding property.
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2.1 Materials
2.1.1 Oligonucleotides
Oligonucleotides were ordered lyophilised from Eurofins (UK) and stored as 100 μM
stock. Polymerase chain reaction (PCR) and Mutagenesis primers (Tables 2.1 and 2.3)
were used at 10 μM working dilution, and sequencing primers (Table 2.2) were sent to
Source Bioscience at concentration of 3.2 pmol/μl.
Table 2.1: PCR primers for amplification of MSP3.4 and MSP3.8 DBL domains.
Primer Sequence Annealing
Temperature (◦C)
3.4 Forward atc ggc cat ggt ttt ctg caa ggg cat caa 68.1
3.4 Reverse gtt ttg tca gat ctg ttg tcc agg tcc 65.0
3.8 Forward cgg aat tcg atc tgc aag gac ttc agc 61.0
3.8 Reverse ttg tca gat cta acc atg gcg tcc tgc a 66.6
Table 2.2: Sequencing primers
Primer Sequence Annealing
Temperature (◦C)
M13 F tgt aaa acg acg gcc agt 48.0
M13 R cag gaa aca gct atg acc 48.0
3.4MutF gcc gtt aca gat cca agc tg 54.0◦C
3.4MutR cca cgc atg tga cct cag 55.0◦C
Fc mut-1:5’ acc ctg ctt gct caa ctc t 57◦C
Fc mut-1:3’ tgg ttt gtc caa act cat caa 57◦C
Table 2.3: Mutagenesis primers
Primer Sequence Annealing
Temperature (◦C)
3.4 Forward atc ggc cat ggt ttt ctg caa ggg cat caa 68.1◦C
3.4 Reverse gtt ttg tca gat ctg ttg tcc agg tcc 65.0◦C
3.8 Forward tcg cgg cgc aat tcg atc tgc aag gac 69.5◦C
3.8 Reverse cgg aat tcg atc tgc aag gac tta gc 66.6◦C
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2.1.2 Plasmids
Commercially available plasmids were used for cloning (Table 2.4). See Appendix A for
plasmid maps and sequences.
Table 2.4: Commercial plasmids used for cloning
Plasmid Features Supplier
pFUSE-hIgG1-Fc2 hIgG1-Fc (human), hEF1-HTLV prom,
IL2 ss, MCS, SV40 pAn, ori, CMV enh
/ hFerL prom, EM2KC, Zeo, βGlo pAn
Invivogen
pCR2.1-TOPO LacZα fragment, M13 Reverse
priming site, Multiple cloning site,
T7 promoter/priming site, M13 Forward
priming site, f1 origin, Kanamycin
resistance, Ampicillin resistance, pUC
origin
Life
Technologies
2.1.3 Competent Cells
The following competent cells were used for transformations.
Table 2.5: Commercial competent cells
Name Transformation Efficiency
(transformants/μg control
DNA per 50 μL reaction)
Supplier
One Shot TOP10 > 1x109 Life Technologies
Subcloning Efficiency Dh5α > 1x106 Life Technologies
XL1-blue > 1x108 Agilent
2.1.4 Antibodies
The following antibodies were used for Western blots, immunoblots and Enzyme linked
immunosorbent assays (ELISAs).
Table 2.6: Primary antibodies
Antibody Working Dilution Supplier Catalogue No
hIgM 5 μg/ml Sigma I8260
Gammagard IVIG 1 mg/ml Baxter 0944-2656-03
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Table 2.7: Antibodies for Westerns and Immunoblots
Antibody Host Dilution Supplier Cat No
αhIgG (Fc specific) AP Goat 1:5000 Sigma A9544
αrbIgG (whole molecule) AP Goat 1:15,000 Sigma A9919
αrbIgG (whole molecule) AP Goat 1:15,000 Sigma A3687
αmsIgG AP Goat 1:10,000 Thermo Scientific 31322
Polyclonal αMSP3.4 Sanger (UK)
Polyclonal αMSP3.8 Sanger (UK)
Monoclonal αMSP3.4 Sanger (UK)
Monoclonal αMSP3.8 Sanger (UK)
Table 2.8: Antibodies for ELISAs
Antibody Host Dilution Supplier Cat No
αhIgG (Fc specific) AP Goat 1:5000 Sigma A9544
αhIgM (μ-chain specific) AP Goat 1:5000 Sigma A9794
αhIgM (μ-chain specific) Mouse 1:5000 Sigma I6385
αhIgM (μ-chain specific) Goat 1:5000 Sigma I2386
αhIgG (Fc specific) Goat 1:1000 Life
Technologies
H10000
Monoclonal αhIgG (Fc
specific)
Mouse 1:1000 Sigma I6260
αhIgG (Fc specific) HRP Goat 1:500 Sigma A0170
2.1.5 Kits
The following commercials kits were used according to manufacturer’s instructions.
Table 2.9: Commercial Kits
Kit Supplier Cat No
High Pure PCR cleanup Micro Kit Roche 04983955001
QIAprep Spin Mini prep Kit Qiagen 27106
QIAGEN Plasmid Maxi Kit Qiagen 12165
QIAGEN Plasmid Midi Kit Qiagen 12145
Genemorph II Random Mutagenesis Kit Agilent Technologies 200550
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2.1.6 Reagents
The following reagents were used according to manufacturer’s instructions.
Table 2.10: PCR and ligation reagents
Reagent Supplier Cat No
rSAP and CutSmart buffer NEB M0371S
Antarctic phosphatase and standard buffer NEB M0289
Taq polymerase and standard Taq buffer NEB M0273
Phusion High Fidelity DNA polymerase NEB M0530
dNTPs NEB N0447
T4 DNA ligase and buffer NEB M0202
Table 2.11: DNA and protein standards and dyes
Standard Supplier Cat No
Gel filtration standard Bio-Rad 151-1901
SeeBlue Pre-stained Protein Standard Life Technologies LC5625
1kbp DNA gel ladder NEB N3232
Gel loading dye (6x), Blue NEB B7021S
Ethidium bromide Sigma E7637
Coomassie Brilliant Blue R-250 Bio-Rad 161-0436
Coomassie Brilliant Blue R-250 Destaining Bio-Rad 161-0438
Table 2.12: Substrates for ELISA, Western blot and Immunoblot
Name Supplier Cat No
SigmaFast p-NPP tablets Sigma N2770
SigmaFast BCIP/NBT Sigma B5655
5’5’3’3’ Tetramethylbenzidine dihyrochloride Sigma T3405
Table 2.13: Transformation and transfection reagents
Name Supplier Cat No
FuGene Promega E2311
IPTG Life Technologies 15529-019
X-Gal Sigma B4252
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2.1.7 Restriction Enzymes and Buffers
Restriction enzymes were used according to manufacturer’s instructions alongside their
recommended buffers.
Table 2.14: Restriction Enzymes and corresponding buffers
Enzyme Restriction Site Buffer Supplier Cat No
NcoI 5’ C↓CATGG 3’
3’ GGTAC↑C 5’
NEBuffer 3.1 NEB R0193
BglII 5’ A↓GATCT 3’
3’ TCTAG↑A 5’
NEBuffer 3.1 NEB R0144
EcoRI 5’ G↓AATTC 3’
3’ CTTAA↑G 5’
NEBuffer EcoRI NEB R0101
EcoRV 5’ GAT↓ATC 3’ 3’
CTA↑TAG 5’
NEBuffer 3.1 NEB R0195
2.1.8 General Buffers
• 10x Phosphate Buffered Saline (PBS) contains 1.37 M NaCl, 27 mM KCl, 100 mM
Na2HPO4, 18 mM KH2PO4.
• Phosphate Buffered Saline + 0.05% Tween (PBST).
• Blocking buffer consists of PBST + 5% dried milk powder.
2.1.9 Gel Electrophoresis Buffers
• Tris-borate-EDTA (TBE) buffer contains 89 mM Tris base, 89 mM boric acid, 2 mM
EDTA.
• Tris-EDTA (TE) buffer contains 10 mM Tris-HCl pH 8 + 1 mM EDTA.
• Loading dye contains 0.25% bromophenol blue w/v, 0.25% xylene cyanol w/v, 50%
glycerol, 1% Tris-HCl pH 8.
2.1.10 ELISA Buffers
• 0.5 M carbonate-bicarbonate buffer; dissolve one capsule in 100 ml deionised water
(Sigma, C3041). This is used as a coating buffer for ELISA plates.
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• 0.05 M phosphate-citrate buffer; dissolve one capsule in 100 ml deionised water
(Sigma, P4809). This is used to develop the substrate 5’5’3’3’ tetremethylbenzidine
dihydrochloride according to manufacturer’s instructions.
2.1.11 SDS-Page Electrophoresis Buffers
• MOPS-SDS running buffer (50 mM MOPS, 50 mM Tris base, 0.1% SDS, 1 mM
EDTA, pH 7.7), bought as a 20x stock (Life Technologies, NP0001).
2.1.12 Western Blot Buffers
• Transfer buffer (25 mM bicine, 25 mM bis-tris, 1 mM EDTA pH 7.2, 20% methanol),
bought as a 20x stock (Life Technologies, NP0006).
2.1.13 Fast protein liquid chromatography (FPLC) Buffers
All FPLC buffers were filtered using Steritop GP Sterlisation Unit 0.22 μm PES membrane
(Millipore).
• 20 mM sodium phosphate, pH 7 (mix 20 mM NaH2PO4 (monobasic) and 20
mMNa2HPO4 (dibasic) stock solutions to the required pH).
• Hank’s Balanced Salt Solution (HBSS) (Life Technologies, 14185045).
• 0.1M Glycine - HCl, pH 2.5 - 2.7.
2.1.14 Antibiotics
• zeocin (Invivogen, ant-zn-ip).
• ampicillin (Sigma, A0166).
2.1.15 Cell culture media
• Dulbecco’s Modified Eagle’s Medium (DMEM, Life Technologies) plus 10% ultra-low
IgG foetal bovine serum (Life Technologies), 1% L-glutamine (Life Techologies), 1%
penicillin/streptomycin (Life Technologies).
• Ham’s F10 medium (Life Technologies) plus 10% ultra-low IgG foetal bovine serum
(Life Technologies), 1% penicillin/streptomycin (Life Technologies).
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• DMEM or Ham’s F10 selection media were supplemented with zeocin at 400 μgml−1.
2.1.16 Microbiological media
• Terrific Broth (TB) containing enzymatic casein digest 12 mgml−1, yeast extract 24
mgml−1, K2HPO4 9.4 mgml
−1, KH2PO4 2.2 mgml
−1, glycerol 10 mgml−1
• Lysogeny Broth (LB) containing bacto-tryptone 10 mgml−1, bacto-yeast extract 5
mgml−1, NaCl 10 mgml−1.
• For agarose plates, the media were supplemented with bacto-agar 15 mgml−1.
• TB or LB selection media were supplemented with ampicillin 50 μgml−1 or zeocin
25 μgml−1.
2.1.17 Software
Molecular visualisation software
• PyMOL v 1.7.4.5 Edu Enhanced for Mac OS X
• Chimera v 8.6.1
• MODELLER v 9.16
Software for analysis of DNA
• 4Peaks sequence viewer
• EnzymeX
• Sequence Manipulation Suite: bioinformatics.org
• BLAST (NCBI)
• Primer3plus (Andreas Untergasser, Harm Nijveen, Xiangyu Rao, Ton Bisseling,
Ren Geurts, and Jack A.M. Leunissen: Primer3Plus, an enhanced web interface
to Primer3 Nucleic Acids Research 2007 35: W71-W74; doi:10.1093/nar/gkm306)
• MEGA v 6
Plasmid map design
• Savvy (Bioinformatics.org, Scalable Vector Graphics Plasmid Map)
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2.2 Molecular Biology Methods
2.2.1 Primers
All primers were synthesised by Eurofins UK. Stock solutions of 100 μM were stored
long-term and PCR reactions composed from a working solution of 10 μM.
When designing primers, the base composition was considered as well as the primer
length and melting temperature. Primer pairs were designed with melting temperatures
(Tm) within 5
◦C of each other. Primers were also checked to avoid self-complementarity
and excessive repeats and runs.
2.2.2 PCR Protocol
PCR amplifications were performed in 25 µl volumes. When larger volume reactions were
needed, a larger volume reaction mix was made and this split into multiple tubes with
total 25 μl volume in each before amplification in the thermocycler. For each reaction, the
appropriate polymerase and buffer was used, with 1mM deoxyribonucleotide triphosphates
(40mM dNTPs mix) and the reaction performed according to standard procedures using
a Progene thermocycler (Techne, Cambridge, UK).
2.2.3 Purification of PCR product from solution
In order to remove salts, primers, unincorporated nucleotides, and DNA polymerase, PCR
products were routinely purified. This was done using one of two methods:
1. High Pure PCR cleanup micro kit (Table 2.9) was used according to the
manufacturer’s instructions. This involved adding a binding buffer which contains
the chaotropic salt guanidine thiocyanate and enables binding of DNA of over 100
bases in length to glass fibres packed into a filter tube. Bound DNA was then washed
and purified using a series of wash and spin steps before being eluted by a low salt
elution buffer.
2. Ethanol precipitation. 1/10 volume of sodium acetate pH 5.2 was added to the
sample followed by 2.5 volumes of cold 100% ethanol and the solution mixed well.
This was then incubated at −20◦C for a minimum of 20 minutes to precipitate the
DNA. The DNA was pelleted by spinning in a tabletop centrifuge at maximum speed
for 15 minutes and the supernatant decanted carefully. The DNA was washed by
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adding 1 ml 70% ethanol, mixing well and spinning briefly before decanting the
supernatant. The pellet was then air-dried and resuspended in dH2O.
2.2.4 Restriction Digest
Plasmids and inserts were digested using restriction enzymes (NEB) in order to cut out
compatible sticky ends ready for the ligation step. All digests were performed according
to the manufacturer’s instructions.
2.2.5 DNA gel electrophoresis
DNA gel electrophoresis was routinely done using on 0.8 - 1% TBE agarose gels (UltraPure,
Invitrogen) (Section 2.1.9) containing 40 μg/μl Ethidium Bromide. Samples were loaded
in Bromophenol blue dye (Section 2.1.9) and a 1 kbp ladder from NEB (Figure 2.1) used
as a molecular marker. The gel was then electrophoresed in TBE running buffer at 80 V.
The DNA bands were analysed using a UV illuminator.
Figure 2.1: NEB 1 kb ladder used to size DNA fragments on agarose gel.
2.2.6 Extraction of DNA from agarose gel
DNA was routinely extracted from agarose gel using the High Pure PCR cleanup micro
kit (Table 2.9). This was done according to the manufacturer’s instructions and involved
cutting out the DNA band, and heating it at 56◦C in binding buffer to dissolve the gel.
Binding buffer contains the chaotropic salt guanidine thiocyanate and enables binding of
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DNA of over 100 bases in length to glass fibres packed into a filter tube. Bound DNA was
then washed and purified using a series of wash and spin steps before being eluted by a
low salt elution buffer.
2.2.7 Vector de-phosphorylation
In order to prevent vector DNA from self-ligating it was dephosphorylated. This was done
using either Antarctic phosphatase or Shrimp Alkaline phosphatase (rSAP) according to
manufacturer’s instructions.
2.2.8 Ligation Protocol
For ligation reactions typically 90 ng of vector and 60 ng of insert were used in line with
the recommended vector:insert ration of 1:3. T4 DNA ligase and T4 DNA ligase buffer
(Invitrogen) were used according to manufacturer’s instructions. Ligation reactions were
held at 16◦ C for 16 hours using a Progene thermocycler.
2.2.9 Making competent E.coli cells
50 ml of LB medium (Section 2.1.16) was inoculated using glycerol stock of E.coli cells
(XL1-blue, Dh5α or TOP10). These were grown at 37◦C in an orbital shaker set to 225
rpm until an OD of 0.6 - 0.8 was achieved. Bacterial cultures were spun at 2,600 xg
for 5 mins in a chilled (4◦C) centrifuge and the pellet was resuspended in 25 ml of 100
mM ice-cold MgCl2. Cells were spun at 2,600 xg (4
◦C) for 5 mins and the supernatant
discarded. The pellet was resuspended in 25 ml of 100 mM ice-cold CaCl2 and the cell
suspension was incubated on ice for 60 mins. The suspension was then spun at 2,600
xg (4◦C) for 5 mins and the supernatant discarded. The pellet was resuspended in 5 ml
ice-cold 85 mM CaCl2 containing 15% glycerol. 100 μl aliquots were stored at −80◦C.
2.2.10 Transformation of competent E.coli cells
Competent E.coli cells were defrosted on ice and 1–5 μl of the ligated construct added
and the mixture incubated on ice for 30 mins. The cells were then given a heat shock of
42◦C for 30 seconds in order to create pores in the cell membranes. The cells were then
returned to ice for 2 mins. 200 – 500 μl of SOC media was added and then the cells shaken
at 225 rpm, 37◦C for 1 hour.
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5–200 μl of the transformation reaction was spread onto pre-warmed agarose plates
containing the appropriate antibiotic for selection and plates incubated at 37◦C overnight
for colonies to form.
2.2.11 Mini-prep
Plasmid DNA was routinely purified using the QIAprep Spin Miniprep kit (Table 2.9). A
single bacterial colony containing the plasmid DNA was grown in 5 ml media containing
the appropriate antibiotic required for selection (see Section 2.1.16 for bacterial growth and
selection media routinely used) for 12-16 hours at 37◦C with vigorous shaking (225 rpm).
The bacteria was harvested and the plasmid DNA purified according to the manufacturer’s
instructions. This involved the preparation and clearance of lysate, followed by purification
on a silica membrane and finally elution of the DNA from the membrane. First, bacterial
cells were pelleted by centrifugation and resuspended in buffer containing RNase. The cells
were lysed in NaOH/SDS buffer in order to release the cell contents whilst at the same
time, denaturing chromosomal and plasmid DNA as well as proteins. The product was
then neutralised and adjusted to high-salt concentration. This causes denatured proteins,
chromosomal DNA, cellular debris, and SDS to precipitate, while renaturing the smaller
plasmid DNA which stayed in solution. The solution was then passed across a silica
membrane to which the plasmid DNA bound. Bound DNA was then washed and purified
using a series of wash and spin steps before being eluted by a low salt elution buffer.
The concentration of the purified plasmid DNA was then established using a nanodrop
spectro-photometer (Section 2.2.15).
2.2.12 Screening Positive Colonies
Blue-white screening
For TOPO transformation, blue-white screening was used to select positive colonies. This
works via a mutant form of the E. coli enzyme β-galactosidase that has its N-terminal
residues deleted (the ω-peptide) and is inactive. The enzyme can be restored to it’s active
state by the presence of an α-peptide. When a vector containing this α-peptide is expressed
by a cell containing the ω-peptide, they form a functional β-galactosidase enzyme. This
enzyme hydrolyses the chromogenic substrate X-gal, which subsequently confers a blue
colour on the bacterial colony.
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This process is interrupted if DNA is inserted into the plasmid LacZα gene, stopping
production of the α-peptide. Consequently, E. coli that contain the vector plus insert
can’t produce a functional β-galactosidase and the colony will appear white.
Using this method, white colonies were picked for screening and grown overnight in
media containing 50 μg/ml ampicillin. Plasmid DNA was then isolated by mini-prep
(Section 2.2.11).
Restriction Digest screening
For TOPO transformation, once the white colonies had been selected and the DNA
isolated by mini-prep, plasmid DNA was then digested using restriction enzymes to identify
whether the insert was present.
For pFUSE and Mutazyme transformations, all large colonies were selected and
plasmid DNA isolated by mini-prep. This plasmid DNA was then digested using restriction
enzymes to identify whether the insert was present.
The restriction digest solution consisted of the following:
• Restriction enzyme 1 1 μl
• Restriction enzyme 2 1 μl
• Compatible Buffer 5 μl
• BSA (10x) 5 μl
• Plasmid DNA 1 μg
• dH2O up to 50 μl
Restriction digests were incubated at 37◦C for 2 hours and then the product visualised
by gel electrophoresis.
2.2.13 Sequencing
Plasmid DNA was sequenced using Sanger sequencing (Source Bioscience, Nottingham,
UK). Sequences were then analysed using 4Peaks and the Basic Local Alignment
Search Tools (BLAST) available at http://blast.ncbi.nlm.nih.gov/Blast.cgi as well
as the 6 frame translation tool available at http://www.bioinformatics.org/sms2/
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translate.html. 3’ sequences were reverse complemented and aligned with the 5’
sequence in order to clarify any misreads in either strand. In order to speed up this process,
a script has been written in Python to identify the sequence number of the nucleotide in
question so that it can be located quickly in the ab1 file.
2.2.14 Midi-prep and Maxi-prep
Plasmid DNA was routinely purified using the QIAprep Spin Midiprep kit and QIAprep
Spin Maxiprep kit (Table 2.9). A single bacterial colony containing the plasmid DNA
was grown in 5 ml media containing the appropriate antibiotic required for selection (see
Section 2.1.16 for bacterial growth and selection media routinely used) for 8 hours at 37◦C
with vigorous shaking. The culture was then transferred to a further 50 ml (midi) or 200
ml (maxi) of media containing the antibiotic and grown for a further 12-16 hours. The
bacteria was harvested and the plasmid DNA purified according to the manufacturer’s
instructions. This involved the preparation and clearance of lysate, followed by binding to
a silica membrane, elution of the DNA from the membrane and finally the concentration
and desalting of DNA by isopropanol precipitation.
First, bacterial cells were pelleted by centrifugation and resuspended in buffer
containing RNase. The cells were lysed in NaOH/SDS buffer in order to release the
cell contents whilst at the same time, denaturing chromosomal and plasmid DNA as
well as proteins. Acidic potassium acetate was added to neutralise the lysate. The
lysate was then cleared by passing the solution through a QIAfilter cartridge. Cleared
lysate was loaded onto a QIAGEN-tip and passed through by gravity flow. As plasmid
DNA was then bound to the membrane, contaminants were removed by washing with
a medium-salt buffer before elution by a high-salt buffer. The eluted plasmid DNA was
desalted and concentrated by isopropanol precipitation, washed with ethanol and dissolved
in TE buffer. The concentration of the purified plasmid DNA was established using a
nanodrop spectro-photometer.
2.2.15 Nanodrop
Nucleic acid concentrations were quantitated using a spectrophotometer (Nanodrop
ND-1000). DNA absorbance was measured at 260 nm.
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2.2.16 Glycerol stocks
700 μl of bacterial culture was added to 300 μl 50% glycerol and mixed well. Stocks were
stored at −80◦C
2.3 Tissue Culture Methods
2.3.1 Preparation and maintenance of cells
Tissue culture reagents were pre-warmed to 37◦C in a water-bath prior to cell culture
work.
CHO–K1 (Sigma 85051005) and HeK (Sigma 85120602) cells were cultivated and
maintained in growth medium (Section 2.1.15), incubated at 37◦C with 5% CO2 and
split when 70− 80% confluent.
To prepare a new passage of cells for growth, 1 ml pre-warmed media (Section 2.1.15)
was added to cells to defrost rapidly and the suspension added to 5 ml media (Section
2.1.15) in 15 ml falcons. The suspension was centrifuged at 180 xg for 5 mins and
supernatant discarded to remove all dimethyl sulfoxide (DMSO). 5 ml media was added
to the cells and the pellet re-suspended. The final suspension was added to 15 ml media
in Nunc EasYFlasks (Sigma-Aldrich, UK) and incubated at 37◦C with 5% CO2.
2.3.2 Splitting Cells
Cells were cultured in Nunc EasYFlasks (Sigma) in either growth media or selection
media (Section 2.1.15). Cells were split into new flasks when 70 − 80% confluent. First,
supernatant was discarded and cells washed in 2 − 20 ml sterile PBS (depending on the
size of the flask). 1 - 5 ml trypsin was added to coat the cells and excess poured off. The
flasks were then incubated at 37◦C for 5 mins to release cells. Cells were resuspended in
2− 20 ml of the correct media (depending on length of culture) and then added to a flask
containing media to make up the maximum volume for the flask.
2.3.3 Transfection of cells
Cells were transfected using Fugene 6 transfection reagent (Promega), according to the
manufacturer’s instructions. After 24 hours, the medium was replaced with medium
containing zeocin to select for successfully transfected cells.
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2.3.4 Production of monoclonal population
Monoclonal populations were developed by diluting cells down to 1 x 102/ml and adding
100 μl to each well of a 96 well plate. When colonies formed from a single cells, these were
expanded further and immunoblotting used to analyse protein secretion and select for the
best expressing colonies.
2.3.5 Freezing cells for long-term storage
The medium was discarded and the cells washed in PBS then washed in trypsin/EDTA,
and the flasks returned to 37◦C to loosen the cells. Cells were resuspended in 5 ml selection
medium (Section 2.1.15) and spun at 180 xg for 5 mins. The medium was discarded, the
cells resuspended in 1 ml freezing media (10 %DMSO in FBS) and transferred to a cryovial.
This was transferred to a freezing container (Thermo Scientific) and incubated at −80◦C
overnight, before being placed in liquid nitrogen for long-term storage.
2.4 Methods for Protein Purification and Analysis
2.4.1 Fast protein liquid chromatography FPLC
DBL-Fc recombinant protein was purified from supernatant using a protein G sepharose
column using the liquid chromatography system A¨KTA-FPLC Frac-950 (Amersham
Biosciences/GE Healthcare, Uppsala, Sweden). Filter-sterilised cell supernatant was either
pure or diluted 1:1 in the appropriate binding buffer and then passed over the column in
order to allow the protein to bind. The column was then washed in binding buffer to
remove any unbound material. Protein was eluted from the column in 0.1 M Glycine pH
2.5 - 2.7 using a linear gradient and collected in 2 ml fractions. Fractions were neutralised
using 1 M Tris HCl pH 9.
The Beer-Lambert equation was used for quantification of protein concentration from
FPLCs:
Concentration =
OD280nm
 ∗ pathlength (1)
where path length is 0.2 cm. The molar absorptivity of the DBL-Fc fusion proteins
were calculated as 103915 for DBL 3.4 and 101395 for DBL 3.8 (calculated using the
ExPASy bioinformatics tool available at http://web.expasy.org/protparam/). Percent
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solution extinction coefficients were calculated as 1.664 and 1.630 respectively.
2.4.2 Immunoblot Analysis
Immunoblot analysis was used to show the presence of protein. 5 μl of solution containing
protein was coated on nitrocellulose and subsequently blocked with PBST plus 5% milk
for 2 hours at room temperature. The membrane was then washed in PBST before adding
the detecting antibody αhIgG-AP (1:5000) and incubating overnight at room temperature.
The blot was developed using NBT/BCIP tablets (Table 2.12) according to manufacturer’s
instructions.
2.4.3 Ultrafiltration
Protein was concentrated using ultrafiltration spin columns Vivaspin 2, 5000 MWCO PES
(Sartorius) or Ultra-4 centrifugal filter devices (Amicon). Samples were added to the
concentrator at max volume of 2 ml and then spun at 4000 x g in a tabletop centrifuge
until the desired concentration was achieved.
2.4.4 Size Exclusion Chromatography
Protein aggregation was analysed by gel filtration using the liquid chromatography system
A¨KTA-FPLC Frac-950 with gel filtration column Superdex 200 10/300 GL (Amersham
Biosciences) according to manufacturer’s instructions.
The location of peaks was compared to the gel filtration standards in order to identify
molecular weight (Figure 2.2).
2.4.5 Bio-Rad Protein Assay
The Bio-Rad protein assay was used in order to quantify protein concentrations. This
assay, based on the Bradford method, detects a colour change in dye in response to various
protein concentrations.
The standard procedure followed for proteins concentrations in the range 0.05 mg/ml
to 0.5 mg/ml was as follows: 10 μl of each sample was added to duplicate wells of
Nunc-maxisorp micrometer plates (Thermo/Fisher) and 200 μl diluted dye reagent (1
part dye reagent concentrate to 4 parts dH2O, filtered to remove particulates) added to
each well. Colour was left to develop at room temperature for 5 minutes and absorbance
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Figure 2.2: BioRad gel filtration standards. Peaks correspond to the molecular markers A)
Tryroglobulin (bovine) - 670,000 Da, B) γ-globulin (bovine) - 158,000 Da, C) Ovalbumin
(chicken) - 44,000 Da, D) Myoglobin (horse) - 17,000 Da and E) Vitamin B12 - 1,350 Da.
read at 595 nm on an Infinite F50 plate reader (Tecan). IVIG concentrations ranging from
0.05 mg/ml to 0.5 mg/ml were used as protein standards for comparison.
The micro assay procedure followed for protein concentrations in the range 8.0 μg/ml
to 80 μg/ml was as follows: 160 μl of each sample was added to duplicate wells of
Nunc-maxisorp micrometer plates (Thermo/Fisher) and 40 μl diluted dye reagent added to
each well and mixed. Colour was left to develop at room temperature for 20 minutes and
absorbance read at 595 nm on an Infinite F50 plate reader (Tecan). IVIG concentrations
ranging from 8.0 μg/ml to 80 μg/ml were used as protein standards for comparison.
2.4.6 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)
Protein samples were prepared with NuPAGE sodium dodecyl sulphate (SDS) sample
buffer, and loaded either under reducing and non-reducing conditions, using dithiothreitol
(DTT) as a reducing agent. The samples were centrifuged at 27,396 xg for 30 seconds and
then heated at 95◦ C for 5 minutes before loading onto a NuPAGE Novex 4-12% Bis-Tris
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pre-cast gel (Life Technologies, CA, USA). An XCell SureLock Mini-Cell electrophoresis
system (Life Technologies) was used to run the gels in NuPAGE MOPS SDS Running
Buffer (Life Technologies; 50 mL MOPS buffer in 950 mL of deionised water) at 200 V
constant until the samples reached the end of the gel. SeeBlue Plus 2 Prestained Protein
Marker (NEB) was used as a molecular weight marker (Figure 2.3). The proteins were
either Coomassie stained (Section 2.4.7) or transferred to a membrane for Western blotting
(Section 2.4.8).
2.4.7 Coomassie Blue staining
The gels were then removed from their housing cassettes and stained in 20 mL of Page Blue
Protein Staining Solution (2.1.6) by microwaving at full power (750 watts) for 30 seconds.
To optimize staining, the gels were then left to stain for a further 30 minutes on a platform
shaker (Stovall Life Sciences Inc., Ringer, UK), before being left to destain for two hours in
destaining solution. Protein bands were directly visualized on the destained gel and their
respective molecular weights (kDa) were estimated by comparison with SeeBlue Plus2
prestained standards (Invitrogen).
Figure 2.3: SeeBlue Plus2 prestained standard used as molecular weight markers to analyse
the size of protein bands.
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2.4.8 Western blot
SDS-PAGE gels were transferred to Protran nitrocellulose transfer membrane (GE
Healthcare) in transfer buffer (Section 2.1.12) at 40V for one hour, using an XCell IITM
blot module according to manufacturer’s instructions. To block non-specific binding, the
membrane was incubated in blocking solution for one hour, followed by three washes
(PBST). The membrane was then incubated with primary antibody overnight on a rocker
at room temperature, followed by washing and incubation with a secondary antibody
conjugated to an appropriate substrate for three hours. On occasion when a primary
antibody was not necessary, the membrane was directly coated with the conjugated
secondary antibody overnight.
Proteins were visualised by developing horseradish peroxidase (HRP)-conjugated
Abs with the chromogen 3’,3’-Diaminobenzidine (DAB; DAKO), or alkaline
phosphatase (AP)-conjugated antibodies with a developing buffer composed of
5-bromo-4-chloro-indolyl-phosphate/Nitroblue tetrazolium (BCIP/NBT, 100 mM
Tris/Cl, pH 9.5, 100 mM NaCl, 5 mM MgCl2), according to manufacturer’s instructions.
2.4.9 Enzyme-linked immunoabsorbent assay (ELISA)
Sandwich ELISA was used to measure the amount of protein between a capture and
detection antibody. The capture antibody was diluted in 0.5 M carbonate/bicarbonate
buffer (pH 9.6), coated down on a Nunc-maxisorp micrometer plates (Thermo/Fisher)
and incubated at 4◦C overnight in order to bind to the plate. Any uncoated material was
then discarded and the plates were blocked with 200 μl blocking buffer (Section 2.1.8) and
incubated for 1 hour at room temperature on a rocker. Wells were washed in PBST 5
times before the addition of protein or antibody in the appropriate dilution. The plate was
incubated for 2 hours at room temperature on a rocker before washing all wells 5 times
in PBST. This was repeated depending on the purpose of the ELISA. Wells were finally
washed 5 times in PBST before the addition of the detection antibody (Alkaline Phosphate
conjugate) which was incubated for 1 hour at room temperature. Plates were then washed
as before and then developed using SIGMAFASTTM p-Nitrophenyl Phosphate tablets (20
ml solution containing 1.0 mg/ml pNPP, 0.2 M Tris buffer and 5 mM magnesium chloride).
100 μl of substrate buffer was added to each well and the plate was allowed to develop.
The absorbance was read at 405 nm on an Expert plus plate reader (Biochrom, SLS).
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DBL Domains
61
3 PRODUCTION OF RECOMBINANT MSPDBL1 AND MSPDBL2 DBL DOMAINS
3.1 Background
MSP3 family
The MSP3 family of proteins are secreted polymorphic antigens associated with the
merozoite and erythrocytic shizonts in the blood stages of P. falciparum infection and
consists of six proteins: MSP3 (MSP 3.1), MSP6 (MSP 3.2), H101 (MSP 3.3), MSPDBL1
(MSP 3.4), H103 (MSP 3.7) and MSPDBL2 (MSP 3.8) (Singh et al., 2009). MSP3
proteins are synthesised simultaneously in the schizont stages of infection, after which they
undergo proteolytic processing before being released by schizonts upon rupture (McColl
and Anders, 1997). Most of the cleaved fragments are secreted, however some associate
non-covalently to the merozoite surface (McColl and Anders, 1997). MSP3 proteins are
highly conserved amongst isolates and are a target of naturally occurring antibodies which
are able to cross-react across the gene family (Singh et al., 2009; Demanga et al., 2010).
Anti-MSP3 antibodies have been associated with acquired clinical immunity (Roussilhon
et al., 2007; Osier et al., 2007) and in phase-1 vaccine trials have elicited antibodies both
in vitro and in vivo that mediate effective killing of P. falciparum (Druilhe et al., 2005).
Anti-MSP3 antibodies therefore play an important role in protective immunity against
malaria.
Members of the MPS3 family are characterised by sequence homology in their
C-terminals and share a NLR(K/A)(A/G/N) signature motif (Figure 3.1). The C
terminal region varies between each paralog but is highly conserved amongst isolates,
which suggests that they may play a role in parasite survival. Each member also has
a secreted polymorphic antigen associated with merozoites (SPAM) domain in the C
terminal region, the role of which remains elusive but is thought to be involved in
oligomerisation. MSPDBL1 and MSPDBL2 also contain an additional DBL domain which
is found in var and ebl genes.
MSPDBL1 and MPSDBL2
MSPDBL1 and MSPDBL2 are the only MSPs to contain DBL domains which are
well-known binding domains present in other Plasmodium protein families (Cowman et al.,
2012). Both proteins appear to localise on the merozoite surface (Hodder et al., 2012;
Wickramarachchi et al., 2009; Cowman et al., 2012) and have been identified as part of
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the MSP1 complex, thought to be involved in erythrocyte invasion (Lin et al., 2014).
Figure 3.1: Structure of the MPS3 family of merozoite surface proteins.
Schematic shows the structural characteristics of MSP3 family of proteins. Adapted from
(Hodder et al., 2012).
It has been confirmed that the DBL domains are able to bind erythrocytes although
the receptors have not yet been identified (Hodder et al., 2012; Wickramarachchi et al.,
2009). MSPDBL1 and MSPDBL2 have also been observed to bind the Fc portion of
natural IgM through their DBL domain (Crosnier et al., 2016). This characteristic has also
been reported in DBL variants from PfEMP1 and is thought to protect the parasite from
PfEMP1-specific IgG (Czajkowsky et al., 2010). In the case of PfEMP1, IgM-binding has
been linked to several virulence-associated phenotypes including rosetting with uninfected
RBC in severe childhood malaria as well as binding to CSA in placental malaria (Semblat
et al., 2015). Due to their implied role in the erythrocyte invasion process as well as their
interesting binding properties, MSPDBL1 and MSPDBL2 deserve attention as blood stage
vaccine candidates (Chiu et al., 2015).
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Structure of MSPDBL1 and MSPDBL2 DBL domains
The three-dimensional crystal structure of the DBL domain of MSPDBL2 contains a
boomerang-like shaped α-helical core with three cysteine rich subdomains (Figure 3.2)
and shows structural similarities with DBL domains from PfEMP1 such as VAR2CSA,
DBL6e, DBL3X and PfEBA-175 (Hodder et al., 2012). The structure is stabilised by six
inter-chain disulphide bonds which show a different linkage pattern than DBL domains in
the PfEMP1 and EBL family. DBL domains from the EBL family do not typically have
disulphide connectivity between subdomains 1 and 2 and although PfEMP1 DBL domains
do, they typically have a modified linkage pattern in subdomain 3 (Hodder et al., 2012).
Figure 3.2: Ribbon schematic and surface potential diagram of DBL domains
from MSPDBL1/2. (A) Ribbon schematic and surface potential diagrams showing the
modelled structure of the MSPDBL1 DBL domain. This homology model is based on the
crystal structure of MSPDBL2 and was modelled using Phyre 2. (B) Ribbon schematic
and surface potential diagrams showing structure of the MSPDBL2 DBL domain including
loops missing in the x-ray structure (PDB accession code 3VUU) which were modelled
using Phyre 2 (adapted from (Hodder et al., 2012))
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MSPDBL1 and MSPDBL2 bind IgM through DBL domains
The focus of this chapter is the ability of the DBL domains from MSPDBL1 and MSPDBL2
to bind the Cμ4 domain of human IgM. Interestingly this is the same region on the Ab
that the FcμR is known to bind. In a recent study, reduced binding of the full-length
proteins to immune IgG was observed when complexed with IgM (Crosnier et al., 2016).
This suggests that binding of the MPSDBL1 and MSPDBL2 proteins to IgM is an evasion
mechanism which acts to mask the merozoite from the immune system (Crosnier et al.,
2016).
Expression of recombinant DBL-Fc fusion proteins
Fc-fusion proteins have shown a great deal of success as therapeutics, with nine currently
in clinical use (reviewed in Section 1.2). The increased half-life from the interaction with
the neonatal Fc receptor (FcRn) improves the therapeutic potential of the protein partner.
Fc-fusion proteins used for drug delivery mainly target receptor-ligand interactions either
working to block receptor binding or to directly stimulate receptor function and alter
immune activity (Czajkowsky et al., 2012). Fc-fusion proteins also have potential for
vaccine use as they are able to effectively deliver an antigen which can prime the immune
response. Creating Fc-fusion proteins from malarial antigens (e.g. RTS,S) may improve
on existing vaccine delivery by this improved priming effect.
DBL-Fc fusion proteins may be used as therapeutics for IgM-related autoimmune
diseases due to their high affinity for IgM. Removal of IgE by the drug Omalizumab is
highly effective for the treatment of asthma. Omalizumab reduces the clinical symptoms
caused by hypersensitivity that is induced from overproduction of IgE (Strunk and
Bloomberg, 2006). Anti-TNF therapy in rheumatoid arthritis and other inflammatory
conditions such as ulcerative colitis blocks the action of the tumour necrosis factor (TNF)
the overproduction of which is responsible for the inflammatory response (Feldmann, 2002;
Prince et al., 2011). Removal of IgM from serum may reduce the symptoms of diseases such
as Waldenstro˝m’s macroglobulinemia and Schnitzler’s syndrome, peripheral neuropathies
such as Anti-MAG demyelinating neuropathy, and systemic deposition of IgM (Simon
et al., 2013; Camp and Magro, 2012; Audard et al., 2008; Baldini et al., 1994). Reduction
of IgM and prevention of complement activation may also be useful for the treatment of
diseases and infections associated with type II cryoglobulinemia (Terrier et al., 2012). The
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treatment of such diseases with DBL-Fc fusion proteins would allow direct targeting of
nIgM and would be more beneficial than mAbs-directed therapeutics because there would
be no cross-linking of the IgM BCR.
Expressing the merozoite DBL domains as Fc-fusion proteins provides a proof of
concept for the production of malarial DBL-based Fc-fusion proteins and the techniques
used for production may be developed and applied to further therapeutic antigens. The
expression of the DBL domains with the Fc tag also provides a useful purification tool.
Protein G can be used for purification, streamlining protein production in order to focus
on the binding characteristics of these interesting protein domains.
The DBL-Fc fusions themselves could also be used for IgM purification due to their
high affinity for hIgM. IgM purification is a challenge due to its size and susceptibility
to denaturation (Gautam and Loh, 2011) and cost-effective purification is not as readily
available and reliable as it is for IgG. Protein-based affinity ligands are used for purification,
such as mannose-binding protein (MBP) which currently is immobilised on agarose beads
for commercial IgM purification. However, not all glycosylation variants of hIgM are
purified by this method, leading to products which are only 90% pure. Other commercially
available human IgM purification kits use ligands bound to sepharose but purities above
95% cannot be reached (Gautam and Loh, 2011).
The high A:T content of the Plasmodium genome results in low codon compatibility in
heterologous expression systems and makes expression of recombinant protein difficult.
Highly repetitive amino acid sequences and high molecular weights introduce further
technical challenges. However, recombinant proteins have been successfully expressed in a
diverse range of systems from bacteria, yeast and plants to mammalian systems (Birkholtz
et al., 2008; Ferna´ndez-Robledo and Vasta, 2010; Stowers et al., 2001; Tsai et al., 2006;
van Bemmelen et al., 2000; Ghosh et al., 2002; Gregory et al., 2012; VanBuskirk et al.,
2004; Tolia et al., 2005; Tsuboi et al., 2008). Escherichia coli is currently the most popular
expression system due to low cost and relatively high protein yield. However, producing
protein under reducing conditions in the bacterial cytoplasm inhibits the formation of
the disulphide bonds that are critical for structural stability. Extracellular proteins in
particular contain structurally critical disulphide bonds. This means that when producing
recombinant Plasmodium extracellular vaccine candidates in E. coli great care must be
taken to create a properly folded disulphide-bonded protein, and the process can be
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laborious and complex.
In eukaryotic cells, the endoplasmic reticulum (ER) provides an oxidative environment
for disulphide bond formation, thus mammalian expression systems can make the the
disulphide bond structure essential for Plasmodium extracellular proteins, however often
produce low yields. Unnecessary N-linked glycosylation is often a problem in eukaryotic
expression of recombinant Plasmodium surface proteins because, unlike most other
eukaryotic extracellular protein, these surface and secreted proteins are not modified by
N-linked glycans. Mammalian expression of the Fc-fusion proteins enables disulphide bond
formation while potential glycosylation sites within the DBL domain have been removed.
The production of recombinant DBL domains from both MSPDBL1 and MSPDBL2
will allow functional and molecular characterisation of these exciting protein domains. A
mammalian expression system can be used to produce functional protein with the correct
disulphide bond structure, which is critical for the stability of the protein. The methods
used to develop recombinant Fc-fusion DBL proteins can be applied to other malarial
antigens, paving the way for the therapeutic use of malarial Fc-fusion proteins.
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3.2 Objectives
The aim of this chapter is to produce recombinant DBL domains from MSPDBL1 and
MSPDBL2 with an IgG-Fc fusion and to investigate the binding properties of the DBL
domains. The specific objectives include:
• Produce novel Fc-fusion constructs for mammalian expression of the recombinant
protein.
• Express recombinant DBL-Fc fusion protein.
• Show IgM binding of the DBL domains using the recombinant Fc-fusion proteins.
• Show that MSPDBL1 and MSPDBL2 bind to the Cμ4 domain of human IgM.
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3.3 Methods
3.3.1 DNA preparation
The DBL domains from MSPDBL1 and MSPDBL2 will be referred to as DBL 3.4 and
DBL 3.8 respectively.
 
- Glycans    KCPDENFCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINK 
DBL 3.4      KCPDENFCKGIKNVLSCPPKNSTGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINK 
             **********************:************************************* 
 
- Glycans    VWHRIKDEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDY 
DBL 3.4      VWHRIKDEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDY 
             ************************************************************ 
 
- Glycans    QITKNINRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNM 
DBL 3.4      QITKNINRALDKILRNETSNDKIKKRVDWWEANKSAFWDAFMCGYKVHIGNKPCPEHDNM 
             *****************:****************:************************* 
 
- Glycans    DRIPQYLRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKH 
DBL 3.4      DRIPQYLRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKH 
             ************************************************************ 
 
- Glycans    YEEWVNRRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNTFKEFK 
DBL 3.4      YEEWVNRRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNTFKEFK 
             ************************************************************ 
 
- Glycans    D 
DBL 3.4      D 
             *	
(a)
 
- Glycans    KCPTEEICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRITLQDF 
DBL 3.8      KCPTEEICKDFSNLPQCRKNVHERNNWLGSSVKNFSSDNKGVLVPPRRQSLCLRITLQDF 
             ***********************************:************************ 
 
- Glycans    RTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTP 
DBL 3.8      RTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTP 
             ************************************************************ 
 
- Glycans    TSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNI 
DBL 3.8      TSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNI 
             ************************************************************ 
 
- Glycans    DDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKY 
DBL 3.8      DDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKY 
             ************************************************************ 
 
- Glycans    EEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEKCPECKCTKKNLQDVFELTFD 
DBL 3.8      EEWYNKRKTEWTEQSIKYNNDKINYTDIKTLSPSEYLIEKCPECKCTKKNLQDVFELTFD 
             *************************:********************************** 
	
(b)
Figure 3.3: Alignment of the wild type amino acid sequences of (a) DBL 3.4 and (b)
DBL 3.8 with the N-linked glycan sites removed (- Glycans). Glycan sites in the WT are
highlighted in red.
Mutation of N-linked glycosylation sites
In order to prevent the inappropriate addition of large glycans that are absent in P.
falciparum, potential N-linked glycosylation sites of the form N-X-S/T have been mutated
with Serine/Threonine residues substituted by Alanine (Figure 3.3). Three glycosylation
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sites have been removed from the 3.4 DBL domain and two from the 3.8 DBL domain. The
removal of N-linked glycosylation sites in the mammalian expression of the P. falciparum
protein RH5 has previously been shown to increase protein yield 5.5 fold (Crosnier et al.,
2013).
Codon optimisation for mammalian expression
The high A:T content of Plasmodium gene sequences means that codon usage is
significantly different to mammalian systems. In order to express DBL 3.4 and DBL
3.8 domains in mammalian expression systems the codon usage in the genes must be
modified. Codon optimised DNA for mammalian expression was kindly provide by Gavin
Wright (Wellcome Trust Sanger Institute, Hinxton, Cambridge).
Location of the DBL domains
When the work for this Chapter started, the exact DBL location was unknown. The DBL
sequence published by Wickramarachchi et al. (2009) is 44 amino acids shorter than the
sequence of the crystal structure published by Hodder et al. (2012). Prior to beginning
the cloning work for this Chapter, the DBL domain location was discussed and on advice
from Matt Higgins (University of Oxford) and Richard Pleass (Liverpool School of Tropical
Medicine) an extended version of the sequence by Wickramarachchi et al. (2009) was used.
The crystal structure was determined after the work in this Chapter was undertaken which
identified the exact location of the DBL. This was thirteen amino acids longer than the
DBL sequence used here, with six extra residues included at the N terminus and seven extra
at the C terminus. The location of the DBL domain and the Secreted polymorphic antigen
associated with merozoites (SPAM) domain is shown within the full length MSPDBL1
(Figure 3.4) and MSPDBL2 (Figure 3.5). The beginning and end of the shorter DBL
sequence used in this Chapter is marked with |.
70
3 PRODUCTION OF RECOMBINANT MSPDBL1 AND MSPDBL2 DBL DOMAINS
(a)
 
 
gccaccatggagtttcagacccaggtactcatgtccctgctgctctgcatgtctggtgcggccgccaac
gacctgatcaactacaacgacgccaacctgcggaacggcctgctgaacaacgccctggacctgaccaac
ggcctgaacaacaaggacaacagcttcatcgacagcaagatcgaggaacacgagaacaaggcctaccag
aacaaggataacaatatcgccatcgtgggccaggacgtgcccatcaccagcgtgtacagcagcaagatc
atcaacgccaacgatctggaaggcaacagcatcgacgacaccaagggcctgagcgtgaccaacagcggc
ttcgacgacggcagcgcctttggcggcggactgcctttcagcggctacagccccctgcagggcaaccac
aacaagtgccccgacgagaac|ttctgcaagggcatcaagaacgtgctgagctgccctcccaagaacag
cgccggcagaaacggcgactggatcagcgtggccgtgaaagagagcagcaccaccaacaagggcgtgct
ggtgccccccagacggaccaagctgtgcctgcggaacatcaacaaagtgtggcaccggatcaaggacga
gaagaacttcaaagaggaattcgtcaaggtcgcactgggcgagagcaacgccctgatgaagcactacaa
agagaagaacctgaacgccctgaccgccattaagtacggcttcagcgacatgggcgacatcatcaaggg
caccgacctgatcgattaccagatcaccaagaacatcaaccgggccctggacaagatcctgagaaacga
ggccagcaacgacaagatcaagaaacgggtggactggtgggaggccaacaaggccgccttctgggacgc
cttcatgtgcggctacaaggtgcacatcggcaacaagccctgccccgagcacgacaacatggaccggat
cccccagtacctgcggtggtttcgcgagtggggcacctacgtgtgcagcgagtacaagaacaagttcga
ggacgtgatcaagctgtgcaacatccagcagttcaccaaccaggacgacagccagctgctggaaatcag
caagaaagacaagtgcaaagaggccctgaaacactacgaggaatgggtcaaccggcggaggcccgagtg
gaagggccagtgcgataagttcgagaaagagaagtctaagtacgaggacaccaagagcatcaccgccga
gaagtacctgaaagaaatctgcagcgagtgcgactgcaagtacaaggacctggacaac|accttcaaag
aattcaaggacaacgtggccctgctgaaggccgtgatcgacaacaagaagaaccaggacagcctgacca
ccacaagcctgagcaccagcatcaacagcgtgcgggacagcagcaacctggaccagcggggcaacattg
ccaccagccagggcaacagccaccgggctaccgtggtgcagcaggtggaccagaccaacagactggaca
acgtgaacagcgtgacccagagaggcaacaacaactacaacaacaatctggaacggggcctgggctctg
gcgccctgcccggcaccaacatcatcaccgaggaaaagtacagcctggaactgattaagctgaccagca
aggacgaagaggatatcatcaagcacaacgaggacgtgcgcgaggaaattgaggaacagcaggaagata
ttgaagaggacgaggaagaactggaaaacgagggcgaggaaacaaaagaagaggacgacgaggaaaaga
acgaggccaacgacgccgaggacaccgacgacaccgaggatacagaggacatcgaagaggaaaacaaag
agaaagagctgagcaaccagcagcagagcgagaagaaatccatcagcaaggtggacgaggactcctacc
ggatcctgagcgtgtcctataaggacaacaacgaagtgaagaacgtggccgagagcatcgtgaagaagc
tgttcagcctgttcaacgataacaacaacctggaaaccatcttcaagggcctgaccgaggacatgaccg
acctgttccagaagggcgcgccgtcgacctccatcacggcctataagagtgagggggagtcagcggagt
tctccttcccactcaaccttggagaggaaagcctgcagggagagttgagatggaaggcagagaaggctc
cttcttcccagtcctggatcaccttctccctaaagaaccaaaaggtgtctgtgcagaagtctactagca
accccaagttccagctgtccgaaacgctcccactcacccttcagataccccaggtctcccttcagtttg
ctggttctggcaacctgaccctgactctggacagagggatactgtatcaggaagtgaacctggtggtga
tgaaagtgactcagcccgacagcaacactttgacctgtgaggtgatgggacccacctcacccaagatga
gactgatcttgaagcaggagaatcaggaggccagggtctccaggcaggagaaagtgattcaagtgcagg
cccctgaagcaggggtgtggcaatgtctactgagtgaaggtgaagaggtcaagatggactccaagatcc
aggttttatccaaagggttgaattccggatcactgcatcatattctggatgcacagaaaatggtgtgga
atcatcgttaa 
(b)
Figure 3.4: (a) Location of the 3.4 DBL within the full length MSPDBL1 amino acid
sequence. (b) Location of the 3.4 DBL within the full length MSPDBL1 nucleotide
sequence. The DBL domain is shown in red and the SPAM domain in green. The
DBL domain expressed in this Chapter is missing residues at either end compared to
the literature, the start and end location of the DBL expressed is marked with |.
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(a)
 
gccaccatggagtttcagacccaggtactcatgtccctgctgctctgcatgtctggtgcggccgcctac
agcacctgtttcgtggtcaacgagggcaaccccaacctgcggaacaacatcatcaacgacgacgagctg
aagggcaaggcctacaacaacgccatcgacgccaacaaccagaacatcgagtacaacaagaacctgaag
cacaacgtgaacagcgcccacatcagcaagttcagcgacatcatggaccaggaagataagggcgacaac
gagaacagccacgacatcaagttcgaggaaaagaagaacatcaacaaggccctggacgccgagagcaac
tacggcatcaacgagatcagcatcaccggcaacgacgccaactccgacaacagcaaccagaatatcttc
cccgacggcagcgagctggctggcggcatcccccggtccatctacaccatcaacctgggcttcaacaag
tgccccaccgaggaa|atctgcaaggacttcagcaacctgccccagtgccggaagaacgtgcacgagcg
gaacaactggctgggcagcagcgtgaagaacttcgccagcgacaacaagggcgtgctggtgccccccag
acggcagagcctgtgcctgagaatcaccctgcaggacttccggaccaagaagaagaaagagggcgactt
cgagaagttcatctacagctacgccagcagcgaggcccggaagctgcggaccatccacaacaacaacct
ggaaaaggcccaccaggccatccggtacagcttcgccgacatcggcaacatcatccggggcgacgacat
gatggacacccccaccagcaaagagacaatcacctatctggaaaaggtgctgaagatctacaatgagaa
caacgacaagcccaaggacgccaagaagtggtggaccgagaaccggcaccacgtgtgggaggccatgat
gtgcggctaccagagcgcccagaaagacaaccagtgcaccggctacggcaacatcgacgatatccccca
gttcctgcggtggttccgcgagtggggcacctacgtgtgcgaagagtccgagaagaacatgaataccct
gaaggccgtgtgcttccccaagcagcccagaaccgaggccaaccctgccctgaccgtgcacgagaacga
gatgtgcagcagcaccctgaagaaatacgaggaatggtacaacaagcgcaagaccgagtggaccgagca
gagcatcaagtataacaacgataagatcaactacgccgacatcaagaccctgagccccagcgagtacct
gatcgagaagtgccccgagtgcaagtgcaccaagaaaaacctgcaggac|gtgttcgagctgaccttcg
acggcaaggccctgctggaaaagctgaagaaagaagagtcccccgtctccaacagcgtgaacgccctgc
ccgagcccggccagatcaccctgcccgatcccagcctgaagcagaccacccagcaggaaaaccagcccg
tcgtcgaaacccccgtgaccaccgccgtgatcaacgagcaccagggccagaccgagcccaacaaggggg
acaacaacaatgagagagagaaccacgagagcaacgtgggcagcatccaggaagtgaaccagggcagcg
tgtccgaggaaagccacagcaagaccatcgaccccagcaagatcgacgaccggctggaactgagcagcg
gcagcagcagcctggaacagcacagcaaagaagatgtgaagaagggctgcgccctggaactggtgcccc
tgagcctgagcgacatcgagcagatcgccaacgaggccgaggacgtgctggaagagatcgaggaagaga
tcaacaccgacggcgagatcgagtacatcaccgaagaggaaatcaaagaggacattgaggaagagacag
aagaggatattgaagaggaaaccgaggaagaaaccgaagaagagactgaggaagaagccgacgaggaaa
ccgtgaaagagattgaggacaagcccgagcaggaaatcaagaacaaagccctggaagagaagcagatcg
acaagaacaccgacaccagcgagaagaagggattcaacaacgccgagaaggacgagaaggcccggaacc
tgatcagcaagaactacaagaattacaacgagctggacaagaatgtgcacaccctggtcaacagcatca
tcagcctgctggaagaaggcaacggcgccgactccaccctgaacagcctgagcaaggacatcaccaatc
tgttcaagaatggcgcgccgtcgacctccatcacggcctataagagtgagggggagtcagcggagttct
ccttcccactcaaccttggagaggaaagcctgcagggagagttgagatggaaggcagagaaggctcctt
cttcccagtcctggatcaccttctccctaaagaaccaaaaggtgtctgtgcagaagtctactagcaacc
ccaagttccagctgtccgaaacgctcccactcacccttcagataccccaggtctcccttcagtttgctg
gttctggcaacctgaccctgactctggacagagggatactgtatcaggaagtgaacctggtggtgatga
aagtgactcagcccgacagcaacactttgacctgtgaggtgatgggacccacctcacccaagatgagac
tgatcttgaagcaggagaatcaggaggccagggtctccaggcaggagaaagtgattcaagtgcaggccc
ctgaagcaggggtgtggcaatgtctactgagtgaaggtgaagaggtcaagatggactccaagatccagg
ttttatccaaagggttgaattccggatcactgcatcatattctggatgcacagaaaatggtgtggaatc
atcgttaa 	 (b)
Figure 3.5: (a) Location of the 3.8 DBL within the full length MSPDBL2 amino acid
sequence. (b) Location of the 3.8 DBL within the full length MSPDBL2 nucleotide
sequence. The DBL domain is shown in red and the SPAM domain in green. The
DBL domain expressed in this Chapter is missing residues at either end compared to
the literature, the start and end location of the DBL expressed is marked with |.
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3.3.2 Amplification of DNA
PCR primers for amplification of DBL 3.4 and DBL 3.8 from MSPDBL1 and
MSPDBL2 digested products.
Primers were designed to remove the DBL domain from the full length gene and to
introduce flanking restriction enzyme (RE) sites before and after the DBL domain by
PCR for subcloning. For DBL 3.4, BglII and NcoI sites were chosen as they are unique
RE sites present in the multiple cloning region of the pFUSE vector. For DBL 3.8, EcoRI
and NcoI sites were chosen (see Table 3.1 for oligonucleotide sequences).
Table 3.1: PCR primers for amplification of DBL 3.4 and DBL 3.8 domains. Restriction
sites are highlighted in red.
Primer Sequence Annealing
Temperature (◦C)
3.4 Forward atc ggc cat ggt ttt ctg caa ggg cat caa 68.1
3.4 Reverse gtt ttg tca gat ctg ttg tcc agg tcc 65.0
3.8 Forward cgg aat tcg atc tgc aag gac ttc agc 61.0
3.8 Reverse ttg tca gat cta acc atg gcg tcc tgc a 66.6
PCR reaction
The PCR solution used to amplify the MSPDBL domains and to add restriction sites was
composed of:
• dNTP (2.5 mM) 20 μl
• Forward primer (10 μM) 10 μl
• Reverse primer (10 μM) 10 μl
• DNA 200 ng
• Taq buffer 20 μl
• Taq polymerase 10 μl
• dH2O up to 200 μl
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The following PCR program was used:
94◦ C 3 mins
25 cycles

94◦ C 1 min
60◦ C 1 min
74◦ C 1 min
72◦ C 5 mins.
A small amount of the PCR product was run on an agarose gel to check that the
band of interest had been amplified (Section 2.2.5). Once it was confirmed that the PCR
reaction was successful, the rest of the PCR product was purified from solution (Section
2.2.3) prior to ligation.
3.3.3 TOPO Ligation to the 3.4 DBL and 3.8 DBL domains
Due to the use of Taq polymerase in the PCR reaction, which adds a single deoxyadenosine
(A) to the 3’ end of the PCR product, the PCR product was cloned by TOPO cloning.
The PCR product was added directly into the Topoisomerase 1-activated pCR2.1-TOPO
plasmid which contains a single 3’ thymidine (T) overhang and has Topoisomerase 1
covalently bound. The reaction was done according to manufacturer’s instructions.
The following reaction was set up on ice:
• PCR product 4 μl
• Salt solution 1 μl
• TOPO vector 1 μl.
The ligation reaction was incubated at room temperature for 5 minutes before being
placed on ice and transformed into competent cells.
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3.3.4 Transformation of competent cells with pCR2.1-TOPO-3.4 and
pCR2.1-TOPO-3.8 constructs
Before transforming competent cells with the TOPO constructs, agarose plates containing
50 μg/ml ampicillin (Section 2.1.16) were prepared by spreading 40 μl of 40 mg/ml
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) and 40 μl of 100mM Isopropyl
β-D-1-thiogalactopyranoside (IPTG) on the plates and drying them at 37◦C prior to use.
2 μl of the TOPO ligation reaction was added to a vial of OneShot (TOP10) competent
cells which had been pre-thawed on ice, and the mixture was incubated on ice for 30
minutes. Cells were then heat shocked in a water bath at 42◦C for 30 seconds before
immediately being transferred to ice. 250 μl of pre-warmed S.O.C media was added to the
cell mixture and the tube shaken horizontally for 1 hour at 225 rpm in a shaker incubator
at 37◦C. 10 - 50 μl of each transformation was spread onto the prepared selective plates
and incubated overnight at 37◦C. White or light blue colonies were selected for screening
(Section 2.2.12).
Restriction digest analysis of positive colonies
White and light blue colonies selected for screening were grown in overnight cultures and
DNA extracted by mini-prep (Section 2.2.11). DNA was then digested using restriction
enzymes in order to identify correct orientation of the insert.
The digestion reaction consisted of the following solution:
• Restriction enzyme 1 1 μl
• Restriction enzyme 2 1 μl
• Compatible Buffer 5 μl
• BSA (10x) 5 μl
• DNA 1 μg
• dH2O up to 50 μl.
For the pCR2.1-TOPO-3.4 construct, restriction enzymes Nco1 and BglII were used
with NEB buffer 3.1. For the pCR2.1-TOPO-3.8 construct, restriction enzymes Nco1 and
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EcoRI were used with NEB buffer 3.1. Restriction digests were incubated at 37◦C for
2 hours and then the product checked by gel electrophoresis (Section 2.2.5) in order to
confirm the presence of the insert.
DNA Sequencing
In order to confirm the pCR2.1-TOPO-3.4 and pCR2.1-TOPO-3.8 constructs, DNA from
any positive colony which had the presence of the insert confirmed by restriction digest,
was sent for sequencing (Section 2.2.13). The commercially available universal M13F and
M13R sequencing primers were used (Table 2.2).
Maxi-prep
Once the pCR2.1-TOPO-3.4 and pCR2.1-TOPO-3.8 constructs were confirmed by
sequencing, plasmid DNA was transformed (Section 2.2.10) directly into competent cells
and a single colony transferred to a large scale culture in order to amplify the plasmid.
Plasmid DNA was then purified using QIAprep Spin Maxiprep kit (Section 2.2.14) and
sequenced again to confirm the construct.
3.3.5 DNA preparation for sub-cloning into pFuse construct
Restriction digest of TOPO constructs
The DNA inserts were cut out of the TOPO constructs by restriction digest. The digestion
reaction consisted of the following solution:
• Restriction enzyme 1 1 μl
• Restriction enzyme 2 1 μl
• Compatible Buffer 5 μl
• BSA (10x) 5 μl
• pCR2.1-TOPO-DBL construct 1 μg
• dH2O up to 50 μl
For the pCR2.1-TOPO-3.4 construct restriction enzymes NcoI and BglII were used
with NEB buffer 3.1. For the pCR2.1-TOPO-3.8 construct restriction enzymes NcoI and
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EcoRI were used with NEB buffer 3.1. Restriction digests were incubated at 37◦C for
2 hours and the products separated by gel electrophoresis (Section 2.2.5). 3.4 DBL
and 3.8 DBL inserts were identified, excised and gel purified (Section 2.2.6). DNA
concentrations of the purified inserts were calculated using a nanodrop spectrophotometer
(Section 2.2.15).
Restriction digest of pFUSE plasmid
The pFUSE plasmid was prepared for sub-cloning by restriction digest. Two preparations
were made for sub-cloning in each of the DBL domains.
The digestion reaction consisted of the following solution:
• Restriction enzyme 1 1 μl
• Restriction enzyme 2 1 μl
• Compatible Buffer 5 μl
• BSA (10x) 5 μl
• pFUSE-hIgG1-Fc2 1 μg
• dH2O up to 50 μl
For preparation of sub-cloning with the 3.4 DBL domain, restriction enzymes NcoI
and BglII were used with NEB buffer 3.1. For preparation of sub-cloning with the
3.8 DBL domain, restriction enzymes NcoI and EcoRI were used with NEB buffer 3.1.
Restriction digests were incubated at 37◦C for 2 hours and the products separated by gel
electrophoresis (Section 2.2.5). Digested vectors were identified, excised and gel purified
(Section 2.2.6). DNA concentrations of the purified vectors were calculated using a
nanodrop spectrophotometer (Section 2.2.15).
pFUSE vector de-phosphorylation
In order to prevent self-ligation of the pFUSE vector, the digested vectors were
de-phosphorylated using Shrimp Alkaline phosphatase (rSAP) prior to gel elution.
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The following reaction was setup on ice:
• Vector 5μg
• Shrimp alkaline phosphatase 20 μl
• Cutsmart buffer 20 μl
• dH2O up to 200 μl.
The reaction was held at 37◦C in a water bath for 1 hour before placing on a heat
block set to 65◦C for 30 minutes to deactivate the phosphatase.
3.3.6 pFUSE ligation to the 3.4 DBL and 3.8 DBL domains
The following reaction with a molar ratio of 1:3 vector to insert was set-up on ice:
• 10x T4 DNA ligase buffer 2 μl
• Vector DNA (4.2 kb) 31 ng
• Insert DNA (860 bp) 19 ng
• T4 DNA ligase 1 μl
• dH2O up to 20 μl.
The ligation reaction was held at 16◦ for 16 hours using a Progene thermocycler.
3.3.7 Transformation of competent cells with pFUSE-3.4 and pFUSE-3.8
A 50 μl vial of competent TOP10 cells was defrosted on ice. 5 μl of the ligated construct
was added and the cells incubated on ice for 30 mins. The cells were given a heat shock in
a water bath at 42◦C for 30 seconds and then returned to ice for 2 mins. 250 μl of S.O.C
media was added and then the cells shaken at 225 rpm, 37◦C for 1 hour.
Agarose plates containing 25 µg/ml zeocin (Section 2.1.16) were prepared and
pre-warmed to 37◦C. 5–200 μl of the transformation reaction was spread onto the agarose
plates and plates incubated at 37◦C overnight for colonies to form.
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Restriction digest analysis of DNA from positive colonies
Single colonies were grown overnight at 37◦C in 5 ml cultures with vigorous shaking (225
rpm) and DNA purified by mini-prep (Section 2.2.11). DNA was then digested using
restriction enzymes NcoI and BglII with NEB buffer 3.1 for the pFuse-3.4 construct, and
NcoI and EcoRI with NEB buffer 3.1 for the pFuse-3.8 construct.
The digestion reaction consisted of the following solution:
• Restriction enzyme 1 1 μl
• Restriction enzyme 2 1 μl
• Compatible Buffer 5 μl
• BSA (10x) 5 μl
• pFUSE-DBL construct 1 μg
• dH2O up to 50 μl.
Restriction digests were incubated at 37◦C for 2 hours and then the product visualised
by gel electrophoresis (Section 2.2.5). DNA preparations with the correct inserts were
identified and sent for DNA sequencing to confirm (Section 2.2.13).
Maxi-prep
1 μl DNA containing the confirmed pFUSE-DBL constructs was transformed directly
into TOP10 cells and colonies picked and grown for 8 hours at 37◦C (225 rpm) in 5 ml
cultures before being transferred to 250 ml cultures and grown overnight under the same
conditions. The DNA was then extracted using QIAprep Spin Maxiprep kit (Section
2.2.14) and sequenced (Section 2.2.13).
Primers for sequencing of the pFUSE constructs
Primers for the sequencing of the pFUSE constructs were designed using Primer3Plus
http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/ (Table
2.2).
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3.3.8 Expression of 3.4 and 3.8 DBL recombinant protein
Once the DBL-Fc fusion constructs had been made they were expressed in mammalian
cells.
CHO-KI cell transfection
CHO-KI cells were prepared for transfection (Section 2.3.1) by growing cultures until the
cells were 50 − 80% confluent. Cells were transfected using the FuGENE 6 Transfection
Reagent. In a sterile tube containing 3 μg of plasmid DNA, 100 μl of medium was added
and 9 μl of FuGENE 6 was added directly to the mixture. The tube was vortexed gently
to mix and incubated at room temperature for 15 mins.
5 x 105 cells were added to 10 ml DMEM and, following incubation, the DNA/FuGENE
was added to the CHO-KI cells, mixed and added to tissue-culture plates. 24 hours after
transfection, the medium was replaced with DMEM selection media (Section 2.1.15).
Production of polyclonal population
After 7 - 9 days, transfected cells were passaged to expand the polyclonal population.
Cells were washed in 10 ml sterile PBS before coating with trypsin and incubating for 5
mins at 37◦C. Cells were resuspended in DMEM selection medium and expanded in small
then medium-sized flasks. Polyclonal populations were frozen down for long-term storage
when 80% confluent (Section 2.3.5).
Production of monoclonal population
Polyclonal populations were diluted to 10 cells/ml and 100 μl plated in each well of 96 well
plate. 10 μl of supernatant from wells where single cells could be seen to have formed a
colony was harvested after 9 days, and protein detected by immunoblot analysis (Section
2.4.2). The colonies found to be producing the most protein were expanded further. A
single colony was transferred to a single well of a 24-well plate before being expanded to
a small flask, and subsequently into medium flasks to expand the clonal cell line. Finally,
clonal cell lines were cultured in 4 large tissue-culture flasks for 10 days to produce 200 ml
supernatant containing protein from the monoclonal population. Timescales for expanding
the single colony up to medium flasks was flexible depending on the rate of cell growth.
However, all cultures seeded into large flasks were cultured for a period of exactly 10 days
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to produce protein.
FPLC purification of recombinant DBL protein
Cell supernatants containing protein were filter sterilised by vacuum using Steritop GP
Sterlisation Unit 0.22 μm PES membrane (Millipore). Sterile cell supernatants were
purified using the liquid chromatography system A¨KTA-FPLC Frac-950 (Amersham
Biosciences/GE Healthcare, Uppsala, Sweden). A 1 ml protein-G sepharose HiTrap
column (GE Healthcare) was used and equilibrated by washing with a minimum 20 ml
of HBSS buffer. Supernatant was loaded onto the column at a flow rate < 0.5 ml/min.
Once fully loaded, the column was thoroughly washed with a minimum 30 ml of HBSS
buffer to remove any unbound sample. Protein was eluted using an increasing gradient of
0.1M glycine-HCl, pH 2.5 and collected in 2 ml fractions. Eluates were neutralised with
1M Tris-HCl pH 9 and stored with 0.2% sodium azide at 4◦C.
Immunoblot to test for the presence of recombinant DBL protein
FPLC fractions were tested for the presence of recombinant DBL protein using immunoblot
analysis. 5 μl of each fraction was blotted onto nitrocellulose and blocked with PBS-tween
plus 5% milk for 2 hours at 37◦C on a rocker. The nitrocellulose was washed in PBST and
anti-human IgG (Fc-specific) Alkaline Phosphatase antibody (Sigma A9544) was added
at a dilution of 1:5,000 and incubated overnight at 37◦C on a rocker. The blot was
developed using NBT/BCIP tablets (Table 2.12) according to manufacturer’s instructions.
Fractions containing protein were combined and concentrated by ultrafiltration (Section
2.4.3). The flow-through liquid was also tested for protein; if protein was still present in
the flow-through it was passed over the column again in order to extract all the sample.
3.3.9 ELISA for Fc detection
Duplicate wells of Nunc-maxisorp micrometer plates were coated with 100 μl of αhIgG-Fc
(Life Technologies H1000) at a dilution of 1:1000 in 0.5 M carbonate/bicarbonate buffer
(pH 9.6) and incubated at 4◦C overnight. Any uncoated material was then discarded and
the plates were blocked with 200 μl blocking buffer (Section 2.1.8) and incubated for 1
hour at room temperature on a rocker. Wells were washed in PBST (PBS + 0.05% Tween
20) 5 times before the addition of tissue culture supernatants and IVIG in duplicate wells.
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Supernatants were coated in pure, 1:10 and 1:100 dilutions in media and intravenous
immunoglobulin (IVIG) was coated in doubling dilutions starting at 50 μg/ml and reducing
to 0.19 μg/ml. The plate was incubated at room temperature for 2 hours on a platform
shaker. Wells were washed in PBST 5 times before the addition of 100 μl per well of
detecting antibody αhIgG(Fc specific)-HRP (A0170, Sigma) at a dilution of 1:500 in PBS.
The plate was incubated for 1 hour at room temperature on a platform shaker. Plates were
washed as before and then developed using 3’3’5’5’tetramethylbenzidine dihydrochloride
(one tablet in 10 ml phosphate citrate buffer). 100 μl of substrate buffer was added to
each well and the plate was allowed to develop for 10 - 20 mins. 50 μl H2SO4 was added
per well to stop the reaction. The absorbance was read at 450 nm on an Expert plus plate
reader (Biochrom, SLS).
Protein concentrations were calculated by plotting absorbance on the IVIG standard
curve and adjusting for dilution.
3.3.10 IgM-binding ELISA
Duplicate wells of Nunc-maxisorp micrometer plates were coated with 100 μl of
unconjugated αhIgM (Sigma I6385) at a dilution of 1:5000 in 0.5 M carbonate/bicarbonate
buffer (pH 9.6) and incubated at 4◦C overnight. Any uncoated material was then discarded
and the plates blocked with 200 μl blocking buffer (Section 2.1.8) and incubated for 1 hour
at room temperature on a rocker. Wells were washed in PBST 5 times before the addition
of hIgM at a concentration of 10 μg/ml in PBS. The plate was incubated for 2 hours at
room temperature on a rocker before washing all wells 5 times in PBST. DBL domain
proteins were added at a range of dilutions in 0.1 M Glycine Tris-HCl pH 7.0. The plate
was further incubated for 2 hours at room temperature on a rocker. Wells were washed
5 times in PBST before the addition of αhIgG-AP (Sigma A9544) at a dilution of 1:5000
in PBS, and incubated for 1 hour at room temperature. Plates were then washed as
before and then developed using SIGMAFASTTM p-Nitrophenyl Phosphate tablets (20ml
solution containing 1.0 mg/ml pNPP, 0.2 M Tris buffer and 5 mM magnesium chloride).
100 μl of substrate buffer was added to each well and the plate was allowed to develop.
The absorbance was read at 405 nm.
Protein concentration was plotted against absorbance for each DBL domain. This
enabled binding to be compared directly between different DBL domains.
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3.3.11 Western blot
Proteins were run on a NuPAGE Novex 4-12% Bis-Tris pre-cast gel (Section 2.4.6) and
transferred to nitrocellulose for Western blotting (Section 2.4.8). After blocking for 2
hours the membrane was washed three times.
To detect the presence of the IgG-Fc, the membrane was incubated with αhIgG-Fc-AP
(Sigma A9544) at a dilution 1:5000 in PBST overnight at 37◦C on a rocker. The membrane
was again washed three times before proteins were visualised by developing BCIP/NBT
tablets (Sigma) according to manufacturer’s instructions.
3.3.12 Gel filtration of recombinant DBL domains
Recombinant DBL proteins were separated by gel filtration using the Superdex 200
10/300 GL column (GE Healthcare) on the liquid chromatography system A¨KTA-FPLC
Frac-950. The column was equilibrated by washing with a minimum of 50 ml of 20 mM
sodium phosphate pH 7.0. Lyophilised gel filtration standards (Bio-Rad) were prepared
to manufacturer’s instructions and 0.1 - 0.5 ml injected at a flow rate of < 0.85 ml/min.
Fractions were eluted and collected, and peaks corresponding to the molecular weight
markers were noted (Figure 2.2). The column was washed again with 50 ml of 20 mM
sodium phosphate pH 7.0 to remove any trace of the markers. A volume of between 0.1
- 0.5 ml DBL-Fc construct were then added to the column and proteins separated and
collected using the same flow rate as the markers.
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3.4 Results
3.4.1 Production of pCR2.1-TOPO-DBL constructs
DBL 3.4 and DBL 3.8 were first cloned into the PCR2.1-TOPO vector (Invitrogen, UK).
TOPO TA cloning was chosen so that the DNA could be quickly inserted into the plasmid.
Amplification with Taq polymerase adds a single Adenosine (A) to the 3’ end. The
vector PCR2.1-TOPO contains single 3’-thymidine (T) overhangs and is activated with
Topoisomerase I so that the Taq-amplified DNA can be inserted directly. This produced
a stock of cloning plasmid quickly, reliably and at a low cost which was used for further
sub-cloning.
The DBL domains were amplified from the full-length gene and flanking restriction
sites introduced by PCR to enable sub-cloning into the pFUSE vector (Section 3.3.2 for
methods). For DBL 3.4, BglII and NcoI sites were used and for DBL 3.8, EcoRI and NcoI
sites were used. These restriction sites were also used for checking the constructs.
3.4.1.1 Restriction Digest
Restriction digest of DNA extracted from white colonies after transformation of
competent cells confirms that the DBL domains have been inserted in the correct
orientation into the pCR2.1-TOPO plasmid. The constructs produced have been named
pCR2.1-TOPO-DBL3.4 and pCR2.1-TOPO-DBL3.8 (See Appendix A.2 and A.3 for
plasmid maps). When cut by restriction digest (NcoI and BglII for DBL 3.4 and EcoRI
and NcoI for DBL 3.8), the plasmids have fragments of size 596bp, 872bp, 994bp, 2347bp
and 869bp, 1578bp, 2334bp respectively (Figure 3.6) which is as predicted.
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Figure 3.6: Lane 1: pCR2.1-TOPO-DBL3.4 digested with restriction sites NcoI and BglII.
The restriction digest releases fragments of 596bp, 872bp, 994bp and 2347bp from the
4809bp plasmid. Lane 2: pCR2.1-TOPO-DBL3.8 digested with restriction sites EcoRI
and NcoI. The restriction digest releases fragments of 869bp, 1578bp and 2335bp, from
the 4782bp plasmid.
3.4.1.2 Sequencing Results
pCR2.1-TOPO-DBL3.4 sequencing results show the nucleotide sequence of the positive
colony selected from transformation of the construct into E.coli cells and identified by
restriction digest. The sequence is aligned against the 3.4 DBL domain nucleotide sequence
(Figure 3.7). Restriction sites NcoI and BglII are shown in red. The sequences have 100%
sequence identity.
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3.4 DBL        -------------------------------------------TTCTGCAAGGGCATCAA 
3.4 +VE        AACGGCCGCCAGTGTGCTGGAATTCGGCTTATCGGCCATGGTTTTCTGCAAGGGCATCAA 
                                                          ***************** 
 
3.4 DBL        GAACGTGCTGAGCTGCCCTCCCAAGAACAGCGCCGGCAGAAACGGCGACTGGATCAGCGT 
3.4 +VE        GAACGTGCTGAGCTGCCCTCCCAAGAACAGCGCCGGCAGAAACGGCGACTGGATCAGCGT 
               ************************************************************ 
 
3.4 DBL        GGCCGTGAAAGAGAGCAGCACCACCAACAAGGGCGTGCTGGTGCCCCCCAGACGGACCAA 
3.4 +VE        GGCCGTGAAAGAGAGCAGCACCACCAACAAGGGCGTGCTGGTGCCCCCCAGACGGACCAA 
               ************************************************************ 
 
3.4 DBL        GCTGTGCCTGCGGAACATCAACAAAGTGTGGCACCGGATCAAGGACGAGAAGAACTTCAA 
3.4 +VE        GCTGTGCCTGCGGAACATCAACAAAGTGTGGCACCGGATCAAGGACGAGAAGAACTTCAA 
               ************************************************************ 
 
3.4 DBL        AGAGGAATTCGTCAAGGTCGCACTGGGCGAGAGCAACGCCCTGATGAAGCACTACAAAGA 
3.4 +VE        AGAGGAATTCGTCAAGGTCGCACTGGGCGAGAGCAACGCCCTGATGAAGCACTACAAAGA 
               ************************************************************ 
 
3.4 DBL        GAAGAACCTGAACGCCCTGACCGCCATTAAGTACGGCTTCAGCGACATGGGCGACATCAT 
3.4 +VE        GAAGAACCTGAACGCCCTGACCGCCATTAAGTACGGCTTCAGCGACATGGGCGACATCAT 
               ************************************************************ 
 
3.4 DBL        CAAGGGCACCGACCTGATCGATTACCAGATCACCAAGAACATCAACCGGGCCCTGGACAA 
3.4 +VE        CAAGGGCACCGACCTGATCGATTACCAGATCACCAAGAACATCAACCGGGCCCTGGACAA 
               ************************************************************ 
 
3.4 DBL        GATCCTGAGAAACGAGGCCAGCAACGACAAGATCAAGAAACGGGTGGACTGGTGGGAGGC 
3.4 +VE        GATCCTGAGAAACGAGGCCAGCAACGACAAGATCAAGAAACGGGTGGACTGGTGGGAGGC 
               ************************************************************ 
 
3.4 DBL        CAACAAGGCCGCCTTCTGGGACGCCTTCATGTGCGGCTACAAGGTGCACATCGGCAACAA 
3.4 +VE        CAACAAGGCCGCCTTCTGGGACGCCTTCATGTGCGGCTACAAGGTGCACATCGGCAACAA 
               ************************************************************ 
 
3.4 DBL        GCCCTGCCCCGAGCACGACAACATGGACCGGATCCCCCAGTACCTGCGGTGGTTTCGCGA 
3.4 +VE        GCCCTGCCCCGAGCACGACAACATGGACCGGATCCCCCAGTACCTGCGGTGGTTTCGCGA 
               ************************************************************ 
 
3.4 DBL        GTGGGGCACCTACGTGTGCAGCGAGTACAAGAACAAGTTCGAGGACGTGATCAAGCTGTG 
3.4 +VE        GTGGGGCACCTACGTGTGCAGCGAGTACAAGAACAAGTTCGAGGACGTGATCAAGCTGTG 
               ************************************************************ 
 
3.4 DBL        CAACATCCAGCAGTTCACCAACCAGGACGACAGCCAGCTGCTGGAAATCAGCAAGAAAGA 
3.4 +VE        CAACATCCAGCAGTTCACCAACCAGGACGACAGCCAGCTGCTGGAAATCAGCAAGAAAGA 
               ************************************************************ 
 
3.4 DBL        CAAGTGCAAAGAGGCCCTGAAACACTACGAGGAATGGGTCAACCGGCGGAGGCCCGAGTG 
3.4 +VE        CAAGTGCAAAGAGGCCCTGAAACACTACGAGGAATGGGTCAACCGGCGGAGGCCCGAGTG 
               ************************************************************ 
 
3.4 DBL        GAAGGGCCAGTGCGATAAGTTCGAGAAAGAGAAGTCTAAGTACGAGGACACCAAGAGCAT 
3.4 +VE        GAAGGGCCAGTGCGATAAGTTCGAGAAAGAGAAGTCTAAGTACGAGGACACCAAGAGCAT 
               ************************************************************ 
 
3.4 DBL        CACCGCCGAGAAGTACCTGAAAGAAATCTGCAGCGAGTGCGACTGCAAGTACAAGGACCT 
3.4 +VE        CACCGCCGAGAAGTACCTGAAAGAAATCTGCAGCGAGTGCGACTGCAAGTACAAGGACCT 
               ************************************************************ 
 
3.4 DBL        GGACAAC----------------------------------------------------- 
3.4 +VE        GGACAACAGATCTGACAAAACAAGCCGAATTCTGCAGATATCCATCACACTGGCGGCCGC 
               *******                                                      
 
 Figure 3.7: Alignment of pCR2.1-TOPO-DBL3.4 nucleotides with 3.4 DBL shows 100%
sequence identity.
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3.8 DBL       ------------------------------------------------------------ 
3.8 +VE       TAGTAACGGCCGCCAGTGTGCTGGAATTCGGATCCACTAGTAACGGCCGCCAGTGTGCTG 
                                                                           
 
3.8 DBL       ---------------------ATCTGCAAGGACTTCAGCAACCTGCCCCAGTGCCGGAAG 
3.8 +VE       GAATTCGCCCTTCGGAATTCGATCTGCAAGGACTTCAGCAACCTGCCCCAGTGCCGGAAG 
                                   *************************************** 
 
3.8 DBL       AACGTGCACGAGCGGAACAACTGGCTGGGCAGCAGCGTGAAGAACTTCGCCAGCGACAAC 
3.8 +VE       AACGTGCACGAGCGGAACAACTGGCTGGGCAGCAGCGTGAAGAACTTCGCCAGCGACAAC 
              ************************************************************ 
 
3.8 DBL       AAGGGCGTGCTGGTGCCCCCCAGACGGCAGAGCCTGTGCCTGAGAATCACCCTGCAGGAC 
3.8 +VE       AAGGGCGTGCTGGTGCCCCCCAGACGGCAGAGCCTGTGCCTGAGAATCACCCTGCAGGAC 
              ************************************************************ 
 
3.8 DBL       TTCCGGACCAAGAAGAAGAAAGAGGGCGACTTCGAGAAGTTCATCTACAGCTACGCCAGC 
3.8 +VE       TTCCGGACCAAGAAGAAGAAAGAGGGCGACTTCGAGAAGTTCATCTACAGCTACGCCAGC 
              ************************************************************ 
 
3.8 DBL       AGCGAGGCCCGGAAGCTGCGGACCATCCACAACAACAACCTGGAAAAGGCCCACCAGGCC 
3.8 +VE       AGCGAGGCCCGGAAGCTGCGGACCATCCACAACAACAACCTGGAAAAGGCCCACCAGGCC 
              ************************************************************ 
 
3.8 DBL       ATCCGGTACAGCTTCGCCGACATCGGCAACATCATCCGGGGCGACGACATGATGGACACC 
3.8 +VE       ATCCGGTACAGCTTCGCCGACATCGGCAACATCATCCGGGGCGACGACATGATGGACACC 
              ************************************************************ 
 
3.8 DBL       CCCACCAGCAAAGAGACAATCACCTATCTGGAAAAGGTGCTGAAGATCTACAATGAGAAC 
3.8 +VE       CCCACCAGCAAAGAGACAATCACCTATCTGGAAAAGGTGCTGAAGATCTACAATGAGAAC 
              ************************************************************ 
 
3.8 DBL       AACGACAAGCCCAAGGACGCCAAGAAGTGGTGGACCGAGAACCGGCACCACGTGTGGGAG 
3.8 +VE       AACGACAAGCCCAAGGACGCCAAGAAGTGGTGGACCGAGAACCGGCACCACGTGTGGGAG 
              ************************************************************ 
 
3.8 DBL       GCCATGATGTGCGGCTACCAGAGCGCCCAGAAAGACAACCAGTGCACCGGCTACGGCAAC 
3.8 +VE       GCCATGATGTGCGGCTACCAGAGCGCCCAGAAAGACAACCAGTGCACCGGCTACGGCAAC 
              ************************************************************ 
 
3.8 DBL       ATCGACGATATCCCCCAGTTCCTGCGGTGGTTCCGCGAGTGGGGCACCTACGTGTGCGAA 
3.8 +VE       ATCGACGATATCCCCCAGTTCCTGCGGTGGTTCCGCGAGTGGGGCACCTACGTGTGCGAA 
              ************************************************************ 
 
3.8 DBL       GAGTCCGAGAAGAACATGAATACCCTGAAGGCCGTGTGCTTCCCCAAGCAGCCCAGAACC 
3.8 +VE       GAGTCCGAGAAGAACATGAATACCCTGAAGGCCGTGTGCTTCCCCAAGCAGCCCAGAACC 
              ************************************************************ 
 
3.8 DBL       GAGGCCAACCCTGCCCTGACCGTGCACGAGAACGAGATGTGCAGCAGCACCCTGAAGAAA 
3.8 +VE       GAGGCCAACCCTGCCCTGACCGTGCACGAGAACGAGATGTGCAGCAGCACCCTGAAGAAA 
              ************************************************************ 
 
3.8 DBL       TACGAGGAATGGTACAACAAGCGCAAGACCGAGTGGACCGAGCAGAGCATCAAGTATAAC 
3.8 +VE       TACGAGGAATGGTACAACAAGCGCAAGACCGAGTGGACCGAGCAGAGCATCAAGTATAAC 
              ************************************************************ 
 
3.8 DBL       AACGATAAGATCAACTACGCCGACATCAAGACCCTGAGCCCCAGCGAGTACCTGATCGAG 
3.8 +VE       AACGATAAGATCAACTACGCCGACATCAAGACCCTGAGCCCCAGCGAGTACCTGATCGAG 
              ************************************************************ 
 
3.8 DBL       AAGTGCCCCGAGTGCAAGTGCACCAAGAAAAACCTGCAGGAC------------------ 
3.8 +VE       AAGTGCCCCGAGTGCAAGTGCACCAAGAAAAACCTGCAGGACGCCATGGTTAGATCTGAC 
              ******************************************                   
 
3.8 DBL       --------------------------------- 
3.8 +VE       AAAGCCGAATTCTGCAGATATCCATCACACTGG	
Figure 3.8: Alignment of pCR2.1-TOPO-DBL3.8 nucleotides with 3.8 DBL shows 100%
sequence identity.
pCR2.1-TOPO-DBL3.8 sequencing results show the sequenced nucleotide sequence
of the positive colony selected from transformation of the construct into E.coli cells and
identified by restriction digest. The sequence is aligned against the confirmed DBL domain
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nucleotide sequence (Figure 3.8). Restriction sites EcoRI and NcoI are shown in red. The
sequences have 100% sequence identity.
Alignment of the protein sequences translated from sequencing results with the
known DBL sequences confirms the correct insertion of the DBL domain inserts into
the pCR2.1-TOPO plasmid (Figure 3.9). The pCR2.1-TOPO-3.4 and pCR2.1-TOPO-3.8
constructs have successfully been produced and are ready for sub-cloning.
3.4 TOPO    FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK   
            FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 
3.4 DBL     FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK   
 
3.4 TOPO    DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI   
            DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 
3.4 DBL     DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI   
 
3.4 TOPO    NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY   
            NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 
3.4 DBL     NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY   
 
3.4 TOPO    LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN   
            LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 
3.4 DBL     LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN   
 
3.4 TOPO    RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDN   
            RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDN 
3.4 DBL     RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDN 
 
 
 
 
 	
(a)
3.8 TOPO    ICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRITLQDFRTKKKK   
            ICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRITLQDFRTKKKK 
3.8 DBL     ICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRITLQDFRTKKKK   
 
3.8 TOPO    EGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETI   
            EGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETI 
3.8 DBL     EGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETI   
 
3.8 TOPO    TYLEKVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQF   
            TYLEKVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQF 
3.8 DBL     TYLEKVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQF   
 
3.8 TOPO    LRWFREWGTYVCEESEKNMNTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNK   
            LRWFREWGTYVCEESEKNMNTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNK 
3.8 DBL     LRWFREWGTYVCEESEKNMNTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNK   
 
3.8 TOPO    RKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEKCPECKCTKKNLQD   
            RKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEKCPECKCTKKNLQD 
3.8 DBL     RKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEKCPECKCTKKNLQD   
 
 
 	 (b)
Figure 3.9: Alignment of (a) pCR2.1-TOPO-DBL3.4 and (b) pCR2.1-TOPO-DBL3.8
amino acids with the known DBL amino acid sequences.
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3.4.2 Production of pFUSE constructs
The pCR2.1-TOPO-DBL3.4 and pCR2.1-TOPO-DBL3.8 constructs were used to
sub-clone DBL 3.4 and DBL 3.8 into the pFuse-hIgG1-Fc2 plasmid to create the expression
vectors pFuse-hIgG1-Fc2-DBL3.4 and pFuse-hIgG1-Fc2-DBL3.8.
Firstly, the DBL domain was cut out of the pCR2.1-TOPO-DBL3.4 plasmid using
restriction enzymes NcoI and BglII while the pFuse-hIgG1-Fc2 plasmid was prepared by
digestion using the same restriction enzymes. Similarly, the DBL domain was cut out of
the pCR2.1-TOPO-DBL3.8 plasmid using restriction enzymes NcoI and EcoRI while the
pFuse-hIgG1-Fc2 plasmid was also prepared by digestion using NcoI and EcoRI (Section
3.3.5). Digested inserts were separated from TOPO plasmid by gel electrophoresis and
purified (Section 2.2.6) while digested pFUSE-hIgG1-Fc2 plasmid was also purified from
agarose. The cut vector was de-phosphorylated to prevent self-ligation (Section 3.3.5).
Prepared pFUSE-hIgG1-Fc2 plasmid was ligated to the prepared DBL inserts (Section
3.3.6).
3.4.2.1 Screening of positive colonies
The ligation product was transformed into TOP10 competent cells (Section 2.2.10) and
colonies screened for the insert using restriction digest (Figure 3.10). Most colonies were
positive as the inserts of 864 bp or 861 bp were seen by restriction digest. Of these, three
colonies were selected and sequenced to confirm the result.
Figure 3.10: Restriction digest to screen colonies grown from transformation
of pFUSE constructs. Lanes 1 - 19: pFUSE 3.4 colonies. Lanes 20-38: pFUSE 3.8
colonies. Colonies are positive if they contain the DBL insert (864 bp or 861 bp). Lanes
1 and 3-19 contain positive 3.4 colonies and lanes 20-21 and 23-38 contain positive 3.8
colonies.
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3.4.2.2 Sequencing Results
Sequencing results show the pFUSE-hIgG1-Fc2-DBL3.4 nucleotide sequence aligned
against the pFUSE-hIgG1-Fc2-DBL3.4 master nucleotide sequence (Figure 3.11)
and the pFUSE-hIgG1-Fc2-DBL3.8 nucleotide sequence aligned against the
pFUSE-hIgG1-Fc2-DBL3.8 master nucleotide sequence (Figure 3.12). In both cases
the sequences have 100% sequence identity.
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+ve colony   ACCATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAAT  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   ACCATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAAT  169 
 
+ve colony   TCGATATCGGCCATGGTTTTCTGCAAGGGCATCAAGAACGTGCTGAGCTGCCCTCCCAAG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   TCGATATCGGCCATGGTTTTCTGCAAGGGCATCAAGAACGTGCTGAGCTGCCCTCCCAAG  229 
 
+ve colony   AACAGCGCCGGCAGAAACGGCGACTGGATCAGCGTGGCCGTGAAAGAGAGCAGCACCACC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   AACAGCGCCGGCAGAAACGGCGACTGGATCAGCGTGGCCGTGAAAGAGAGCAGCACCACC  289 
 
+ve colony   AACAAGGGCGTGCTGGTGCCCCCCAGACGGACCAAGCTGTGCCTGCGGAACATCAACAAA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   AACAAGGGCGTGCTGGTGCCCCCCAGACGGACCAAGCTGTGCCTGCGGAACATCAACAAA  349 
 
+ve colony   GTGTGGCACCGGATCAAGGACGAGAAGAACTTCAAAGAGGAATTCGTCAAGGTCGCACTG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   GTGTGGCACCGGATCAAGGACGAGAAGAACTTCAAAGAGGAATTCGTCAAGGTCGCACTG  409 
 
+ve colony   GGCGAGAGCAACGCCCTGATGAAGCACTACAAAGAGAAGAACCTGAACGCCCTGACCGCC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   GGCGAGAGCAACGCCCTGATGAAGCACTACAAAGAGAAGAACCTGAACGCCCTGACCGCC  469 
 
+ve colony   ATTAAGTACGGCTTCAGCGACATGGGCGACATCATCAAGGGCACCGACCTGATCGATTAC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   ATTAAGTACGGCTTCAGCGACATGGGCGACATCATCAAGGGCACCGACCTGATCGATTAC  529 
 
+ve colony   CAGATCACCAAGAACATCAACCGGGCCCTGGACAAGATCCTGAGAAACGAGGCCAGCAAC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   CAGATCACCAAGAACATCAACCGGGCCCTGGACAAGATCCTGAGAAACGAGGCCAGCAAC  589 
 
+ve colony   GACAAGATCAAGAAACGGGTGGACTGGTGGGAGGCCAACAAGGCCGCCTTCTGGGACGCC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   GACAAGATCAAGAAACGGGTGGACTGGTGGGAGGCCAACAAGGCCGCCTTCTGGGACGCC  649 
 
+ve colony   TTCATGTGCGGCTACAAGGTGCACATCGGCAACAAGCCCTGCCCCGAGCACGACAACATG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   TTCATGTGCGGCTACAAGGTGCACATCGGCAACAAGCCCTGCCCCGAGCACGACAACATG  709 
 
+ve colony   GACCGGATCCCCCAGTACCTGCGGTGGTTTCGCGAGTGGGGCACCTACGTGTGCAGCGAG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   GACCGGATCCCCCAGTACCTGCGGTGGTTTCGCGAGTGGGGCACCTACGTGTGCAGCGAG  769 
 
+ve colony   TACAAGAACAAGTTCGAGGACGTGATCAAGCTGTGCAACATCCAGCAGTTCACCAACCAG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   TACAAGAACAAGTTCGAGGACGTGATCAAGCTGTGCAACATCCAGCAGTTCACCAACCAG  829 
 
+ve colony   GACGACAGCCAGCTGCTGGAAATCAGCAAGAAAGACAAGTGCAAAGAGGCCCTGAAACAC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   GACGACAGCCAGCTGCTGGAAATCAGCAAGAAAGACAAGTGCAAAGAGGCCCTGAAACAC  889 
 
+ve colony   TACGAGGAATGGGTCAACCGGCGGAGGCCCGAGTGGAAGGGCCAGTGCGATAAGTTCGAG  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   TACGAGGAATGGGTCAACCGGCGGAGGCCCGAGTGGAAGGGCCAGTGCGATAAGTTCGAG  949 
 
+ve colony   AAAGAGAAGTCTAAGTACGAGGACACCAAGAGCATCACCGCCGAGAAGTACCTGAAAGAA  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   AAAGAGAAGTCTAAGTACGAGGACACCAAGAGCATCACCGCCGAGAAGTACCTGAAAGAA  1009 
 
+ve colony   ATCTGCAGCGAGTGCGACTGCAAGTACAAGGACCTGGACAACAGATCTG  949 
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
3.4 master   ATCTGCAGCGAGTGCGACTGCAAGTACAAGGACCTGGACAACAGATCTG  1058	
Figure 3.11: pFUSE-hIgG1-Fc2-DBL3.4 sequencing results. The sequencing
results of DNA extracted from the positive colony had 100% sequence identity with the
pFUSE-hIgG1-Fc2-DBL3.4 master sequence. The leader sequence is shown in black, the
DBL sequence is purple and restriction sites (NcoI and BglII) shown in blue.
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+ve colony   CACCATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   CACCATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAA  168 
 
+ve colony   TTCGATCTGCAAGGACTTCAGCAACCTGCCCCAGTGCCGGAAGAACGTGCACGAGCGGAA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   TTCGATCTGCAAGGACTTCAGCAACCTGCCCCAGTGCCGGAAGAACGTGCACGAGCGGAA  228 
 
+ve colony   CAACTGGCTGGGCAGCAGCGTGAAGAACTTCGCCAGCGACAACAAGGGCGTGCTGGTGCC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   CAACTGGCTGGGCAGCAGCGTGAAGAACTTCGCCAGCGACAACAAGGGCGTGCTGGTGCC  288 
 
+ve colony   CCCCAGACGGCAGAGCCTGTGCCTGAGAATCACCCTGCAGGACTTCCGGACCAAGAAGAA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   CCCCAGACGGCAGAGCCTGTGCCTGAGAATCACCCTGCAGGACTTCCGGACCAAGAAGAA  348 
 
+ve colony   GAAAGAGGGCGACTTCGAGAAGTTCATCTACAGCTACGCCAGCAGCGAGGCCCGGAAGCT  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   GAAAGAGGGCGACTTCGAGAAGTTCATCTACAGCTACGCCAGCAGCGAGGCCCGGAAGCT  408 
 
+ve colony   GCGGACCATCCACAACAACAACCTGGAAAAGGCCCACCAGGCCATCCGGTACAGCTTCGC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   GCGGACCATCCACAACAACAACCTGGAAAAGGCCCACCAGGCCATCCGGTACAGCTTCGC  468 
 
+ve colony   CGACATCGGCAACATCATCCGGGGCGACGACATGATGGACACCCCCACCAGCAAAGAGAC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   CGACATCGGCAACATCATCCGGGGCGACGACATGATGGACACCCCCACCAGCAAAGAGAC  528 
 
+ve colony   AATCACCTATCTGGAAAAGGTGCTGAAGATCTACAATGAGAACAACGACAAGCCCAAGGA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   AATCACCTATCTGGAAAAGGTGCTGAAGATCTACAATGAGAACAACGACAAGCCCAAGGA  588 
 
+ve colony   CGCCAAGAAGTGGTGGACCGAGAACCGGCACCACGTGTGGGAGGCCATGATGTGCGGCTA  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   CGCCAAGAAGTGGTGGACCGAGAACCGGCACCACGTGTGGGAGGCCATGATGTGCGGCTA  648 
 
+ve colony   CCAGAGCGCCCAGAAAGACAACCAGTGCACCGGCTACGGCAACATCGACGATATCCCCCA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   CCAGAGCGCCCAGAAAGACAACCAGTGCACCGGCTACGGCAACATCGACGATATCCCCCA  708 
 
+ve colony   GTTCCTGCGGTGGTTCCGCGAGTGGGGCACCTACGTGTGCGAAGAGTCCGAGAAGAACAT  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   GTTCCTGCGGTGGTTCCGCGAGTGGGGCACCTACGTGTGCGAAGAGTCCGAGAAGAACAT  768 
 
+ve colony   GAATACCCTGAAGGCCGTGTGCTTCCCCAAGCAGCCCAGAACCGAGGCCAACCCTGCCCT  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   GAATACCCTGAAGGCCGTGTGCTTCCCCAAGCAGCCCAGAACCGAGGCCAACCCTGCCCT  828 
 
+ve colony   GACCGTGCACGAGAACGAGATGTGCAGCAGCACCCTGAAGAAATACGAGGAATGGTACAA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   GACCGTGCACGAGAACGAGATGTGCAGCAGCACCCTGAAGAAATACGAGGAATGGTACAA  888 
 
+ve colony   CAAGCGCAAGACCGAGTGGACCGAGCAGAGCATCAAGTATAACAACGATAAGATCAACTA  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   CAAGCGCAAGACCGAGTGGACCGAGCAGAGCATCAAGTATAACAACGATAAGATCAACTA  948 
 
+ve colony   CGCCGACATCAAGACCCTGAGCCCCAGCGAGTACCTGATCGAGAAGTGCCCCGAGTGCAA  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
3.8 master   CGCCGACATCAAGACCCTGAGCCCCAGCGAGTACCTGATCGAGAAGTGCCCCGAGTGCAA  1008 
 
+ve colony   GTGCACCAAGAAAAACCTGCAGGACGCCATGG  932 
             |||||||||||||||||||||||||||||||| 
3.8 master   GTGCACCAAGAAAAACCTGCAGGACGCCATGG  1040 
 
 
Figure 3.12: pFUSE-hIgG1-Fc2-DBL3.8 sequencing results. The sequencing
results of DNA extracted from the positive colony had 100% sequence identity with the
pFUSE-hIgG1-Fc2-DBL3.8 master sequence. The leader sequence is shown in black, the
DBL sequence is red and restriction sites (EcoRI and NcoI) shown in blue.
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The translated amino acid sequence from the positive colonies is as expected from the
master sequence (Figure 3.13).
MYRMQLLSCIALSLALVTNSISAMVFCKGIKNVLSCPPKNSAGRNGDWISVAV
KESSTTNKGVLVPPRRTKLCLRNINKVWHRIKDEKNFKEEFVKVALGESNALM
KHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNINRALDKILRNEASN
DKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQYLRWFREW
GTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN
RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE
SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPGK*VLA 
(a)
 
MYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFASDN
KGVLVPPRRQSLCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNN
LEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKD
AKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVC
EESEKNMNTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNKRKTEW
TEQSIKYNNDKINYADIKTLSPSEYLIEKCPECKCTKKNLQDAMVRSDKTHTC
PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI
EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG
QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
KSLSLSPGK*VLA 
 
 
 
 
 
 
 		
RRATMYRMQLLSCIALSLAL 
VTNSICKDFSNLPQCRKNVH 
ERNNWLGSSVKNFASDNKGV 
LVPPRRQSLCLRITLQDFRT 
KKKKEGDFEKFIYSYASSEA 
RKLRTIHNNNLEKAHQAIRY 
SFADIGNIIRGDDMMDTPTS 
KETITYLEKVLKIYNENNDK 
PKDAKKWWTENRHHVWEAMM 
CGYQSAQKDNQCTGYGNIDD 
IPQFLRWFREWGTYVCEESE 
KNMNTLKAVCFPKQPRTEAN 
PALTVHENEMCSSTLKKYEE 
WYNKRKTEWTEQSIKYNNDK 
INYADIKTLSPSEYLIEKCP 
ECKCTKKNLQDAMVRSDKTH 
TCPPCPAPELLGGPSVFLFP 
PK 	
(b)
Figure 3.13: Translated amino acid sequences of DNA extracted from the positive colonies.
The lead sequence of the pFUSE-hIgG1-Fc2 plasmid is in black. (a) The 3.4 DBL domain
is in purple and the IgG-Fc sequence is in red. (b) The 3.8 DBL domain is in brown and
the IgG-Fc sequence is in red.
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3.4.2.3 Restriction Digest
Restriction digest confirms the construction of the pFUSE-hIgG1-Fc2-DBL3.4 and
pFUSE-hIgG1-Fc2-DBL3.8 plasmids which, when cut by restriction digest, have inserts
of size 864bp and 861bp respectively (Figure 3.14). This is the expected size from the
plasmids produced.
Figure 3.14: Bands observed from restriction digest are as expected for the plasmids
produced. Lane 1: pFUSE-hIgG1-Fc2-DBL3.4 digested with restriction sites NcoI and
BglII. The restriction digest releases a fragment of 864 bps from the 4192 bp plasmid.
Lane 2: pFUSE-hIgG1-Fc2-DBL3.8 digested with restriction sites EcoRI and NcoI. The
restriction digest releases a fragment of 861 bps from the 4196 bp plasmid.
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3.4.3 Expression of recombinant MSPDBL1 and MSPDBL2 DBL domains
CHO–K1 cells were transfected with pFUSE-hIgG1-Fc2-DBL3.4 and
pFUSE-higG1-Fc2-DBL3.8 plasmids using the FuGENE transfection reagent. Zeocin
was used to select for successfully transfected cells and a monoclonal population of high
expression cells produced (Section 3.3.8).
3.4.3.1 Immunoblotting
Cell lines grown from single cells were selected for high protein expression by
immunoblotting (Figure 3.15) and further expanded. Cell supernatant was removed from
each culture and filter sterilised after 10 days of selection.
Figure 3.15: Single cells were added to a 96-well plate and after 9 days, colonies could
be observed in some wells. 10 μl of cell supernatant was tested for protein expression
by immunoblotting. For the pFUSE-3.4 transfection, 35 cell lines were produced and the
highest two expressing protein were selected. Cell lines 7 and 22 were expanded to large
cultures and cell supernatant with protein collected after 10 days. For the pFUSE-3.8
transfection, 47 cell lines were produced and the highest two expressing protein were
selected. Cell lines 21 and 24 were expanded to large cultures and cell supernatant with
protein collected.
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3.4.3.2 FPLC protein purification
DBL-Fc recombinant protein was purified from supernatant by affinity chromatography,
using a protein G sepharose column (Section 3.3.8). A linear gradient of 0.1M glycine-HCl,
pH 2.7 was used to elute the protein from the column (Figure 3.16).
(a)
(b)
Figure 3.16: FPLC elution profile of (a) 3.4 DBL recombinant protein and (b) 3.8 DBL
recombinant protein. UV profile of the eluted protein is shown in blue and linear glycine
gradient is green. The recombinant protein comes off the sepharose beads as the glycine
gradient increases. Peaks were collected in fractions which are shown in red.
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Fractions were collected and immunoblotted with αhIgG-AP to show that the protein
was present in the fraction corresponding to the FPLC peak (Figure 3.17) (Section 3.3.8).
Fractions containing protein were pooled and concentrated by Vivaspin 2 ultrafiltration
columns (Section 2.4.3).
Figure 3.17: Fractions A1-A11 from the FPLC elution were tested by immunoblotting for
the presence of protein. These were compared to a blot of the cell supernatant (sup) prior
to purification as well as the flow-through (FT) to check that all protein had been removed
as well as a negative control (-ve) containing only media.
Binding and elution conditions were maximised and it was found that diluting the
cell supernatant 1:1 with binding buffer prior to loading improved binding. The optimal
binding buffer was determined as 20 mM sodium phosphate pH 7.0. The pH of the elution
buffer was also optimised and found to give sharper peaks at pH 2.5.
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3.4.4 Characterisation of recombinant protein
In order to characterise the DBL-Fc fusion proteins, reduced and non-reduced samples
were separated by SDS-page electrophoresis and stained with Coomassie Blue (Section
2.4.6) or transferred to a membrane and IgG Fc detected using αhIgG-Fc-AP (Sigma)
(Figure 3.18). The proteins had difficulty folding with the addition of the Fc tag and were
unable to form dimers. However, an ∼60 kDa band visible in the Western blot suggests
that there is a small amount of monomeric DBL-Fc present.
Due to the disruption to oligomerisation by SDS, in order to investigate native structure
of the fusion proteins the recombinant protein was run by gel filtration on a Superdex 200
10/300 GL column (Section 3.3.12). Each fraction collected from the gel filtration was
immunoblotted to test for the presence of IgG Fc (Figure 3.19). There was IgG Fc detected
in all fractions between A8 and B5 from the gel filtration experiment (corresponding to
700 - 1kDa). This suggests that protein aggregates are being formed. Large peaks might
explain the smears at the top of the protein gel and Western blot (Figure 3.18).
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(a) Coomassie stain
(b) Western blot
Figure 3.18: DBL-Fc fusion proteins have difficulty folding. SDS-PAGE of
recombinant (a) IgG Fc control visualised with Coomassie blue stain; (b) the Fc detected
using an αhIgG-Fc alkaline phosphotase conjugated antibody. Protein samples were
either reduced (R) or non-reduced (N). The bands observed for the IgG Fc control agree
with predictions (50 kDa non-reduced and 25 kDa reduced). Bands were predicted for
non-reduced DBL-Fc fusion proteins at 120 kDa. The lack of these bands suggests that
the proteins have difficulty forming homodimers. However, a band at ∼60 kDa suggests
the presence of a monomeric DBL-Fc fusion.
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(a) Size exclusion standards (b) 3.4 DBL size exclusion peaks
(c) 3.8 DBL size exclusion peaks (d) IgG-Fc size exclusion peaks
(e) Immunoblot of size exclusion fractions
Figure 3.19: Size exclusion profiles of the 3.4 DBL and 3.8 DBL recombinant
proteins. (a) shows the peaks for 500 μl of the protein standards, (b) and (c) show the
3.4 DBL and 3.8 DBL size exclusion profiles respectively. (d) Immunoblot of the 3.4 and
3.8 DBL size exclusion fractions shows fractions where IgG Fc is detected.
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3.4.5 Functional analysis of DBL domains
It has recently been shown that the DBL domains from MSPDBL1 and MSPDBL2 bind
hIgM (and not IgE, IgG or IgA) and that binding occurs irrespective of whether the IgM
was bound to antigen or not (Crosnier et al., 2016). It was shown by SPR analysis that the
binding interaction occurs at high affinity (Kd = 0.3 nM for the MSPDBL1 DBL domain
and Kd = 1.1 nM for the MSPDBL2 DBL domain) and that no binding occurs via the
SPAM domain. A series of IgM/A domain swap antibodies showed that binding occurs
in the Cμ4 domains of human IgM (Crosnier et al., 2016). Interestingly, the Cμ4 domain
is the same domain that is known to bind hFcμRs (Kubagawa et al., 2009). We aimed to
show that the recombinant DBL-Fc protein produced binds hIgM and that the merozoite
DBL proteins bind the Cμ4 domain of hIgM.
3.4.5.1 The recombinant DBL-Fc domains bind human IgM
IgM-binding of the DBL-Fc fusion proteins was investigated by sandwich ELISA (Section
3.3.10). IgM was captured by αhIgM, and the purified DBL proteins added and allowed
to bind before αhIgG-Fc-AP was added as the detection antibody. Media was used as a
negative control and a t-test performed which showed that the positive MSPDBL3.4 and
MSPDBL3.8 binding results were statistically significant.
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Figure 3.20: Recombinant DBL domains bind human IgM. (a) IgM-binding was
detected by sandwich ELISA. IgM was captured by αhIgM coated down on the plate and
DBL 3.4 and DBL 3.8 detected by αhIgG-Fc-AP. Results are shown from two repeat
experiments. *p<0.05, ***p<0.001. IgM-binding of the IgG Fc was not detected in a
separate experiment using the same sandwich ELISA protocol and a recombinant IgG Fc
control (Appendix B).
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3.4.5.2 Malarial MSPDBL1 and MSPDBL2 bind the Cμ4 domain of human
IgM
The Cμ4 domain on IgM has been shown to bind FcμRs (Kubagawa et al., 2009) and
malarial MSPDBL1 and MSPDBL2 have recently been shown to bind Cμ4 (Crosnier et al.,
2016). We aimed to show that the merozoite DBL proteins bind the Cμ4 domain. As IgM
and IgA are closely related secretory Abs containing tailpieces, in order to investigate the
binding region we used IgG/M domain swap mutants.
Figure 3.21: IgG/IgM domain swap mutants. Domain-swap mutants described by
Ghumra et al. (2008) were used to investigate the role of the Cμ4 domain in MSP DBL-IgM
binding. Two controls were used, IgM-Fc and L309C-μTP, which contains the Cγ1-3
regions with an IgM tailpiece. The L309C-Cμ4 mutant was used to investigate the role of
the Cμ4 domain in IgM-binding. L309C is a single Leucine/Cysteine mutation in the IgG
domain (homologous to the cysteine in the corresponding region of IgM); this mutant has
been shown to have a greater ability to polymerise (Sørensen et al., 1999).
A panel of previously generated domain-swap Abs (Ghumra et al., 2008) was used to
characterise the interaction of the full-length MSPDBL1 and MSPDBL2 with hIgM by
ELISA (Figure 3.21). These experiments were performed by Professor Pleass (Liverpool
School of Tropical Medicine) using full-length recombinant biotinylated MSPDBL1 and
MSPDBL2 (kindly provided by Cecile Crosnier, Sanger Institute). The experiment showed
that the Cμ4 domain was critical for binding of MSPDBL1 and MSPDBL2 to domain-swap
antibodies. No binding was detected in the L309C-μTP mutant which lacked the Cμ4
domain. Binding was, however, detected in the γL309C Cμ4 mutant where the Cγ3
domain was swapped with Cμ4 from IgM. These results showed the ability of recombinant
MSPDBL1 and MSPDBL2 to bind the Cμ4 domains of hIgM.
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(a) MSPDBL1
(b) MSPDBL2
Figure 3.22: MSPDBL1 and MSPDBL2 bind to the Cμ4 domain of human
IgM. An indirect ELISA was used to show binding of recombinant full-length biotinylated
MSPDBL1 and MSPDBL2 to hIgM. Binding of the complete Fc section of hIgM (IgG-Fc)
was compared to two domain-swap Ab mutants. Binding was shown in γL309C Cμ4 which
contains the Cμ4 domain and was not present in the same mutant where the Cμ4 domain
was replaced by a Cγ3 domain. The mean ± SD are shown for two experiments.
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3.5 Summary
MSPDBL1 and MSPDBL2 are two new malaria vaccine candidates which have been
identified recently with interesting binding properties. The only two merozoite surface
proteins to contain a DBL domain, thought to be a virulence factor in P. falciparum
infection, they have recently been shown to bind the Cμ4 domain of human IgG through
this domain (Crosnier et al., 2016). In this chapter DBL domains from MSPDBL1 and
MSPDBL2 were expressed as Fc-fusion proteins in a mammalian expression system. There
was some difficulty expressing the Fc-fusion as a homodimer as the recombinant protein
had some difficulty folding correctly. Monomeric DBL-Fc produced was shown to be fully
functional although the yield was low. There was evidence of IgM binding and it was
shown that the MSPDBL proteins bind the Cμ4 domain of human IgM.
Previously, DBL domains have been expressed more frequently in E.coli due to high
protein yield and low costs, however recombinant proteins are either expressed as truncated
forms or precipitate in insoluble inclusion bodies in the bacterial cells (Flick et al., 2004).
Methods to obtain correctly folded proteins have been developed but are complex and
laborious (Crosnier et al., 2013). We set out to create novel Fc-fusion constructs to express
the DBL domains in a mammalian expression system. An Fc-fusion protein has the benefit
of extending half-life of the recombinant protein as well as adding a convenient tag for
protein purification, thus streamlining production. TOPO-TA cloning was used to create a
parking plasmid containing the DNA and suitable restriction sites for sub-cloning. DNAs
were sub-cloned into the pFUSE-hIgG1-Fc plasmid to create a DBL-Fc fusion construct.
The Fc-fusion constructs were expressed in CHO-KI cells and purified using the Fc-tag on
a protein G sepharose column.
The cloning was challenging, particularly cloning the 3.8 DBL as there were limited
transformants and amplification of plasmids was difficult due to slow growth of bacterial
cultures. Various E. coli strains were tried which exhibit a range of transformation
efficiency as well as strains which stabilise the insert but growth was not improved. This
suggests that the DNA may be toxic to E.coli cells.
Protein expression of both constructs was also particularly challenging. Although
purification methods were optimised extensively, yields were still low. The constructs
were efficiently transfected into CHO-K1 cells (compared to HeK cells in which transfection
proved difficult), however, the cells produced low protein yield. Monoclonal populations
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were produced from cells selected for high protein expression. This produced better results
than the polyclonal population, however yields were still low suggesting that the cells
have difficulty producing the protein. Protein purification was optimised and efficient
purification techniques were developed to extract all protein produced by the cells.
Characterisation of the protein produced suggests that the DBL domain has difficulty
folding as an Fc-fusion protein. Typical Fc-fusion proteins consist of two effector molecules
because each molecule attaches to one chain of the Fc dimer. The DBL-Fc fusion proteins
produced contain a single DBL domain attached to a single chain of the Fc which is unable
to form a homodimer, possibly because the DBL domain is too large and disulphide bonds
in the hinge region are unable to form between two chains of the Fc. The monomeric
DBL-Fc fusion was, however, shown to be functional and was therefore used for further
analysis.
The recombinant protein produced was tested for binding to human IgM. Binding
was observed by both DBL domains, using sandwich ELISA, and was significantly higher
for the 3.4 DBL domain than the 3.8, which is in agreement with another recent study
where affinity was reportedly 10-fold higher in the full MSPDBL1 compared to MSPDBL2
(Crosnier et al., 2016). In this study, the Cμ4 domain was identified as the binding site for
the DBL-IgM interaction which is the same domain where the FcμR binds to the Ab. In
this Chapter it was shown that the Cμ4 domain was necessary for binding to the MSPDBL1
and MSPDBL2 proteins. In an ELISA, binding was knocked out in a domain-swap Ab
mutant where the Cμ4 domain had been replaced with a Cγ3 domain.
The main obstacle in the work presented here was the generation of adequate quantities
of correctly folded recombinant protein. Although the DBL-Fc fusion had difficulty folding
into a homodimer, some functional monomeric protein was produced and IgM-binding was
observed using this recombinant protein. The protein produced was functional with respect
to both IgM and protein G binding, however, the cells have great difficulty in producing an
adequate amount of protein for further functional investigations. This problem of folding
was addressed in Chapter 5 while the protein produced here has been used for further
investigations in Chapter 4, due to the IgM-binding observed in the monomeric DBL-Fc
fusion.
106
Chapter 4
Analysis of Known IgM Binding DBL domains
107
4 ANALYSIS OF KNOWN IGM-BINDING DBL DOMAINS
4.1 Background
In Chapter 3 it was shown that the DBL domains from MSPDBL1 and -2 bind human IgM.
The Cμ4 domain (Figure 4.1) appears to be important for the interaction, in agreement
with a recent study by Crosnier et al. (2016). The Cμ4 domain has also been identified
as part of the binding region for FcμRs on the surface of B and T lymphocytes as well as
NK cells (Kubagawa et al., 2009).
Figure 4.1: Model of IgM. The Cμ4 domain is important in binding to DBL domains
and is shown on the model of IgM in red (adapted from Pleass et al. (2015)).
MSPDBL1 and MSPDBL2 are the only merozoite surface proteins to contain a DBL
domain. This domain is also a feature of PfEMP1 proteins located on the erythrocyte
surface, encoded by the var multigene family, and is thought to be responsible for their
cytoadherent and subsequently virulent nature. These multi-domain proteins contain
up to five DBL domains along with cysteine-rich inter-domain regions (CIDR) and are
responsible for mediating adhesion of IEs to a multitude of host receptors. The DBL
domains belonging to PfEMP1 are classified into six classes based on amino acid sequence
(DBL α, β, γ, δ, ξ, ε) and within the DBL domains ten semi-conserved regions, or homology
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blocks, have been categorised (Rask et al., 2010).
DBL classes have been associated with specific pathogenesis. For example, the DBLβ
class has affinity for ICAM-1 and DBLδ for platelet-endothelial cell adhesion molecule 1
(PECAM-1) (Springer et al., 2004; Berger et al., 2013). DBLα is associated with heparin
sulphate (HS) binding, complement receptor 1 (CR1) and blood group A antigen (Carlson
et al., 1990; Mayor et al., 2005; Barragan et al., 2000b). CR1 binding is associated
with coating of IE with uninfected erytrocytes, also known as rosetting (Rask et al.,
2010). However, sequence diversity within each DBL class is high. It is therefore difficult
to identify functional regions which mediate binding based on sequence analysis alone
(Higgins and Carrington, 2014; Lau et al., 2015).
PfEMP1 and MSPDBL1 show structurally similar domain architecture, as do DBL
domains from the erythrocyte binding-like (EBL) family of proteins such as EBA-175
which binds glycophorin A, the major glycoprotein found on human erythrocytes, during
erythrocyte invasion. Interestingly, although DBL structures are relatively conserved,
there is great variation in the host receptors with which they interact (Hodder et al.,
2012). DBL domains consist of three α-helical, cysteine-rich subdomains. A study by
Hodder et al. (2012) which compared the known structure of eight DBL domains found in
Plasmodium spp. showed that the size and location of major helices are highly conserved.
However, the extent of the connecting loops varies within each structure and the disulphide
bond architecture, which stabilises each structure, appears to be unique to each protein
family.
MSPDBL1 and MSPDBL2 contain an interesting leucine zipper-like region at the C
terminus which is part of the SPAM domain, a domain present in most other members of
the MSP3 family (Singh et al., 2009). This region has been shown to be responsible for
oligomerisation of MSP3. It has been suggested that its presence enables MSP3 to form a
highly extended and oligomeric structure on the merozoite surface allowing it to interact
with erythrocytes at a relatively long distance (Burgess et al., 2005; Hodder et al., 2012).
Since MSPDBL1 and MSPDBL2 also contain this region, it is likely that they are also
long extended molecules with far-reaching interactions (Hodder et al., 2012).
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4.1.1 IgM-binding DBL domains
The P. falciparum genome contains ∼60 var genes which encode for PfEMP1. Several
PfEMP1 DBL domains are known to bind the Fc region of human IgM (Table 4.1).The
function of DBL-Fcμ binding is not fully understood but the expression of these Fcμ
binding proteins is linked to severe malaria. This phenotype appears to be driven by
parasite evasion of human immune effector mechanisms (Pleass et al., 2015) (Figure 4.2).
Table 4.1: Known hIgM-binding and non-binding Plasmodium falciparum proteins.
Adapted from Pleass et al. (2015).
Binds to hIgM Protein DBL domain Reference
Yes FCR3var1csa DBLε7 (Semblat et al., 2006)
FCR3var2csa DBLε6 (Semblat et al., 2006)
HB3var06 DBLξ2 (Stevenson et al., 2015a)
MAL6P1.4 DBLε2 (Jeppesen et al., 2015)
MAL5P1.4 DBLε3 (Jeppesen et al., 2015)
PFL0020w DBLε4 (Jeppesen et al., 2015)
PFL0030c DBLεPAM5 (Jeppesen et al., 2015)
TM274var1 DBLξ4 (Ghumra et al., 2008; Semblat
et al., 2015)
No FCR3var1csa DBLε4 (Semblat et al., 2006)
FCR3var1csa DBLξ6 (Semblat et al., 2006)
FCR3var2csa DBLε4 (Semblat et al., 2006)
FCR3var2csa DBLε5 (Semblat et al., 2006)
HB3var06 DBLε13 (Stevenson et al., 2015a)
HB3var06 DBLε14 (Stevenson et al., 2015a)
ITvar9/R29var1 DBLε3 (Stevenson et al., 2015a)
MAL6P1.4 DBLε7 (Jeppesen et al., 2015)
PF07 0139 DBLε4 (Jeppesen et al., 2015)
PFL0020w DBLξ5 (Jeppesen et al., 2015)
PFL0030c DBLεPAM4 (Jeppesen et al., 2015)
PFL0030c DBLξPAM10 (Jeppesen et al., 2015)
TM284var1 DBLε3 (Ghumra et al., 2008)
TM284var1 DBLε5 (Ghumra et al., 2008)
Var0 DBLξ (Vigan-Womas et al., 2012)
CSA-binding IEs which are involved in the pathogenesis of placental malaria, are known
to bind IgM, mediated by a type of PfEMP1 called Var2csa (Semblat et al., 2006). This
interaction appears to be protective as it prevents phagocytic clearance of IgG-opsonised
IEs without compromising the CSA-adhesive function of the antigen (Jeppesen et al., 2015;
Pleass et al., 2015).
Another important type of PfEMP1 known to bind IgM is one which also mediates the
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Figure 4.2: Binding of IgM to Plasmodium falciparum erythrocyte membrane
protein 1 (PfEMP1) (Pleass et al., 2015). (A) In CSA-binding isolates, IgM protects
the antigen from destruction by immune IgG. (B) In the case of rosetting isolates, IgM
binding tethers PfEMP1 for stronger interactions with host surface receptor carbohydrates.
(C) IgM also binds to PfEMP1 on infected erythrocytes that neither bind CSA or rosette
(Pleass et al., 2015).
formation of rosettes, which is the masking of an IE by several uninfected erythrocytes.
It has been suggested that IgM augments low-affinity interactions with the erythrocyte
carbohydrate receptor involved in rosetting (Pleass et al., 2015). Pentameric IgM is able
to cross-link PfEMP1 proteins as each molecule can bind two PfEMP1s (Jeppesen et al.,
2015). Interestingly, another abundant serum protein, α2-macroglobulin (α2M) appears
to serve a similar function, binding the same DBL domain, and has a higher potential
for cross-linking individual molecules of PfEMP1 (Stevenson et al., 2015b; Pleass et al.,
2015).
Other PfEMP1 variants which bind IgM, other than those types which bind CSA or
mediate rosetting, have been identified. The addition of these variants may act to expand
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the repertoire of sequestration-supporting host receptors, thereby reinforcing avoidance of
clearance by the spleen (Pleass et al., 2015).
In PfEMP1, the IgM binding domains seem to be situated near the infected erythrocyte
membrane, whereas the single DBL of the MSP suggests that binding is more exposed on
the merozoite surface and possibly allows bridging to host receptors.
As yet, no obvious binding motifs or critical amino acids have been identified, therefore
production of a library of MSP DBL mutants aims to provide insight into the IgM binding
site of these domains. A comprehensive structural analysis of the mutants along with
other known IgM binding and non-binding DBL domains will shed light on the structural
features important for IgM-binding.
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4.2 Objectives
The aim of this Chapter is to analyse known IgM-binding DBL domains and to identify
shared structural properties as well as sequence motifs. The specific objectives include:
• Produce a library of recombinant merozoite DBL mutants to investigate residues
critical for IgM-binding.
• Predict potential binding sites based on the crystal structure and model of IgM
binding.
• Analyse sequences of known IgM binders and non-binders and identify common
features for binding.
• Analyse structures of known IgM binders and non-binders and identify common
features for binding.
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4.3 Methods
4.3.1 PCR for random mutagenesis
The Genemorph II Random Mutagenesis kit (Agilent Technologies) uses Mutazyme II
DNA polymerase. This error-prone polymerase has less mutational bias than other Taq
DNA polymerase mutants. The amount of initial target DNA was calculated in order
to produce a low error frequency of 1 - 2 amino acids. Low frequency errors occur by
increasing the initial template amount, as the more times the target is replicated, the
more errors it accumulates. Targets amplified from high amounts of target DNA undergo
fewer duplications than targets amplified from low concentrations. 600 ng of plasmid DNA
(∼ 4.7 kbp) gives 110 ng of target DNA (∼ 860 bp) which, according to manufacturer’s
instructions, should produce approximately nine mutations/kb and eight mutations within
the DBL target. This corresponds to mutations of approximately four amino acids and is
a common mutational frequency used in directed evolution studies (Cherry et al., 1999;
You and Arnold, 1996).
The PCR solution used for low frequency random mutagenesis was composed of the
following:
• Mutazyme II polymerase 1 μl
• Mutazyme II reaction buffer 5 μl
• dNTPs (40 mM) 1 μl
• Forward primer (10 μM) 3 μl
• Reverse primer (10 μM) 3 μl
• pFuse-DBL plasmid 600 ng
• dH2O up to 50 μl
The same primers that were used to amplify the DNA in Chapter 3 were used for the
mutagenesis reaction (Table 2.1) except that from the forward primer for the 3.8 DBL
reaction which was redesigned adding extra bases in front of the EcoRI site (red) for
optimal cleavage.
3.8-F New: 5’ tcgcggcggaattcgatctgcaaggac 3’
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PCR reaction
A Progene thermocycler (Techne, Cambridge, UK) was used for the PCR reaction.
The following PCR program was used:
94◦ C 3 mins
35 cycles

94◦ C 1 min
60◦ C 1 min
72◦ C 1 min
72◦ C 10 mins.
Purification from PCR product
PCR products were purified from solution using High Pure PCR cleanup micro
kit (Section 2.2.3) and DNA concentration quantified by nanodrop spectro-photometer
(Section 2.2.15).
4.3.2 DNA preparation for sub-cloning of mutated pFuse constructs
Restriction digest of mutated DBL inserts
The amplified mutated DBL insert was cut out by restriction digest. The restriction
digest solution consisted of the following:
• Restriction enzyme 1 1 μl
• Restriction enzyme 2 1 μl
• Compatible Buffer 5 μl
• BSA (10x) 5 μl
• Mutated DNA 1 μg
• dH2O up to 50 μl
Whenever less than 1 μg of DNA was available, a volume of DNA up to 30 μl was added
and the dH2O quantity adjusted accordingly. For the 3.4 DBL construct, restriction
enzymes Nco1 and BglII were used with NEB buffer 3.1. For the 3.8 DBL construct
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restriction enzymes Nco1 and EcoRI were used with NEB buffer 3.1. The restriction digest
reaction was incubated at 37◦C for 2 hours and then the product run by gel electrophoresis
where bands correlating to the correct insert size were excised and purified (Section 2.2.6).
Recovered DNA was quantified by nanodrop spectro-photometer (Section 2.2.15).
4.3.3 Restriction digest of pFUSE plasmid
The pFUSE-hIgG1-Fc2 plasmid was prepared for the insertion of the mutated DBL inserts
in the same way as in Chapter 3 for sub-cloning of the pFUSE constructs. Plasmid
was digested using the appropriate restriction enzymes, de-phosphorylated to prevent
self-ligation, run by gel electrophoresis, excised and purified (Section 3.3.5). Recovered
DNA was quantified by nanodrop spectro-photometer (Section 2.2.15).
4.3.4 pFUSE ligation to the mutated 3.4 DBL and 3.8 DBL domains
The following reaction with a molar ratio of 1:3 vector to insert was set-up on ice:
• 10x T4 DNA ligase buffer 2 μl
• Vector DNA (4.2 kb) 50 ng
• Insert DNA (860 bp) 30 ng
• T4 DNA ligase 1 μl
• dH2O up to 20 μl.
The ligation reaction was held at 16◦C for 16 hours using a Progene thermocycler.
4.3.5 Transformation of competent cells with mutated
pFUSE-hIgG1-Fc2-3.4-DBL and pFUSE-hIgG1-Fc2-3.8-DBL
Cells were transformed using the same method as in Chapter 3 for the transformation of
the original pFUSE constructs. Single colonies were grown and DNA purified by mini-prep
which was then screened to check that it contained the insert by restriction digest (Section
3.3.7).
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DNA sequencing of mutant DBL-Fc fusion constructs
Plasmids containing insert were identified and DNA sent for sequencing. Several
plasmids had mutations which introduced stop codons and many mutations were silent.
Plasmid sequences were checked and mutants were identified for expression.
4.3.6 Expression and purification of mutant 3.4 and 3.8 DBL-Fc fusion
recombinant protein library
Recombinant mutant proteins were expressed in CHO-KI cells using the same methods as
were used in Chapter 3 (Section 3.3.8), however, HAMs F10 media was used instead
of DMEM. CHO-KI cells were transfected using FuGENE 6 transfection reagent and
selected using zeocin selection media. Monoclonal high-expressing colonies were selected
by immunoblot analysis and subsequently cell supernatant was purified using a protein-G
sepharose HiTrap column on the A¨KTA-FPLC. Supernatants were diluted in a new binding
buffer in order to optimise binding conditions. Methods were used as in Chapter 3 but
with 20 mM sodium phosphate pH 7.0 as binding buffer. Protein was eluted using 0.1 M
glycine-HCl, pH 2.7. Immunoblot analysis was used to test for the presence of recombinant
protein in FPLC fractions which were then pooled and concentrated by ultrafiltration.
4.3.7 IgM-binding ELISA
The library of mutants was screened for IgM-binding by ELISA. Methods were used as in
Chapter 3 (Section 3.3.10).
4.3.8 Western blot analysis
After proteins were run on a NuPAGE Novex 4-12% Bis-Tris pre-cast gel by SDS-PAGE
(Section 2.4.6) they were transferred to nitrocellulose for Western blotting (Section 2.4.8).
Detection of MSP 3.4 and 3.8
To detect the presence of the MSP DBL domains αMSPDBL1 and αMSPDBL2, polyclonal
antibodies (kindly provided by Cecile Crosnier, Sanger Institute) were used. Polyclonal
antibodies were diluted to 0.5 μg/ml in PBST and the nitrocellulose blot incubated
overnight at 37◦C on a rocker. The membrane was washed three times before the addition
of an αrabbit-IgG-AP (Sigma A9919) at a dilution of 1:5,000 in PBST which was incubated
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for 2 hours at 37◦C. The membrane was again washed three times before proteins were
visualised by BCIP/NBT (Sigma) according to the manufacturer’s instructions.
Detection of IgG-Fc
To detect the presence of IgG-Fc an αhIgG-Fc-AP was used as in Chapter 3 (Section
3.3.11).
IgM binding
To investigate IgM binding in DBL mutants, 5 μg of each DBL mutant was incubated
with 5 μg of hIgM for 4 hours at 4◦C on a shaker. 50 μl of αhIgM agarose beads were
washed three times and resuspended in 200 μl PBS. The bead suspension was added to
the DBL-IgM complex and incubated overnight at 4◦C on a shaker in order to pull out
any DBL-IgM in complex. The beads were washed three times with PBS, SDS loading
buffer added and the samples held at 95◦C for 5 mins. Samples were run on SDS-Page
before transferring to nitrocellulose (Sections 2.4.6 and 2.4.8). After the membrane was
blocked and washed, αhIgG-Fc-AP was used to visualise proteins as in Chapter 3 (3.3.11).
4.3.9 Gel filtration of recombinant mutant DBL domains
The library of mutants was characterised by gel filtration using the same methods as in
Chapter 3 (Section 3.3.12).
4.3.10 Sequence analysis
Sequence alignments
Multiple sequence alignments were produced using the EMBL-EBI Clustal Omega multiple
sequence alignment web form available at http://www.ebi.ac.uk/Tools/msa/clustalo/
(Sievers et al., 2011).
Local nucleotide and amino acid sequence similarities were analysed using the NCBI
BLAST: Basic Local Alignment Search Tool available at http://blast.ncbi.nlm.nih.
gov/Blast.cgi. BLAST was also used for sequence alignment.
Homology-extended multiple sequence alignments were producing using the multiple
sequence alignment toolbox, PRALINE available on the IBIVU web server at http://
www.ibi.vu.nl/programs/pralinewww/ (Simossis and Heringa, 2005).
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Homology block analysis
Frequent homology block patterns within known IgM-binding and non-binding DBL
domains were data mined using the release version of SPMF Open Source Data
Mining Library and the Apriori Algorithm which is available at http://www.
philippe-fournier-viger.com/spmf/ (Fournier-Viger et al., 2014).
Homology blocks were analysed using the VarDom 1.0 Server http://www.cbs.dtu.
dk/services/VarDom/| (Rask et al., 2010).
Phylogenetic analysis
Maximum likelihood phylograms were constructed using MEGA 6.0 available from http:
//www.megasoftware.net (Tamura et al., 2013).
4.3.11 Structural analysis
DBL-IgM binding simulations
DBL-IgM binding simulations were performed in collaboration with Dr Daniel
Czajkowsky (Shanghai Jiao Tong University). The DBL homology model of MSPDBL1
was developed based on the known structure of the MSPDBL2 DBL domain. Molecular
dynamic simulations were based on the previously modelled DBL-IgM interaction
(Czajkowsky and Shao, 2009; Czajkowsky et al., 2010).
Molecular graphics and analyses were performed with PyMOL (Molecular Graphics
System, v1.7.4.5 Edu Enhanced for Mac OS X, Schrodinger, LLC) and the UCSF
Chimera package (Chimera is developed by the Resource for Biocomputing, Visualization,
and Informatics at the University of California, San Francisco. Supported by NIGMS
P41-GM103311) (Pettersen et al., 2004).
3D structure prediction
3D structure prediction was performed using the Phyre 2 protein fold recognition
server available at http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index
(Kelley et al., 2015) and the SWISS-MODEL protein structure homology-modelling server
available at http://swissmodel.expasy.org (Biasini et al., 2014).
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Stability analysis
Stability of point mutations was analysed using the SDM server at http://mordred.
bioc.cam.ac.uk/~sdm/sdm.php which analyses the local structure of the wild-type and
mutant and calculates a stability score for the point mutation (analogous to free energy
difference) (Worth et al., 2011). Multiple mutations in a single mutant were analysed
separately as point mutations.
4.3.12 Protein-protein interaction site prediction
Protein-protein interaction site prediction was performed using the meta-PPISP web server
available at http://pipe.scs.fsu.edu/meta-ppisp.html (Qin and Zhou, 2007).
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4.4 Results
4.4.1 Generation of Library of MSPDBL mutants
4.4.1.1 Random mutagenesis
A Genemorph II Random Mutagenesis kit (Agilent Technologies) was used for random
mutagenesis, using the Mutazyme II error-prone DNA polymerase. The PCR product
was run on a 1% gel and bands corresponding to the DBL inserts were identified (Figure
4.3).
Figure 4.3: PCR amplified products of the MSP3.4 and MSP3.8 DBL domains on
1% agarose gel. Lanes: 1 MSP3.4 DBL amplified using Phusion High Fidelity DNA
Polymerase, 2 MSP3.4 DBL amplified using Mutazyme II polymerase (Genemorph II
kit), 3 MSP3.8 DBL amplified using Phusion High Fidelity DNA Polymerase, 4 MSP3.8
DBL amplified using Mutazyme II polymerase (Genemorph II Kit)
The PCR products were then purified (Section 2.2.3) and cut by restriction
digest alongside the pFUSE-hIgG1-Fc2-DBL3.4 and pFUSE-hIgG1-Fc2-DBL3.8 plasmids
(Section 4.3.2).
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Digested PCR product
Figure 4.4: Restriction digest of 3.4 DBL and 3.8 DBL domains amplified by both
Phusion and Mutazyme II DNA polymerase as well as pFUSE digested plasmid on 1%
agarose gel. Bands highlighted in red were cut out and purified (Section 2.2.6). Lanes:
1 3.4 DBL amplified with Phusion and cut with restriction sites NcoI and BglII, 2
3.4 DBL amplified with Mutazyme II and cut with restriction sites NcoI and BglII, 3
pFUSE-hIgG1-Fc2-DBL3.4 plasmid digested with NcoI and BglII, 4 3.8 DBL amplified
with Phusion and cut with restriction sites EcoRI and NcoI, 5 3.8 DBL amplified with
Mutazyme II and cut with restriction sites EcoRI and NcoI, 6 pFUSE-hIgG1-Fc2-DBL3.8
plasmid digested with EcoRI and NcoI.
Purified PCR products were ligated into the relevant pFUSE plasmid (Section 2.2.8)
and 5 μl of the ligation reaction transformed into TOP10 cells (Section 2.2.10). Colonies
were grown overnight in ampicillin selection media (Section 2.1.16) before using mini-prep
to isolate the DNA (Section 2.2.11) from each colony.
Screening of positive colonies
Each colony was digested using NcoI/BglII for DBL 3.4 and EcoRI/NcoI for DBL 3.8
(Section 2.2.12) in order to identify colonies which contained the insert (Figure 4.5).
Figure 4.5: Typical restriction digest of colonies grown from transformation. Colonies are
positive if they contain the DBL insert. Lanes: 1-3, 5-8 Positive colonies, 4 Negative
colony.
Mini-prep DNA from colonies identified as positive was checked by sequencing (Source
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Bioscience, Section 2.2.13). From mutagenesis of the 3.4 DBL construct, DNA was
extracted from 116 colonies and 103 were identified as positive by restriction digest
screening. From mutagenesis of the 3.8 DBL construct, DNA was extracted from 80
colonies. Of these, 41 were identified as positive by restriction digest screening.
A script was written in Python to help analyse the sequences. The 5’ sequence was
aligned with the reverse complement 3’ sequence and any mis-matches identified and
corrected using the ab1 file until both sequences were identical. The 5’ sequence was
then aligned with the amino acid sequence from the DBL domain and any mismatches
confirmed as mutations.
Analysis of sequencing results
Sequencing results from all colonies were analysed (Table 4.2). Of the 103 3.4 DBL
colonies, reads could not be obtained for five. Of the remaining 98, only 18 contained
mutations which did not introduce a stop codon, or lose/gain a nucleotide thus introducing
a frame shift. The mutagenesis reaction had a low success rate, as 71.4% of the colonies
contained wild-type DBL inserts. Wild-type inserts occurred either because any mutations
changed only the codon and not the corresponding amino acid, or no mutations occurred.
Of the 41 3.8 DBL colonies sent for sequencing, reads could not be obtained for two.
Of the remaining 39, 30 contained mutations which did not introduce a stop codon, or
introduce a frame shift. This mutagenesis reaction had a much higher success rate as only
10% of the colonies sequenced contained wild-type DBL inserts.
Table 4.2: Analysis of mutant sequencing results. Of the total colonies identified as
positive, a proportion of the colonies sequenced were found to contain wild-type inserts
(WT) with no mutations. A proportion were found to contain mutated inserts with
potential for expression (Mut). Sometimes, a mutation introduced a stop codon (stop) or
introduced a frame shift (FS).
Total
colonies
#
stop
%
stop
# FS % FS #
WT
%
WT
#
Mut
%
Mut
3.4
DBL
98 8 8.2 2 2 70 71.4 18 18.4
3.8
DBL
39 4 10 2 5 4 10 29 75
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The observed difference in success rates of the mutagenesis reaction is interesting
because a higher percentage of colonies selected from the 3.4 DBL mutagenesis reaction
contained an insert when screened by restriction digest. However, upon further analysis
of sequencing results, these inserts were more likely to be wild-type. It was difficult to
produce colonies for the 3.8 DBL mutagenesis reaction, and colonies selected were less
likely to contain an insert when screened by restriction digest. However, upon sequencing
the insert was much more likely to contain a mutation.
4.4.2 Selection of mutants for expression
A molecular simulation of DBL-IgM binding developed by Czajkowsky et al. (2010)
localises the IgM-binding region of both 3.4 DBL and 3.8 DBL to an exposed area of
subdomain 2. This consists of the end of helix 5 (h5) with the loop between helices h5
and h6, and the end of helix 2 (h2) and the start of helix 3 (h3) as well as the loop joining
h2 and h3 (Figure 4.6).
(a) (b)
(c) (d)
Figure 4.6: Model of DBL-IgM binding. (a & b) Model of 3.4 DBL (white) binding
between two monomers of IgM (blue and pink). (c & d) Model of 3.8 DBL (brown)
binding between two monomers of IgM. Both models highlight the end of helix 5 (h5) and
the loop between helix 5 and 6 as well as helices 2 (h2) and 3 (h3) as regions involved in
IgM-binding.
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Ten mutants for each of the MSP DBL domains were selected for protein expression
(3.4: Table 4.3 3.8: Table 4.4). These mutants were selected based on the two regions
identified by the IgM-binding model. Where multiple mutants contained mutations in
these areas, mutants were selected based on changes in charged residues. Those containing
mutations involving cysteine residues were also selected due to their key role in stabilising
the core structure. A complete list of all mutants produced along with the location of
their mutations can be found in Appendix C.
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Table 4.3: Summary of 3.4 DBL mutants. Mutants expressed and their corresponding
amino acid mutations. Sequence location of each mutation is described along with its
helical position and any changes in charge noted. Recombinant protein yield for each
mutant has been summarised with ++ representing equivalent yield to wild-type while +
represents a lower yield and + + + improved yield. IgM-binding is represented by Xwhich
is equivalent to wild-type binding and XXrepresents improved IgM-binding compared to
wild-type. Reduced IgM-binding was not observed for any mutants.
DBL
mutant
Mutation Change in
charge
Position Protein
yield
IgM-bindng
3.4 #10
G169S h1
++ XK194N Y h1
N278D Y h4
C427R Y h9
3.4 #26
K194T Y h1
++ X
Q265H Y h4
E279G Y h4
I285F loop (h4-h5)
N388S h7
3.4 # 36 D323V Y loop (h5-h6) + X
3.4 # 47 I266N h4 + + + X
3.4 # 48
S281G loop (h4-h5)
++ XA294V h5
W300R Y h5
3.4 # 56 I243V h3 + + + X
3.4 # 66
I200V loop (h1-h2a)
++ XH310R Y h5
E318V Y loop (h5-h6)
3.4 # 74
D170E h1
+ XL228P h2
N321Y loop (h5-h6)
3.4 # 77
A175T loop (h1-h2a)
+ XN269D Y h4
C340S h6
K407M Y h7
3.4 # 87 N201Y h2a ++ XX
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Table 4.4: Summary of 3.8 DBL mutants. Mutants expressed and their corresponding
amino acid mutations. Sequence location of each mutation is described along with its
helical position and any changes in charge noted. Recombinant protein yield for each
mutant has been summarised with ++ representing equivalent yield to wild-type while +
represents a lower yield and + + + improved yield. IgM-binding is represented by Xwhich
is equivalent to wild-type binding and XXrepresents improved IgM-binding compared to
wild-type. Reduced IgM-binding was not observed in any mutants.
DBL
mutant
Mutation Change in
charge
Position Protein
yield
IgM-binding
3.8 #4
S210G h1
+ X
S395G h6
3.8 #12
L203V loop (h1a-h1)
+ XR243L Y h5
T396A h7
N424K Y h7
3.8 #17
V202M loop (h1a-h1)
+ X
P205S loop (h1a-h1)
L211P loop (h1-h2a)
K255R h3
T335S loop (h5-h6)
3.8 #23
K200N Y loop (h1a-h1)
+ XD229G Y h2
Y235H Y h2
3.8 #34
G228D Y loop (h2a-h2)
+ X
K330E Y loop (h5-h6)
3.8 #37
W309R Y h5
+ XM321L h5
D421V Y h7
3.8 #38
N300K Y loop (h4-h5)
+ X
K304E Y loop (h4-h5)
3.8 #44
N184S Y loop (h1a-h1)
++ XX
N339D Y loop (h5-h6)
3.8 #65
H257Q Y h3
++ XX
T396A h7
3.8 #70
N199Y Y loop (h1a-h1)
+ X
Q376H Y loop (h6-h7)
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Stability analysis of mutations
The SDM server was used to predict the effect of a mutation on the DBL structure.
This calculates the free energy difference between the wild-type and mutant which is
represented in a stability score (Worth et al., 2011). The aim was to identify mutations
which have an impact on protein structure and may therefore have an impact on function.
Multiple highly destabilising mutations were predicted in various DBL mutants. 3.4
DBL mutants #48 and #77 contain such multiple highly destabilising mutations (S281G,
W300R and C340S) and 3.8 DBL mutant #34 contains exclusively destabilising mutations,
one of which is predicted to have a highly destabilising effect (G228D) (full analysis
can be found in Appendix F). The combined destabilising effect of multiple mutations
is unclear from this analysis as the free energy difference is calculated only from point
mutations. Analysis was therefore not used in selecting mutants for expression, however,
mutants identified from this analysis were investigated further if loss of functionality was
experimentally verified.
Cysteine mutants
While many cysteine residues are conserved, the overall disulphide bond structure of
a DBL domain has been shown to be unique to this protein family (Hodder et al., 2012).
Merozoite DBL domains have a distinct disulphide bond structure which links together
subdomains 1 and 2, as well as stabilising the long alpha-helical subdomain 3. The location
of cysteine residues is shown in the homology model of 3.4 DBL (Figure 4.7). Mutant 3.4
#10 contains the mutation C427R which corresponds to C12a, a cysteine residue located
at the C-terminal and found only in the merozoite DBL domains and PfEMP1 Var2CSA
DBL6ε. This is therefore an interesting mutant to express. 3.4 #77 contains the mutation
C340S which corresponds to C7, a linking cysteine in subdomain 3. While present in both
merozoite DBL domains, this cysteine is also a common feature of PfEMP1 DBL cysteine
architecture. It is seen in some members of the EBA family and could therefore be critical
for stability of the structure.
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(a)
(b) (c)
Figure 4.7: Mutated cysteine residues in 3.4 DBL mutants. (a) Homology model
of 3.4 DBL showing the location of cysteine residues. (b) Homology model showing the
location of C427R in 3.4 DBL mutant 10. (c) Homology model showing the location of
C340S in 3.4 DBL mutant 77.
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4.4.2.1 Expression of recombinant DBL mutants
DBL mutants were expressed using HAMs F10 media and the same methods as Chapter
3. Colonies grown from high-expressing single cells were expanded to large cultures and
following 10 days of growth, the cell supernatant harvested and purified using a protein
G column on an AKTA FPLC. Purification methods were developed to optimise binding
conditions. HBSS was replaced with 20 mM sodium phosphate which was found to be
the optimal binding buffer. Cell supernatant was diluted 1:1 with binding buffer prior to
loading. This ensured optimal ionic strength and pH. Elution conditions were optimised
and the pH for elution was increased to pH 2.7, this still enabled effective elution and
prevented protein denaturing.
Once optimised, the protocol and conditions were repeated exactly for each mutant.
The size of the peaks for most mutants was comparable to that of the wild-type, however
3.4 mutants 36, 77, and 3.8 mutants 12 and 34 had notably lower yields. High expressing
mutants were 3.4 mutants 47 and 56 as well as 3.8 mutant 44. Protein yields are
summarised in Tables (4.3) and (4.4) and FPLC peaks are in Appendix (J).
Immunoblot of FPLC fractions
Fractions were collected and immunoblotted with αhIgG-Ap to show that the protein
was present in the fraction corresponding to the FPLC peak (Figure 4.8). Fractions
containing protein were pooled and concentrated by Vivaspin 2 ultrafiltration columns.
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(a) Immunoblot of 3.4 DBL-Fc mutant FPLC fractions.
(b) Immunoblot of 3.8 DBL-Fc mutant FPLC fractions.
Figure 4.8: Immunoblot of DBL mutant FPLC fractions. Fractions A1-A11 from
the FPLC elution were tested by immunoblotting for the presence of protein. These
were compared to a blot of the supernatant (sup) prior to purification as well as the
flow-through (FT) to check that all the protein had been removed. Media was used as a
negative control (-ve). Immunoblot of (a) 3.4 DBL and (b) 3.8 DBL mutants fractions
after FPLC purification.
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4.4.2.2 Characterisation of recombinant DBL mutants
Variations were observed in protein expression for the recombinant DBL mutants. In order
to check whether there were differences in protein folding caused by mutations, Western
blot analysis was performed.
αIgG-Fc Western blot
Western blots using an αIgG-Fc to detect Fc-fusion proteins showed that protein yield
was low (particularly for 3.8 DBL mutants). There was limited formation of homodimeric
Fc-fusion proteins, and mostly monomeric DBL fusions were produced (Figure 4.9).
(a) Non-reducedWestern blot of DBL 3.4 mutants. (b) Non-reduced Western blot of DBL 3.8 mutants.
(c) Reduced Western blot of DBL 3.4 mutants. (d) Reduced Western blot of DBL 3.8 mutants.
Figure 4.9: Non-reduced and reduced Western blots of 3.4 and 3.8 DBL mutants
detected using αIgG-Fc. Protein expression and folding varied across the mutants.
Monomeric DBL fusions were produced by 3.4 DBL mutants and some 3.8 DBL mutants,
but protein yield was low.
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All 3.4 DBL mutants produced monomeric recombinant protein. Protein production
appears to be particularly difficult for 3.8 DBL compared to the 3.4 DBL domain as yields
are low. Mutants 3.8 DBL mutants 44 and 65 produced more monomeric Fc-fusion protein
compared to other 3.8 DBL mutants. It is possible that a band visible at ∼120 kDa is
homodimer. This band is also present in 3.4 DBL mutant 87 as well as a faint band for
the wild type DBL. This shows an improvement from protein produced in Chapter 3 and
shows successful optimisation of the methods.
3.8 DBL mutant 44, which contains two asparagine substitutions (located in the loops
between helices h1a-h1 and h5-h6) has previously been identified as a high-expressing
mutant. It is likely that the lack of monomeric Fc produced for the other 3.8 DBL
mutants is due to low yield.
αMSPDBL Western blot
To further characterise the protein produced, an αMSPDBL Western blot was used with
detection from αMSPDBL1 and αMSPDBL2 polyclonal antibodies (kindly provided by
Cecile Crosnier, Sanger Institute). This provided evidence of some homodimer formation
as a band was seen at 120 kDa for some mutants (Figure 4.10). Bands seen at 50 kDa
which were detected in αIgG-Fc Western blot analysis suggest that there is more improper
folding of the Fc-fusion protein than initially observed. This band could be a monomeric
fusion protein with improper folding of the Fc.
(a) Non-reduced Western blot of 3.4 DBL mutants (b) Non-reduced Western blot of 3.8 DBL mutants
Figure 4.10: Non-reduced Western blots of 3.4 and 3.8 DBL mutants detected
using αMSPDBL polyclonal antibodies. Western blot analysis provided evidence of
some homodimer formation as a band was detected in some mutants at ∼ 120 kDa.
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Size exclusion
In order to investigate the native structure of the fusion proteins, the recombinant protein
was run by gel filtration (Section 3.3.12). Peaks were spread across fractions A8 to B5
(corresponding to 700 - 1 kDa) as seen in the initial wild-type DBL-fusions produced in
Chapter 3 (Figure 4.11). This again suggests that protein aggregates are being formed.
Two high-expressing mutants 3.4 DBL 56 and 3.8 DBL 44 (Figures 4.11c and 4.11e
respectively) were investigated and their size exclusion profiles found to be similar to
the wild types (Figures 4.11b and 4.11b).
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(a) BioRad size exclusion standards
(b) 3.4 DBL WT (c) 3.4 DBL mutant #56
(d) 3.8 DBL WT (e) 3.8 DBL mutant #44
Figure 4.11: Size exclusion profiles from DBL mutants. (a) Peaks for 100 μl protein
standards. (b) 3.4 DBL WT size exclusion profile and (c) 3.4 DBL mutant 56 size exclusion
profile. (d) 3.8 DBL WT size exclusion profile and (e) 3.8 DBL mutant 44 size exclusion
profile.
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4.4.2.3 IgM-binding analysis of MSPDBL Mutants
In Chapter 3 it was shown that the recombinant DBL Fc-fusion proteins bind human IgM
by ELISA. Increased binding was observed for 3.4 DBL compared to 3.8 DBL which is in
agreement with the literature where 3.8 DBL binds with ten-fold affinity (Crosnier et al.,
2016). A panel of recombinant mutant DBL Fc-fusion proteins has been created which
were further investigated to identify whether any mutations had an impact on IgM-binding.
αIgM Western blot
IgM-binding of the DBL mutants was first investigated using Western blot analysis (Figure
4.12). DBL domains were pre-incubated with hIgM and then pulled out using αIgM agarose
beads. These were reduced and added to SDS-PAGE before transferring to nitrocellulose
and blotting with αIgG-Fc (Section 4.3.8). Protein detected was monomeric, although a
lower band which is also present in αIgG-Fc Western blot analysis (Figure 4.9) suggests
that the fusion proteins have difficulty folding. This band may correspond to an incorrectly
folded monomeric Fc-fusion.
(a) 3.4 DBL mutants (b) 3.8 DBL mutants
Figure 4.12: Reduced Western blots of 3.4 and 3.8 DBL Fc-fusion mutants bound
to hIgM detected using αIgG-Fc. DBL Fc-fusion proteins were pre-incubated with
hIgM and pulled out with αhIgM-agarose before being added under reducing conditions
to SDS-PAGE and transferred to nitrocellulose. Protein was detected using αIgG-Fc.
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IgM binding ELISA
The IgM-binding sandwich ELISA used in Chapter 3 was repeated for the DBL mutants in
order to compare their IgM-binding function compared to the wild-type proteins (Figure
4.13). Interestingly, there was no loss of binding and there appeared to be improved
binding for 3.4 DBL mutant 87 which contains a single mutation N201Y located in helix
2a of the second subdomain. 3.8 DBL mutants 44 and 65 also appeared to improve binding.
This could be due to the presence of homodimers as detected by Western blot analysis.
However, due to high variation in experimental repeats, possibly due the unquantifiable
protein fragments present, these results were not statistically significant (data not shown).
137
4 ANALYSIS OF KNOWN IGM-BINDING DBL DOMAINS
(a) IgM-binding of recombinant 3.4 DBL mutant Fc-fusion proteins.
(b) IgM-binding of recombinant 3.8 DBL mutant Fc-fusion proteins.
Figure 4.13: IgM-binding analysis of (a) 3.4 DBL and (b) 3.8 DBL mutants.
A sandwich ELISA was used to characterise IgM-binding of recombinant mutant DBL
Fc-fusion proteins compared to the wild-type DBL fusion proteins. The mean ± SD are
shown for four experiments.
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The location of the N201Y mutation (helix 2a) is not an area predicted by the binding
model, as helix 2a is thought to be buried in the DBL structure (Figure 4.13). Structural
analysis of DBL mutants predicted that mutations E318V in 3.4 DBL mutant 66 and
N321Y in 3.4 DBL mutant 74 might have an impact on IgM binding, as well as T335S
in 3.8 DBL mutant 17, K330E in 3.8 DBL mutant 34 and N339D in 3.8 DBL mutant 44
(Appendix D). However, this study was not successful in experimentally investigating this.
(a) 3.4 DBL WT asparagine at position 201 (b) 3.4 DBL WT
(c) 3.4 DBL mutant 87, tyrosine at position 201 (d) 3.4 DBL mutant 87
Figure 4.14: 3.4 DBL mutant 87 (N201Y). 3.4 mutant 87 has an Asparagine mutation
in helix 2a which may improve IgM binding.
The experimental results were disappointing, therefore protein interface prediction was
used next to provide structural insight into the IgM-binding region.
4.4.3 Protein-Protein Interaction Prediction (PPIP) analysis
There are a range of web-based servers available for protein-interface prediction, by
identifying conserved residues and the nature of these residues, as well as entropy. Surface
residues are then scored for their properties and binding interfaces are defined as clusters
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of high scoring residues.
Meta-PPISP was used to predict binding interfaces in the merozoite DBL domains
(Appendix G). This server combines the results from three further servers cons-PPISP
(http://pipe.scs.fsu.edu/ppisp.html), Promate (http://bioportal.weizmann.ac.
il/promate), and PINUP (http://sparks.informatics.iupui.edu/PINUP/) in a linear
regression analysis and shows improved performance compared to the individual methods
(Qin and Zhou, 2007).
Meta-PPISP predicted two main binding interfaces in both MSPDBL1 and MSPDBL2
(loops h1a-h1 and h1-h2a in MSPDB2 DBL domain and h2a, h4 in MSPDBL1 DBL
domain). Interestingly, helix 2a is predicted as a common binding region for both proteins
and may therefore correspond to the IgM binding site.
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4.4.4 Sequence analysis of IgM-binding domains
Since the experimental analysis of the library of DBL mutants proved to be inconclusive
and hampered by limited protein yield and lack of proper folding, we next turned to
sequence analysis for further insight into residues critical for IgM-binding. Sequence
alignments for all mutants expressed can be found in Appendix E.
Eight P. falciparum DBL domains have been shown to bind IgM in addition to
MSPDBL2 and MSPDBL2 (Table 4.1). In a recent study by Crosnier et al. (2016), IgM
binding was investigated in eleven MSPDBL1 isolates and nine were found to bind, whereas
isolates 7G8 and 028 did not bind. By sequence alignment it was observed that a Glu
residue at position 310 was common to both non-binding isolates. However when this
residue was substituted for the Gln residue present in isolate 384 (known to bind IgM)
by mutagenesis, this mutation was not sufficient to restore IgM-binding (Crosnier et al.,
2016).
Phylogenetic analysis of all known DBLε IgM-binding and non IgM-binding DBL
domains showed a lack of clustering (Figure 4.15). Sequence alignments of fifteen known
non-binders (Figure 4.16) and ten IgM-binding domains (Figure 4.17) is also consistent
with this result. Analysis of conserved regions revealed that these regions correspond
to homology blocks which make up the core structure of all DBL domains (Figures 4.18
and 4.19). This suggests that the quaternary structure of these DBL domains is highly
important for IgM binding in the context of the native protein. A more comprehensive
analysis awaits the publication of thousands of P. falciparum genomes that are currently
being analysed (Pleass et al., 2015).
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Figure 4.15: Phylogenetic Relationships between IgM Binding and Non-Binding
DBLε Domains. Phylogenetic analysis of eight IgM binding (red) and twelve
non-binding (blue) DBLε domains shows a lack of clustering. Bipartition bootstrap
support (%) is indicated by edge numbers. Amino acid substitutions per site are indicated
by scale bar (Pleass et al., 2015).
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Figure 4.16: Sequence alignment of known non IgM binding DBL domains
highlighting sequence conservation. Sequences are conserved between non
IgM-binding DBL domains in locations of homology blocks common to all DBL domains.
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Results colour-coded for amino acid conservation
The current colourscheme of the alignment is for amino acid conservation.
The conservation scoring is performed by PRALINE. The scoring scheme works from 0 for the least conserved alignment position, up to 10 for the most conserved alignment position.
The colour assignments are:
Unconserved 0 1 2 3 4 5 6 7 8 9 10 Conserved
. . . . . . . . . 10 . . . . . . . . . 20 . . . . . . . . . 30 . . . . . . . . . 40 . . . . . . . . . 50
TM284var1 EESNTTERYI SKEDPQYHPE YKGDGKVNYK YEKGKPKALP SIYPLNCAEK
HB3var06 ---------- ---------- ---------- ---------- ---IDRSAFE
DBLMSP1 ---------- ---------- ---------- ---------- ----------
DBLMSP2 ---------- ---------- ---------- ---------- ----------
NF54MAL6P1_4DBL---------- ---------- ---------- ---------- ----------
NF54PfL003c ---------- ---------- ---------- ---------- ----------
NF54MAL6P1_4DBL---------- ---------- ---------- ---------- ----------
NF54PFL0020W ---------- ---------- ---------- ---------- ----------
FCR3var1csa ---------- ---------- ---------- ---------- ----------
FCR3var2csa ---------- ---------- ---------- ---------- ----------
Consistency 0000000000 0000000000 0000000000 0000000000 0000000000
. . . . . . . . . 60 . . . . . . . . . 70 . . . . . . . . . 80 . . . . . . . . . 90 . . . . . . . . . 100
TM284var1 VADELRMYAE NSLDTNTKLK AKISKSIDTN EQNATNDEID CNIYNNISNG
HB3var06 LYAKAKSDLH G---VKDKLK GNNTKNIYEE TTNGKNDDNI ICKINESISK
DBLMSP1 ---------- ---------- ---------- --------KC PDENFCKGIK
DBLMSP2 ---------- ---------- ---------- --------KC PTEEICKDFS
NF54MAL6P1_4DBL---------- ---------- ---------- ------LNPE CPEDIECSQY
NF54PfL003c ---------- ---------- ---------- --LDRCFDDK SKMKVCDLIG
NF54MAL6P1_4DBL---------- ---------- ---------- -----DLDKC PNNINN----
NF54PFL0020W ---------- ---------- ---------- ----DPLDEC PVDKDECKKY
FCR3var1csa ---------- ---------- ---------- ---------- --------CS
FCR3var2csa ---------- ---------- ---------- ---------- --------CN
Consistency 0000000000 0000000000 0000000000 0000001222 2121221123
. . . . . . . . . 110 . . . . . . . . . 120 . . . . . . . . . 130 . . . . . . . . . 140 . . . . . . . . . 150
TM284var1 QKNTCEHNGN TFHDKDEWDC NKGTNKLYEN DICLPPRRKH MCTKQLENIS
HB3var06 QNNVCKKNEN LFDDIDKWDC KKRTNTVPIE NICIPPRRKL MCAYPLKNLG
DBLMSP1 NVLSCPPKNS TGRNGDWISV AVKESSTTNK GVLVPPRRTK LCLRNINKV-
DBLMSP2 NLPQC--RKN VHERNNWLGS SVKNFSSDNK GVLVPPRRQS LCLRITLQDF
NF54MAL6P1_4DBLGNIPC-RGVS HDDDNDWNSS FVKDNKTTNL GVLVPPRRRH LCLRIDVNKF
NF54PfL003c DAIGCKHKTK LDELDEWNDV DMRDPYNKYK GVLIPPRRRQ LCFSRIVRGP
NF54MAL6P1_4DBLNKNICNKYKK RRICGDLKYS NSL-DHWFGT NTLIPPRRRH LCLRNIIIKK
NF54PFL0020W GRYSCRKNHY NKNPIEWTNH FVKKSIRNYE AVMVPPRRRQ LCLIGNRRFV
FCR3var1csa -----KNDYD NNLDNWNAYL VLNSS-DDNK GVLIPPRRRH LCTRPITAYN
FCR3var2csa KYKNIHDRMK KNNGNFVTDN FVKKSWEISN GVLIPPRRKN LFLYIDPSKI
Consistency 3222623434 3333343243 3553423234 5878****64 8854243422
. . . . . . . . . 160 . . . . . . . . . 170 . . . . . . . . . 180 . . . . . . . . . 190 . . . . . . . . . 200
TM284var1 TASITTTDDL LKEVLITAVN EGKRLKQQWE KTENEAQKKK HFLCDAMKYS
HB3var06 VKK-NTSEVL FNKVLRTAAY EGKHIKESWE KAE-KSKKKK TQICDAMKYS
DBLMSP1 WHRIKDEKNF KEEFVKVALG ESNALMKHYK EK-------N LNALTAIKYG
DBLMSP2 RTKKKKEGDF EKFIYSYASS EARKLRTIHN NN-------L EKAHQAIRYS
NF54MAL6P1_4DBLLRLRNDINNL KTFICKSAFA EAKRLKKVYK DD-------N SKLHQAMKYS
NF54PfL003c A-NLRNLKEF KEEILKGAQS EGKFLGNYYN ED-----KDK EKALEAMKNS
NF54MAL6P1_4DBLNYRKGDISKF KDDLFYAAAS EAKFLFNNYE -------N-K NESLQAIKYT
NF54PFL0020W G-RVKDEKMF KEYLLRDASS EAKMLSQYYN -------FDN EKALQAIKYS
FCR3var1csa YRK-GDKEIL KKKLLTSAFS QGQLLGQKYK SE-------E ELCFEAMKYS
FCR3var2csa CEYKKDPKLF KDFIYWSAFT EVERLKKAYG GA-------R AKVVHAMKYS
Consistency 2242453537 6537534*45 9563945375 2200000105 44535*7988
. . . . . . . . . 210 . . . . . . . . . 220 . . . . . . . . . 230 . . . . . . . . . 240 . . . . . . . . . 250
TM284var1 FADLADIIRG TDIWKGNREQ QKIQERLVKI FRNIYDNLEK DEYEKYKYGT
HB3var06 FADLGDIIRG RDILIFNNGN NEIERDLKAV FQSIYDKWKS DSNNNKDKYP
DBLMSP1 FSDMGDIIKG TDLIDYQ-IT KNINRALDKI LRN-E----- -------TSN
DBLMSP2 FADIGNIIRG DDMMDTP-TS KETITYLEKV LKIYN----- -------ENN
NF54MAL6P1_4DBLFSDIGSVVKG NDM-----ME SPTSDNIAKI FRGMK----- ----------
NF54PfL003c FYDYEYIIKG SDMLTNI-QF KDIKRKLDRL LEKE------ ---------T
NF54MAL6P1_4DBLFADIGDIIKG NDMMDDM-TY KKIKGKLEKV LDKT------ ---------G
NF54PFL0020W FADIGNIIKG DDMLDDG-IS EKIENIFEHK INKRTH---- SSSLSSSSSS
FCR3var1csa YADYSDIIKG TDM-----MD TSLSEKIKKI FETSN----- ----------
FCR3var2csa FTDIGSIIKG DDM-----ME KNSSDKIGKI LGDTD----- ----------
Consistency 96*665998* 4*82211034 5464437467 6432200000 0000000002
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. . . . . . . . . 260 . . . . . . . . . 270 . . . . . . . . . 280 . . . . . . . . . 290 . . . . . . . . . 300
TM284var1 KYQNLRSAWW DAHRKKIWNA MTCSAPGDFL FVKRGKGDGS DIEFLTFSEH
HB3var06 DLTSFRSAWW DANRKDIWKA MTCGAPEDAT LFKKLEKWGI PN---LILSQ
DBLMSP1 DKIKKRVDWW EANKSAFWDA FMCGYKV--- ---------- ---------H
DBLMSP2 DKPKDAKKWW TENRHHVWEA MMCGYQS--- ---------- ---------A
NF54MAL6P1_4DBLYTEINRETWW DLNKYHVWES MLCGYRE--- ---------- ------AGGD
NF54PfL003c NNTEKVDDWW ETNKKSIWNA MLCGYKK--- ---------- ------SGNK
NF54MAL6P1_4DBLNNPETPEKWW EQNKKHVWEA MLCGYKL--- ---------- ------AGGE
NF54PFL0020W GPNITPSTWW EKNKEKIWYV MMCYYTG--- ---------- ------EHKT
FCR3var1csa EATENRKTWW ENNRRQIWHA MLCGYKIA-- ---------- ------TSKV
FCR3var2csa GQNEKRKKWW DMNKYHIWES MLCGYREA-- ---------- ------EGD-
Consistency 43343554** 7488448*47 86*7753000 0000000000 0000002222
. . . . . . . . . 310 . . . . . . . . . 320 . . . . . . . . . 330 . . . . . . . . . 340 . . . . . . . . . 350
TM284var1 KKCGHDKEPP VYDYVPQILR WITEWSEHFC ELQEKNYYLL KEKCADYIQK
HB3var06 HKCGHNDDPP IDDYIPQRLR WMKEWGEYVC KILNENVNDM KNDCDKCTLN
DBLMSP1 IGNKPCPEHD NMDRIPQYLR WFREWGTYVC SEYKNKFEDV IKLCNIQQFT
DBLMSP2 QKDNQCTGYG NIDDIPQFLR WFREWGTYVC EESEKNMNTL KAVCFPKQPR
NF54MAL6P1_4DBLTKKSENCRFP DIERVPQFLR WFQEWTEIFC IKRKTLYDKM VTECQKAE--
NF54PfL003c IIDPSWCTIP TTETPPQFLR WIKEWGTNVC IQKEEHKEYV KSKCSNV---
NF54MAL6P1_4DBLI-KPNDCNIP TEESTHQFLR WLTEWGTQYC KEKQQLKLNM QIPCMTHFDK
NF54PFL0020W A-TSCP-SHN DIDNEDQFLR WMTEWAEYFC KEKKKEVEEL IEKCKTEITT
FCR3var1csa TLDEGWCQLP KDEETNQFLR WLIEWAKQAC KEKKHVSDSL KTKCPPRSNE
FCR3var2csa TETNENCRFP DIESVPQFLR WFQEWSENFC DRRQKLYDKL NSECISAE--
Consistency 3234323435 437355*6** *64**5545* 4556533437 444*333212
. . . . . . . . . 360 . . . . . . . . . 370 . . . . . . . . . 380 . . . . . . . . . 390 . . . . . . . . . 400
TM284var1 DSKPIDDSHN IKCNTCKTKC EEYSKFIKKW NSQYINLEKK FKELYDEANN
HB3var06 DKKCSDEDDG NKCRSCKEKC KEYTKLIYNL KSQFYILEKH YNELYTKAQN
DBLMSP1 NQDDSQLLEI SKKDKCKEAL KHYEEWVNRR RPEWKGQCDK FEKEKSKYED
DBLMSP2 TEANPAL-TV HENEMCSSTL KKYEEWYNKR KTEWTEQSIK YNNDKINYTD
NF54MAL6P1_4DBL---CDTSNGT VKETKCTKAC EEYKSYVLSK KKEYYIQKDK YDNQFKKVL-
NF54PfL003c -TNLGAQ--E SESKNCTSEI KKYQEWSRKR SIQWEAISEG YKKYKGMDEF
NF54MAL6P1_4DBLYGIIENR--I DVHPNCLQGL GKYEIWSNNR IPDWERLSSK FNEVKGTMN-
NF54PFL0020W KTYPTSN--Q NKQSSCYKVL EKYNHWLYNR KLEWNDISKK YQTYYNENSK
FCR3var1csa DNFEASE--L LRQPGCQNDI RKYISLNILI KNTMENLNIK Y---------
FCR3var2csa ---CTNG--S VDNSKCTHAC VNYKNYILTK KTEYEIQTNK Y---------
Consistency 1212343003 35344*4445 56*4454344 5365335537 8332323121
. . . . . . . . . 410 . . . . . . . . . 420 . . . . . . . . . 430 . . . . . . . . . 440 . . . . . . . . . 450
TM284var1 TKSYEELYRI GKPSHRNHYE DENLIQFLQN VKSECNEPNT VDKYLMYTSD
HB3var06 NT-------- ---TYFTNDN DKKVIEFFKK VKKDC-DVGT PDKYLDKAIH
DBLMSP1 TK-------- ------SITA EKYLKEICSE CDCKY---KD LDNTFKEFKD
DBLMSP2 IK-------- ------TLSP SEYLIEKCPE CKCTK---KN LQDVFELTFD
NF54MAL6P1_4DBL---------- ---------N NKDAEEFLNV H--------C LSEYFKDETR
NF54PfL003c ---------- ---------K NTFKNIKEPD ANEP-----N ANEYLKKHCS
NF54MAL6P1_4DBL---------- ---------E NV-------- -KKL-----T AYEYLKQNCS
NF54PFL0020W ---------- ---------S TQ-------- -LKR-----S AQEYVDQRCK
FCR3var1csa ---------- ---------- ---------- ---------- ----------
FCR3var2csa ---------- ---------- ---------- ---------- ----------
Consistency 0000000000 0000000002 3311121111 1211000002 3234332222
. . . . . . . . . 460 . . . . . . . . . 470 . . . . . . . . . 480 . .
TM284var1 CRRVKFSNTI DTNVNKPTAD VT-------- --
HB3var06 CIHYDFTKNG TKSKPYVFNN QPEKYKNLCS CT
DBLMSP1 ---------- ---------- ---------- --
DBLMSP2 ---------- ---------- ---------- --
NF54MAL6P1_4DBLWKNPYESIAD K--------- ---ALKGKCD C-
NF54PfL003c KCPC------ ---------- ---------- --
NF54MAL6P1_4DBLK--CI----- ---------- ---------- --
NF54PFL0020W E--C------ ---------- ---------- --
FCR3var1csa ---------- ---------- ---------- --
FCR3var2csa ---------- ---------- ---------- --
Consistency 0001000000 0000000000 0000000000 00
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Figure 4.17: Sequence alignment of known IgM binding DBL domains
highlighting sequence conservation. Sequences are conserved between IgM binding
DBL domains in locations of homology blocks common to all DBL domains.
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(a) IgM-binding DBL domains
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(b) Non IgM-binding DBL domains
Figure 4.18: Sequence conservation logos for known IgM binding and non-binding DBL
domains highlight only core DBL homology blocks.
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Figure 4.19: Homology blocks common to all DBL domains. Homology blocks 1 - 5
form the core structure of DBL domains and are the most conserved in the seven genomes
analysed by Rask et al. (2010).
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To further investigate whether conserved regions could be identified that are common
to IgM-binding domains, homology block (HB) analysis was performed based on the
homology blocks characterised by Rask et al. (2010). HBs contained in the known
IgM-binding and non-binding DBL domains described by Pleass et al. (2015), were
identified. HBs common to all DBL domains (HB1 - HB5) were removed from the
analysis, as were HBs which only occurred once. A data mining search then was performed
to identify binding motifs amongst HBs common only to IgM-binding DBL domains
(Appendix H) but no HB motifs unique to these domains were identified. Some single
HBs were unique to either IgM-binding or non-binding DBL domains, however these HBs
were considered rare from the seven-genome analysis conducted by Rask et al. (2010). In
such cases, the HB was contained in two DBL domains from the same domain class: such
domains might be expected to have sequence homology and structural similarities.
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4.4.5 Structural analysis of IgM-binding DBL domains
Since sequence analysis suggested that quaternary structure of the DBL domains was
important for binding, we aimed to use structural analysis to identify binding regions.
The predicted effect of DBL mutations using the structural model of IgM binding was
inconclusive, therefore the structure of known IgM-binding DBL domains was compared
to structures of known non-binders.
4.4.5.1 Structural analysis of IgM binding and non-binding MSPDBL domain
isolates
Although sequence analysis of known IgM binding DBL isolates did not highlight
significant residues (Crosnier et al., 2016). The structures of IgM binding DBLMSP
and DBLMSP2 isolates were modelled based on the known crystal structure of the DBL
domains from MSPDBL2. The non-binding DBL domains (isolate 028 and strain 7G9 in
DBLMSP) were superimposed and highlighted in red (Figure 4.20) (Crosnier et al., 2016).
This highlights differences in structure which are likely to be involved in IgM-binding
and were observed in helices h1, h2a, h4 and h7 (Crosnier et al., 2016). There are,
however, polymorphisms in h7 frequently observed around the same positions amongst
DBL domains that have retained their IgM-binding ability, therefore the IgM-binding site
is unlikely to be in h7 (Crosnier et al., 2016).
4.4.5.2 Structural analysis of all known IgM binding and non-binding DBL
domains
The structures of all known IgM binding DBL domains and non-binding DBL domains
(Table 4.1) were similarly superimposed, with binders (red) superimposed on non-binding
domains (Appendix I). Where the structure of a DBL domain was not known, it was
modelled based on the most closely related DBL domain with known structure. While
this highlighted the structural diversity of DBL domains, differences in structure between
IgM binding and non-binding domains were not clear. The analysis was repeated for
DBL domains solely of DBLε class and similarly for DBLζ class. However, the structural
diversity of the DBL domains was too high to identify differences between binding and
non-binding domains.
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Figure 4.20: Structural conservation of known IgM binding MSPDBL DBL
domain isolates vs non-binding isolates. DBL domains from known IgM binding
MSPDBL isolates (cream) vs non-binding isolates (red). Homology models of isolates
were produced using the Phyre2 software based on the crystal structure of MSPDBL2
(Kelley et al., 2015) and superimposed showing structural differences. Figure adapted
from (Crosnier et al., 2016).
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4.5 Summary
The aim of this chapter was to identify critical residues and binding motifs within the
MSPDBL1 and MSPDBL2 DBL domains which are responsible for IgM binding. In order
to do this, a library of DBL mutants was produced using the DBL-Fc fusion constructs
from Chapter 3 which were mutated by random mutagenesis. Out of a total of 47
DBL mutants produced from selection of 137 positive colonies, 20 DBL mutants were
selected (10 from each of MSPDBL1 and MSPDBL2) based on the molecular simulation
of DBL-IgM binding kindly provided by Dan Czajkowsky (Shanghai Institute of Applied
Physics, Shanghai, China).
Improved protein folding was observed and for three mutants possible homodimer
formation was identified. A number of methods were optimised in this chapter in an aim
to improve protein yield and folding. Firstly, for CHO-KI cell growth, HAMs growth and
selection media was used which contains an additional number of supplements (such as
zinc, hypoxanthine and thymidine). Cells were grown in parallel using both DMEM and
HAMs and it was found that the cells grew better in HAMs.
Secondly, protein purification was optimised in order to harvest all recombinant protein
produced by the cells. While HBSS is commonly used as a buffer solution for cells, sodium
phosphate is a more commonly used binding buffer for affinity purification. Protein G-IgG
binding has strongest affinity at pH 7.0 therefore 20 mM sodium phosphate pH 7.0 was
used. The cell supernatant was diluted 1:1 with the new binding buffer prior to loading in
order to adjust the supernatant to the composition of the buffer. This produced improved
binding. Elution was also optimised to prevent harsh conditions for the eluted protein. A
higher pH is optimal to prevent denaturing of the protein. pH was increased from 2.5 to
2.7 which still maintained effective elution while preventing denaturing.
IgM-binding of the recombinant mutant DBL domains was investigated and none of
the mutants produced a knock-out of IgM binding. There was evidence that there was
improved binding for the three mutants which had improved protein folding. One of
these, an MSPDBL1 mutant, has an interesting mutation in which an Asparagine in helix
2a has been replaced with Tyrosine. Protein-protein interaction prediction using the online
meta-PPISP server identified this region of MSPDBL1 as a protein-protein interface by
analysis of surface residues. This analysis also suggested that the binding interface is
different in each of MSPDBL1 and MSPDBL2.
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Functional analysis of the mutant library was disappointing due to low protein yield
and difficulties in protein folding. Sequence analysis was therefore used to identify common
binding motifs. Phlogenetic analysis of known IgM binding and non-binding DBL domains
from P. falciparum recently showed a lack of clustering (Pleass et al., 2015). Sequence
and homology block analysis are consistent with this result.
The structures of IgM-binding MSPDBL1 and MSPDBL2 isolates were modelled using
the Phyre 2 server and superimposed to highlight any differences in structure (Crosnier
et al., 2016). This analysis highlighted regions in helices h1, h2a and h4, consistent with
PPIP prediction results. A similar structural analysis of all known IgM binding and
non-binding DBL domains in P. falciparum was unable to confirm this result and only
highlighted the extreme structural variation between DBL domains.
Further work needs to be done to investigate the role of residues in α-helix 2a on IgM
binding. This could be done experimentally using site-directed mutagenesis of the helix
residues. However, in order to do this, low yield and poor folding of the DBL-Fc fusion
constructs need to be addressed. In Chapter 5, an extended hinge version of the constructs
was designed in order to improve protein folding and homodimer formation.
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Improving the DBL-Fc fusion constructs
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5.1 Background
Expressing recombinant DBL protein with an Fc-fusion has exciting implications for future
therapeutics. To date, no DBL domains have yet been expressed as Fc-fusion proteins,
which is a newly emerging and highly promising technology, and there are no malarial
Fc-fusions with FDA approval. However, a number of commercially successful Fc-fusion
based therapies are currently available in the clinic with a wide range of applications from
autoimmune disease to haemophilia (Summarised in Table 1.2). These exciting molecules
harness the interaction of the salvage neonatal receptor (FcRn) which, by improving
half-life, improves the therapeutic potential of the fused antigen. Further improvements
arise from the formation of a homodimer which increases the avidity of ligand receptor
interactions.
In Chapter 3, novel Fc-fusion proteins were produced from DBL domains belonging
to P. falciparum merozoite surface proteins. DBL domains are particularly interesting
in malaria as they are present in a number of protein families and in many cases are
responsible for cytoadherence, a property highly associated with virulence (Singh et al.,
2006; Chattopadhyay et al., 2004; Vogt et al., 2003; Flick et al., 2001; Miller et al., 1997;
Chen et al., 1998, 2000; Smith et al., 1998, 2000; Barragan et al., 2000a; Buffet et al., 1999).
The DBL-containing MSP proteins have been shown to localise to the merozoite surface
and bind to the MSP1 complex, suggesting their involvement in erythrocyte invasion.
Another interesting feature of DBL domains on the merozoite surface is their ability to
bind to the Fc portion of natural IgM, a characteristic also seen in DBL domains located
on the erythrocyte surface (Crosnier et al., 2016). Merozoite DBL domains were expressed
as Fc-fusion proteins in order to further investigate their IgM binding properties as well
as to provide proof of concept for Fc fusion proteins using malarial antigens.
In Chapter 3 the recombinant DBL-Fc fusions were shown to bind IgM. However it
was identified that the recombinant proteins produced were monomeric, consisting of a
single chain of Fc (Cγ2 and Cγ3 domains) fused to a single DBL domain (Figure 5.1).
Although the DBL domains proved functional in relation to protein G and IgM binding,
the addition of these tightly packed molecules prevented dimerisation of the Fc fusion
construct. This suggests that the DBL domains at ∼ 35 kDa were too large and perhaps
inhibited disulphide bond formation between the two chains, preventing the formation of
homodimers.
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Figure 5.1: Schematic representation of DBL Fc-fusion protein. (A) The expected DBL
Fc-fusion protein was a homodimer. (B) The DBL Fc-fusion protein produced in Chapter
3 is monomeric suggesting that fusion of the DBL to the IgG Fc prevents homodimer
formation.
The aim of this chapter is to improve the Fc-fusion constructs created in Chapter 3 and
produce dimeric DBL-Fc fusion proteins with improved IgM binding. The homodimeric
DBL-Fc fusion should consist of each 25 kDa chain of the Fc (consisting Cγ2 and Cγ3
domains) linked to a single DBL domain (35 kDa). The two chains will be joined together
in the hinge region by disulphide bonds to form a homodimer of 120 kDa. Most Fc-fusion
proteins consist of small antigens or antigenic regions (< 25 kDa) fused to the IgG Fc. The
relative size of the fused antigen may therefore be critical for formation of the homodimeric
Fc-fusion molecule. One of the largest Fc-fusion proteins available commercially at 200
kDa, Eloctate, is known to consist of 39% single chain molecules (Peters et al., 2013;
Buyue et al., 2014). The antihaemophilic factor VIII (80 kDa) is the base protein for this
Fc-fusion which has a tightly packed structure containing five globular domains (Ngo et al.,
2008; Shen et al., 2008). This suggests that the size of the fusion molecule may influence
dimer formation. However, the 251 kDa Fc-fusion drug rilonacept has the IL-1 receptor
as the base protein and forms homodimers. The structure of this receptor is less tightly
packed than the DBL domain, and its shape likened to a question mark (Schreuder et al.,
1997). This suggests that the structure of the base protein also influences homodimer
formation, with tightly packed structures preventing dimerisation.
The relative size of the merozoite DBL domains as well as their compact structure,
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consisting of 3 subdomains made up of a tight α-helical structure, may impact on
homodimer formation within the Fc. It has been shown that an extended linker region
can improve the stability of fusion proteins by increasing the distance between the base
protein and the tag. Fc-fusion proteins already contain a flexible hinge region from IgG1.
In this chapter we have modified and increased the length of the hinge region in order to
decrease the proximity of the two DBL domains from the Fc tag. It is hypothesised that
this may result in improved folding of the DBL Fc-fusion.
5.1.1 Extended hinge Fc-fusion construct
Many studies have investigated the effect of linker length and composition in fusion
proteins (Argos, 1990; George and Heringa, 2002; Bird et al., 1988; Alfthan et al., 1995;
Robinson and Sauer, 1998; Crasto and Feng, 2000) and have been extensively reviewed by
Chen et al. (2013); Zhang et al. (2009). In particular, Argos (1990) investigated natural
protein-linking domains in a database of 51 protein structures in which common residues
were identified. It was noted that small residues were favoured as well as lysine (Lys),
glutamine (Gln) and asparagine (Asn), while hydrophobic residues tend to be avoided
(Argos, 1990). Twelve years on, George and Heringa (2002) performed a similar study
although this time on a database containing 1280 proteins. Proline (Pro), arginine (Arg),
phenylalanine (Phe), threonine (Thr), glutamic acid (Glu) and glutamine (Gln) were
identified as common to linker regions. In both studies, it was concluded that smaller
residues were preferred while hydrophobic residues were uncommon. Pro, Thr and Gln
were identified as most favourable (Chen et al., 2013). The use of smaller amino acids
may increase flexibility of the linker while polar-charged residues are thought to improve
stability. Proline is a unique amino acid with a cyclic side chain which makes it highly
rigid. In recombinant fusion proteins, it is thought that proline prevents interaction of the
linker region with the fused proteins and increases the stiffness of the linker (Chen et al.,
2013). Naturally, proline-rich inter-domain linker regions are common, such as within the
hinge region of IgG3 and IgA1 (Chen et al., 2013; Woof and Russell, 2011).
Studies of linker regions in natural multi-domain proteins has influenced the design of
linkers in recombinant fusion proteins. A sophisticated linker design has the potential to
improve the expression and stability of a recombinant fusion protein (Chen et al., 2013).
A linker region may have a flexible design if a degree of movement between the protein
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domains is required. Alternatively, in situations where a flexible hinger has resulted in
poor expression or loss of functionality, a rigid, helical structure can be used to increase
separation of the protein domains. Linker regions may also be cleavable and have the
ability to release domains in vivo (Chen et al., 2013).
In addition to the careful consideration of linker composition, the linker length must be
optimised. A linker may be extended to increase separation between the linked proteins
in order that they each retain their functionality. Silacci et al. (2014) investigated the
length of the linker region in the Fynomer-Fc fusion protein by producing four mutants
whose hinges varied in length. It was concluded that the fusion protein with the longest
linker region displayed the most potent inhibitory activity (Silacci et al., 2014). However,
it should be noted that an extended hinge region may increase susceptibility to protease
cleavage (Chen et al., 2013).
Currently all Fc-fusions in clinic are of the IgG1 subclass and in chapter 3, a DBL
IgG1-Fc fusion was produced. The flexibility of the hinge regions within the four IgG
subclasses is variable with IgG3 the most flexible, followed by IgG1 (Roux et al., 1997).
The IgG3 hinge is distinct from the other three subclasses and is 62 amino acids in length
compared to the other subclasses which have much shorter hinges ranging 12 - 15 amino
acids (Table 5.1). Each IgG hinge consists of distinct upper, middle and lower regions.
The upper region connects the Fab arms to the middle hinge and is responsible for a
degree of flexibility (Roux et al., 1997). The middle hinge region is a relatively inflexible
proline-rich region containing the interchain cysteine residues. The lower hinge connects
the Fc to the middle hinge region and is responsible for further flexibility in the hinge
(Roux et al., 1997). Although the IgG3 middle hinge region is significantly longer than
the IgG1 middle hinge, the extra flexibility of the IgG3 hinge is more likely due to the
extra residues in the upper hinge.
Table 5.1: Amino acid sequences of hinge regions from the four IgG subclasses.
IgG subclass UH MH LH
IgG1 EPKSCDKTHT CPPCP APELLGGP
IgG2 ERK CCVECPPCP APPVAGP
IgG3 ELKTPLGDTTGT CPRCP(EPKSCDTPPPCPRCP)3 APELLGGP
IgG4 ESKYGPP CPSCP APEFLGGP
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Figure 5.2: Schematic representation of a dimeric Fc-fusion protein with extended hinge
region. The IgG1 hinge regions has been repeated four times with the three additional
hinges closest to the DBL domain mutated (C=A) to prevent formation of further
disulphide bonds.
In this chapter DBL Fc-fusion constructs have been produced with an extended IgG1
hinge consisting of four successive IgG Fc hinge regions designed to extend the distance
between the DBL and Fc domains. The length of the extended IgG1 hinge was increased
to resemble that of the more flexible IgG3 hinge. The original wild type IgG1 hinge is
located next to the Cγ2 region of the Fc and three additional IgG1 hinges have been
added before the DBL domain (Figure 5.2). The additional three hinges have been
mutated by replacing the two cysteine residues with alanine residues. This is to prevent
disulphide bond formation within the extended hinge region and to provide an extra degree
of flexibility. The original hinge region retains cysteine residues responsible for disulphide
bridge formation which aid in polymerisation of the construct.
5.1.2 Location of the DBL domain
When this work was started, the crystal structure of MSPDBL2 had not yet been resolved
and the exact location of the DBL domain within the full-length MSP was unclear. The
DBL domains expressed as Fc-fusion proteins in Chapter 3 are shorter than the DBL
domain that has since been crystallised. There are six amino acids missing at the N
terminus including a cysteine residue, and seven residues missing at the C terminus. In
this chapter, the full-length DBL domains have been expressed in order to investigate the
effect of the missing residues on the functionality of the DBL domains.
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5.2 Objectives
The aim of this chapter is to produce improved DBL Fc-fusion proteins. The specific
objectives include:
• Creating modified DBL Fc-fusion constructs where the hinge region has been
extended, increasing the distance between the DBL domain and the Fc region.
• Expressing a modified, full length DBL domain which includes the extra amino acids
present in the crystal structure of MSPDBL2.
• Characterising the new constructs and identifying any functional improvements.
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5.3 Methods
5.3.1 pFMCS-hIgG1-Fc2 (modified pFUSE-hIgG1-Fc2 plasmid)
A modified pFUSE-hIgG1-Fc2 plasmid was used for cloning. This contains a modified
multiple cloning site for ease of sub-cloning but the rest of the plasmid remains the
same. The multiple cloning site of pFUSE-hIgG2-Fc2 contains extra base residues between
restriction sites, therefore sub-cloning the same insert between different restriction sites
requires additional bases to keep the insert in frame. pFMCS-hIgG2-Fc2 was developed
such that an insert added between any restriction sites remain in frame. Additional
restriction sites BamHI and XhoI were also added for convenience (Figure 5.3).
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A parking plasmid pFMCS was developed for sub-cloning for the DBL inserts. This
contains the modified pFMCS-hIGg1-Fc2 multiple cloning site and has the IgG1-Fc2
portion removed.
5.3.2 pFMCS-4HF-hIgG1-Fc2 (extended flexible hinge construct)
Another modified pFUSE-hIgG1-Fc2 plasmid was used for cloning the flexible four-hinge
constructs. This is the same as the pFMCS-hIgG1-Fc2 (with modified multiple cloning
site) but contains an additional extended hinge region. The extended hinge region
(three hinges) with cysteine residues mutated to alanine was synthesised separately
with compatible restriction sites and sub-cloned into pFMCS-hIgG1-Fc2 to produce the
pFMCS-4HF-hIgG1-Fc2 construct (Figure 5.4).
Figure 5.4: Sub-cloning of the pFMCS-4HF-hIgG1-Fc2 construct. The flexible
four-hinge construct was produced by the addition of a triple hinge insert containing
three modified flexible IgG1 hinge regions to the pFMCS-hIgG1-Fc2 plasmid. The
pFMCS-hIgG1-Fc2 construct (A) was cut by restriction digest with NcoI and BglII (B).
The triple hinge insert was synthesised with the required restriction sites (C) and cut with
NcoI and BglII (D) before being sub-cloned into the pFMCS-hIgG1-Fc2 plasmid (E).
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5.3.3 Plasmid Synthesis
A series of plasmids was synthesised by Eurofins (UK):
1. pFMCS-3.4 FL: pFMCS parking plasmid containing the full length 3.4 DBL
(Appendix A.8).
2. pFMCS-3.8 FL: pFMCS parking plasmid containing the full length 3.8 DBL
(Appendix A.9).
3. pFMCS-3.4 short: pFMCS parking plasmid containing the short 3.4 DBL domain
(Appendix A.10).
4. pFMCS-3.8 short: pFMCS parking plasmid containing the short 3.8 DBL domain
(Appendix A.11).
5. pFMCS-hIgG1-Fc2-3.4 FL: pFMCS-hIgG1-Fc2 containing the full length 3.4
DBL (Appendix A.13).
6. pFMCS-hIgG1-Fc2-3.8 FL: pFMCS-hIgG1-Fc2 containing the full length 3.8
DBL (Appendix A.14).
Short 3.4 and 3.8 DBL pFMCS-hIgG1-Fc2 constructs (5 and 6) were synthesised ready
for transfection and direct comparison of recombinant protein produced with the short
recombinant DBL-Fc fusion proteins from Chapter 3.
The four pFMCS parking plasmids (1 - 4) contained DBL inserts ready for sub-cloning
into the pFMCS-4HF-hIgG1-Fc2 construct.
5.3.4 Sub-cloning the four DBL domains (short and full-length, 3.4 and 3.8)
into the pFMCS-4HF-hIgG1-Fc2 construct
Plasmid preparation
The PfMCS-4HF-hIgG1-Fc2 plasmid was prepared for insertion of the DBL domains
using the same methods as Chapter 3. Plasmid was digested using the appropriate
restriction enzymes (EcoRv/NcoI for sub-cloning 3.4 DBL domains and EcoRI/NcoI for
3.8 DBL domains), run by gel electrophoresis, excised and purified. The plasmid was then
de-phosphorylated to prevent self-ligation (Section 3.3.5). Recovered DNA was quantified
by nanodrop spectro-photometer (Section 2.2.15).
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Insert preparation
The pFMCS parking plasmids were similarly prepared for sub-cloning by cutting out the
DBL domain using the appropriate restriction enzymes (3.4 DBLs: EcoRv/NcoI and 3.8
DBLs: EcoRI/NcoI). The product was run by gel electrophoresis and DBL inserts excised
and purified (Section 3.3.5).
Ligation
The following reaction with a molar ratio of 1:3 vector:insert was set-up on ice for ligation
reactions containing the short DBLs:
• 10x T4 DNA ligase buffer 2 μl
• Vector DNA (4.3 kb) 50 ng
• Insert DNA (860 bp) 30 ng
• T4 DNA ligase 1 μl
• dH2O up to 20 μl.
The following reaction keeping a molar ration of 1:3 vector:insert was used for ligation
reactions containing the full length DBLs:
• 10x T4 DNA ligase buffer 2 μl
• Vector DNA (4.3 kb) 50 ng
• Insert DNA (905 bp) 32 ng
• T4 DNA ligase 1 μl
• dH2O up to 20 μl.
The ligation reactions were held at 16◦ C for 16 hours using a Progene thermocycler.
Transfection
Cells were transformed using the same methods as in Chapter 3. Single colonies were grown
and DNA extracted by mini-prep which was then screened to check that it contained the
insert by restriction digest (Section 3.3.7). Plasmids containing inserts were identified and
DNA sent for sequencing for confirmation (Section 2.2.13).
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5.3.5 Expression of recombinant protein
Recombinant protein was produced in CHO-KI cels using the same methods as in
Chapters 3 and 4 (Section 3.3.8). CHO-KI cells were transfected using FuGENE 6
transfection reagent and selected using zeocin selection media. Monoclonal populations
were produced by selecting for high-expressing colonies formed from single cells using
immunoblot analysis. After 10 days in culture, cell supernatant was purified using a
protein-G sepharose HiTrap column on the A¨KTA-FPLC. Immunoblot analysis was used
to test for the presence of recombinant protein in FPLC fractions which were then pooled
and concentrated by ultrafiltration.
5.3.6 IgM-binding ELISA
The series of constructs were screened for IgM binding by ELISA. The same methods were
used as in Chapters 3 and 4 (Section 3.3.10).
5.3.7 Western blot analysis
The series of constructs were characterised by Western blot analysis. The same methods
were used as in Chapters 3 and 4 (Section 4.3.8).
5.3.8 Gel filtration of recombinant proteins
The series of constructs were characterised by gel filtration using the same methods as in
Chapters 3 and 4 (Section 3.3.12).
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5.4 Results
5.4.1 Sub-cloning the four pFMCS-4HF-hIgG1-Fc2-DBL constructs
Four constructs were produced by sub-cloning DBL inserts into the
pFMCS-4HF-hIgG1-Fc2 plasmid (Figure 5.5).
• pFMCS-4HF-hIgG1-Fc2-3.4DBL-short
• pFMCS-4HF-hIgG1-Fc2-3.4DBL-FL
• pFMCS-4HF-hIgG1-Fc2-3.8DBL-short
• pFMCS-4HF-hIgG1-Fc2-3.8DBL-FL
The pFMCS-4HF-hIgG1-Fc2 plasmid and inserts were prepared by restriction digest
with the required restriction enzymes and then ligated to create the new constructs.
These were transformed into E. coli cells and colonies screened for presence of inserts
by restriction digest. DNA extracted by mini-prep was sent for sequencing to confirm
each construct before DNA was used to transform CHO-K1 cells for protein expression.
5.4.2 Producing full-length DBL domains in pFMCS-IgG1-Fc2
The original pFUSE 3.4 DBL and pFUSE 3.8 DBL constructs were re-transfected and new
monoclonal cell lines produced in parallel with the new full length constructs. The full
length constructs were synthesised directly into the pFMCS-IgG1-Fc2 plasmid. Having
been extracted by maxi-prep, the DNA was confirmed by sequencing and used to transform
CHO-K1 cells for protein expression.
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(a) Sub-cloning 3.4 DBL inserts into pFMCS-4HF-IgG1-Fc2
(b) Sub-cloning 3.8 DBL inserts into pFMCS-4HF-IgG1-Fc2
Figure 5.5: Sub-cloning the (a) 3.4 and (b) 3.8 DBL inserts into the
pFMCS-4HF-IgG1-Fc2 construct. Sub-cloning the 3.4 DBL inserts (both short and
full length) into the pFMCS-4HF-IgG1-Fc2 (A) involved digesting the plasmid using
EcoRV and NcoI (B). The 3.4 DBL inserts (both short and full length) were both
synthesised into the parking pFMCS plasmid (C) which was prepared by cutting with
EcoRV and NcoI (D). The insert was then ligated into the cut plasmid (E). Similarly, the
3.8 DBL inserts (both short and full length) were sub-cloned into pFMCS-4HF-IgG1-Fc2
(A) by digesting the plasmid using EcoRI and NcoI (B). The inserts, synthesised into the
parking pFMCS plasmid (C) were prepared by cutting with EcoRI and NcoI (D). The
insert was then ligated into the cut plasmid (E).
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5.4.3 Expression of the DBL-Fc fusion recombinant proteins
CHO-K1 cells were transfected with the eight constructs (summarised in Section 5.4.3.1), 
using the FuGENE transfection reagent and the same methods as Chapters 3 and 
4 (Section 3.3.8), and monoclonal populations of high-expressing cells were produced 
(Section 3.3.8).
5.4.3.1 Summary of DBL-Fc fusion proteins produced
The eight recombinant DBL-Fc fusion proteins produced are summarised in Figure 5.6. 
The original two DBL-Fc fusion proteins produced in Chapter 3 will be referred to as 
DBL3.4 IgG1 Fc and DBL3.8 IgG1 Fc. The full-length versions of these, which were 
synthesised directly into pFMCS-hIgG1-Fc2 before expression are referred to as DBL 3.4 
FL IgG1 Fc and DBL 3.8 FL IgG1 Fc.
The four extended-hinge constructs were produced by sub-cloning the inserts into the 
pFMCS-4HF-IgG1-Fc2 plasmid. This produced two short DBL Fc fusion recombinant 
proteins with the extended hinge which will be referred to as DBL 3.4 4HF IgG1 Fc and 
DBL 3.8 4HF IgG1 Fc. The full-length versions of these are referred to as DBL 3.4 FL 
4HF IgG1 Fc and DBL 3.8 FL 4HF IgG1 Fc.
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5.4.3.2 FPLC Protein purification
The eight recombinant DBL-Fc fusion proteins were purified from supernatant using a
protein G sepharose column by affinity chromatography (Section 3.3.8). A linear gradient
of 0.1 M glycine-HCl, pH 2.7 was used to elute protein from the column. FPLC profiles
are summarised in Table 5.2 and can be found in Appendix J.
Table 5.2: Summary of FPLC profiles from eight DBL-Fc fusion constructs.
Construct Profile (mAU)
Original 3.4 DBL short 700
Original 3.8 DBL short 400
Full-length 3.4 DBL 600
Full-length 3.8 DBL 500
3.4 DBL short with extended hinge 700
3.8 DBL short with extended hinge 400
Full-length 3.4 DBL with extended hinge 1400
Full-length 3.8 DBL with extended hinge 800
The FPLC purification profiles from recombinant proteins with the original IgG1 hinge
were compared (Appendix J, Figure .21). There were four Fc-fusion proteins produced
with the original hinge, two 3.4 DBL domains (one short and one full-length) and similarly
two 3.8 DBL domains. The full-length DBL fusion proteins had similar profiles to the short
DBL fusion proteins, suggesting that the extra residues included at the beginning and end
of the DBL domains did not improve protein expression.
FPLC purification profiles from the original DBL-Fc fusions were compared to
recombinant protein containing the original DBL domains along with the extended hinge
region (Appendix J, Figure .22). The profiles of the fusion proteins with extended hinges
were similar to those containing the original hinge, suggesting that the extended region
does not improve protein expression.
FPLC purification profiles from the full-length DBL-Fc fusion proteins containing the
original IgG1 hinge were compared to the full-length DBL-Fc fusion proteins containing the
extended hinge region (Appendix J, Figure .23). The purification profile for the full-length
3.4 DBL domain is much bigger with an extended hinge compared to the original IgG1
hinge for the same volume of cell supernatant. However, the 3.8 FL DBL hinge doesn’t
appear to improve protein purification. This might suggest that the cells express the
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extended hinge, full-length 3.4 DBL-Fc fusion better than the same full-length 3.4 DBL
domain with the original hinge. However, protein expression varies between cells therefore
a monoclonal population may be derived from a cell which is a better general expresser of
protein.
Fractions were collected and immunoblotted with αhIgG-AP (Section 3.3.8) to show
that protein was present in the fractions corresponding to the FPLC (Figure 5.7).
Figure 5.7: Immunoblot of fraction from the FPLC elution of the eight DBL-Fc
fusion recombinant proteins. Fractions A1-A11 from the FPLC elution were tested by
immunoblotting for the presence of protein. These were compared to the cell supernatant
(sup) prior to purification as well as the flow-through (FT) to check that all protein had
been removed.
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5.4.4 Characterisation of recombinant protein
In Chapter 3, recombinant DBL-Fc fusion proteins had difficulty forming homodimers.
In order to characterise the new series of DBL-Fc fusion proteins, non-reduced samples
were separated by SDS-PAGE and transferred to a membrane. IgG-Fc was detected using
αhIgG-Fc-AP. The addition of the extended hinge region appears to improve dimerisation
of the DBL-Fc fusion proteins (Figure 5.8). However, monomeric DBL-Fc is still present
and the addition of the hinge region also leads to aberrant folding intermediates. This
suggests that the extension of the hinge may increase susceptibility of the recombinant
protein to cleavage by proteases.
Figure 5.8: Non-reduced αhIgG1-Fc Western blot shows improved folding
of recombinant DBL-Fc fusions with the addition of the extended hinge.
SDS-PAGE of recombinant DBL-Fc fusion proteins was transferred to a membrane and
Fc detected using αhIgG-Fc alkaline phosphatase-conjugated antibody. An IgG-Fc WT
control was used in Lane 1. Lanes 2 and 3 show the original 3.4 DBL-Fc and 3.8 DBL-Fc
fusion proteins respectively. Lanes 4 and 5 show these short DBL-Fc fusion with the
extended hinge. Lanes 6 and 7 show the full-length version of the 3.4 DBL-Fc and
3.8 DBL-Fc fusion proteins respectively. Lanes 8 and 9 show these full-length DBL-Fc
fusions with the extended hinge.
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5.4.5 Recombinant DBL-Fc fusion proteins containing the extended hinge
show improved hIgM binding
In Chapter 3 it was shown by sandwich ELISA that the recombinant DBL-Fc fusion
proteins bind human IgM. DBL 3.4 was shown to bind hIgM better than DBL 3.8, in
agreement with a study by Crosnier et al. (2016) where DBL 3.4 was shown to have
ten-fold higher affinity than the 3.8 DBL domain. The sandwich ELISA was repeated
for the eight DBL-Fc fusion recombinant proteins in order to identify differences in IgM
binding amongst the constructs. Human IgM was captured by coating of an αhIgM on
the ELISA plate. The DBL-Fc fusions were then allowed to bind hIgM and were detected
using αhIgG-Fc-AP. It was shown that the recombinant DBL-Fc fusions containing the
extended hinge region bind hIgM better than those containing the original IgG1 hinge
(Figure 5.9). This was true for both sets of recombinant proteins, those containing the
original short DBL domains (Figure 5.9a) as well as those containing the full-length DBL
domains (Figure 5.9b). There was, however, no notable improvement in binding in the
full-length DBL constructs over the original short DBL domains.
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(a) IgM-binding of recombinant short DBL-Fc fusion proteins
(b) IgM-binding of recombinant full-length DBL-Fc fusion proteins
Figure 5.9: IgM-binding sandwich ELISA showing improved binding by the new
flexible 4H constructs. (a) The short DBL-Fc fusion constructs show improved IgM
binding with the addition of the flexible 4-hinge (4HF). (b) The full length DBL-Fc fusion
constructs show improved IgM-binding with the addition of the flexible 4-hinge (4HF).
Results are shown from four repeat experiments.
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5.5 Summary
The aim of Chapter 3 was to produce novel recombinant DBL-Fc fusion proteins from the
DBL domains unique to two interesting MSP3 proteins, MSPDBL1 and MSPDBL2. DBL
inserts were sub-cloned into the pFUSE-hIgG1-Fc2 plasmid (which contains the IgG1 Fc
and hinge regions) for protein expression in CHO-K1 cells. The subsequent recombinant
protein produced, although functional with respect to protein G and hIgM binding, was
mostly monomeric, suggesting that the Fc-fusion protein had difficulty polymerising. The
aim of this chapter was to improve the DBL-Fc fusion constructs in order to produce
homodimers and to investigate whether there was improved hIgM-binding to the new
recombinant protein.
There were two possible explanations for the lack of dimer formation by the original
recombinant DBL-Fc fusions. Firstly, the DBL inserts were identified as shorter in length
compared to the DBL domains whose crystal structure was resolved by Hodder et al.
(2012). New DBL-Fc fusions were therefore produced using the full-length DBL domains.
This involved the addition of six residues prior to the DBL sequence and seven at the
end. There were no functional improvements observed by adding the extra residues
and protein expression, which had previously proved difficult to produce adequate yields,
was comparable. Secondly, the relative size and compact structure of the DBL domains
compared to the Fc domain was proposed to prevent polymerisation of the fusion proteins.
A modified Fc-fusion construct with an extended hinge region was designed to increase
the distance between the Fc and the DBL domain. The hinge region was designed to give
an extra degree of flexibility to the molecule and it was hypothesised that this would
enable formation of a dimeric Fc-fusion protein. The hinge region was constructed from
four repeated IgG1 hinge regions. The original hinge remains in proximity to the Fc
and three successive modified IgG1 hinges, in which cysteine residues are replaced with
alanine, add an extra element of flexibility. The two cysteine residues remain in the original
Fc-proximal hinge region; these are essential for the formation of disulphide bonds needed
to produce homodimers.
Both of the original short DBL domains and the full-length DBL domains were
sub-cloned into the modified construct containing the extended flexible hinge. An
improved FPLC profile was seen from purification of the full-length 3.4 DBL-Fc fusion
containing the extended flexible hinge compared to the same full-length 3.4 DBL-Fc fusion
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with the original hinge. This suggests either improved protein-G binding or improved
protein expression. Any difference in expression could be due to differences in the protein
expression capacity of different monoclonal cell populations. It is therefore unclear whether
protein production was improved by the extended hinge region, or by better expressing
cells. There was no difference in expression seen from purification of the two full-length
recombinant 3.8 DBL domains with either the extended hinge or the original hinge. In
this case, the extended hinge construct did not improve protein G binding or protein
expression.
In all cases, protein yield was still low, improvements are therefore still needed in order
to produce adequate quantities of protein. However, the recombinant protein was able to
form homodimers, although there is evidence that proteolytic cleavage is occurring. Other
modifications to the hinge region may be necessary to further improve protein folding.
There was an improvement in hIgM-binding seen in the recombinant proteins which
contained the modified hinge. Both 3.4 DBL and 3.8 DBL domains showed improved
hIgM-binding ability when expressed in an Fc-fusion with the modified hinge. For the
full-length 3.4 DBL and full-length 3.8 DBL, the improvement in binding from the modified
hinge was even more striking. The ability to improve functionality suggests that the
modified, extended hinge construct might have useful applications in therapeutics.
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6.1 Overview
Malaria is a vast global problem with approximately half of the world’s population at
risk, particularly in vulnerable communities where the burden is greatest. There were
198 million clinical cases of malaria in 2013, with 584,000 deaths (WHO, 2015). Malaria
vaccine development is urgently needed and the blood stages are pivotal, because it is these
stages of infection that causes clinical symptoms. Merozoite surface proteins MSPDBL1
and MSPDBL2 have recently received recognition as vaccine candidates due to their role
in clinical immunity to malaria (Chiu et al., 2015).
The aim of this study was to identify residues and sequence motifs critical for
IgM-binding of the DBL domains from MSPDBL1 and MSPDBL2 P. falciparum merozoite
surface proteins. The vaccine potential of MSPDBL1 and MSPDBL2 is only just being
recognised and these proteins, which have been shown to localise to the merozoite
surface, are thought to be involved in erythrocyte invasion (Lin et al., 2014). However,
their receptors on the erythrocyte surface have not yet been identified. In a recent
study by Crosnier et al. (2016), the MSP DBL domains have also been shown to bind
the Fc portion of human IgM. Although MSPDBL1 and MSPDBL2 are the only two
merozoite surface proteins to contain DBL domains, such domains are common in other
surface-protein families such as PfEMP1. In PfEMP1 they are responsible for the
cytoadherent properties of infected erythrocytes, some of which also bind IgM, and are
associated with virulence. To further investigate these interesting binding characteristics
of MSPDBL1 and MSPDBL2, this study aimed to:
1. Express the DBL domains from MSPDBL1 and MSPDBL2 as recombinant Fc-fusion
proteins.
2. Produce a library of recombinant DBL mutants to investigate IgM binding.
3. Analyse a wealth of sequence data and structural information from all known
IgM-binding DBL domains to provide further insight into the IgM-binding region.
Fc-fusion proteins are an exciting and successful field of bio-engineering due to their
interaction with the FcRn which facilitates recycling and improves half-life (Levin et al.,
2015; Czajkowsky et al., 2012). Having experienced impressive growth rates compared
to other biologics in the past few years, Fc fusion proteins are now well established
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in the clinic (Aggarwal, 2014). The most successful Fc fusion to date is etanercept, a
TNF receptor-fusion that is able to block the action of the tumour necrosis factor (TNF)
(Czajkowsky et al., 2012; Ioannidis et al., 2013). It is used in rheumatoid arthritis and
other inflammatory conditions to successfully reduce inflammation.
A crucial first stage of this study was to produce recombinant DBL domains from
MSPDBL1 and MPSPDBL2. These were expressed as Fc-fusion proteins which, while
enabling further study of these DBL domains, could have the potential to be developed
for vaccine or therapeutic use. Malaria vaccine development is urgently required as current
vaccines have limited efficacy or are limited by logistical issues. The DBL-Fc fusions could
also be developed for the treatment of IgM-related diseases due to their affinity for IgM.
DBL Fc-fusion constructs were produced by fusing DBL domains to the
pFuse-hIgG1-Fc2 mammalian expression vector. This plasmid is commercially available
and has previously been used in our laboratory to produce successful Fc-fusion proteins
with the malaria antigens MSP119 and MSP142 (Mekhaiel et al., 2011). These merozoite
DNAs were codon optimised for mammalian expression, and N-linked glycan sites removed
from the DBL domain in order to prevent unnecessary glycosylation of the recombinant
proteins. Glycosylation, however, has been shown to be necessary for the Fc glycoprotein
domain. Mammalian expression allowed for the formation of disulphide bonds within the
DBL domains which are known to be critical for structural stability. Recombinant protein
was produced from CHO-K1 cells, as has previously been used for the successful expression
of Fc-fusion proteins (Mekhaiel et al., 2011). CHO-K1 cells are the mostly commonly used
expression system for commercial Fc-fusion proteins (Czajkowsky et al., 2012).
There were several difficulties with the construction of the DBL Fc constructs and
working with the DNA proved problematic. Bacterial growth was challenging, particularly
for the 3.8 DBL domain, which suggests that the DNA may be toxic to E. coli. Bacteria
were found to grow better in a rich TB growth media rather than LB medium. However,
bacterial colonies that did manage to grow mostly contained the correct insert. The use
of the TOPO parking plasmid for efficient amplification of a large amount of the TOPO
vector plus the correct insert was found to be an essential first step.
Protein expression also proved difficult, with low yields of monomeric fusion protein
produced rather than the predicted 120 kDa homodimer. Most Fc fusions currently with
FDA approval contain small (∼25 kDa) antigens fused to the Fc. However, two Fc fusion
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proteins (eloctate and rilonacept) that have had success in the clinic consist of much
larger fused proteins. Eloctate, an antihaemophilic factor fusion, has a molecular weight
of 220 kDa but is 39% single chain molecule (Peters et al., 2013; Buyue et al., 2014).
Rilonacept, a 251 kDa IL-1R fusion, forms homodimers but the shape of IL-1R molecule
isn’t as tightly packed as a DBL domain and has been likened to a question mark in
structure (Schreuder et al., 1997). The malarial Fc-fusion proteins produced by Mekhaiel
et al. (2011) containing the fused MSP119 and MSP142 were able to form homodimers.
Thus it may be that the size or shape of the merozoite DBL domains inhibits homodimer
formation.
There was evidence of glycoform production, proteolytic cleavage and poorly folded
protein. Gel filtration also suggested that aggregates were formed. However, monomeric
Fc fusions were shown to be functional with relation to IgM binding, as the recombinant
3.4 DBL fusion bound better than the 3.8 DBL. This is in agreement with a study by
Crosnier et al. (2016) which saw ten-fold improvement in 3.4 DBL-IgM binding over 3.8.
DBL Fc fusions were therefore successfully expressed as functional recombinant proteins,
albeit monomeric, which allowed further investigation into the IgM-binding properties of
these merozoite protein domains.
In order to investigate the IgM-binding site, a library of DBL mutants was produced
using random mutagenesis. Unlike the site-directed mutagenesis approach, this study did
not rely on any previous knowledge or assumptions about the binding site. Although
a molecular simulation of DBL-IgM binding provided by Dan Czajkowsky (Shanghai
Institute of Applied Physics, China) predicts the regions involved in binding based on
homology, the aim of this study was to either confirm the accuracy of this model or to
provide data for model improvement.
Production of the mutant Fc-fusion constructs again proved difficult, particularly in
the production of sufficient quantities of DNA for ligation. The Genemorph II mutagenesis
kit (Agilent) was used to limit mutational bias. The PCR had to be scaled up, as after gel
purification of the product, the DNA concentrations often proved too low for the ligation
step. After ligation, the false positive rate for 3.4 DBL mutant colonies was high. Although
lower for 3.8 DBL mutants, we obtained very few colonies after 3.8 DBL mutant ligation.
The desired mutation frequency was eight within the DBL domain insert (nine mutations
per kb). This corresponds to approximately four amino acid mutations within the DBL
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insert, after silent mutations are taken into account. The manufacturer’s instructions were
followed in order to get this mutational frequency. However, the average mutation rate
achieved was two amino acid substitutions per DBL domain. This is lower than predicted
and is most likely due to inaccuracies in quantifying the concentration of the target DNA
by nanodrop spectrophotometer.
After creation of the mutant plasmids, protein production proved difficult, with low
yields and poor protein folding observed. Protein produced was predominantly monomeric,
although there was evidence of slight improvements from previous attempts due to
extensive method optimisation. The selection of high-expressing mammalian cell clones
allowed for maximum protein production and optimised purification allowed effective
harvesting of protein. However the yields still varied between mutants, suggesting that
yield was highly dependent on the clonal cell line that was selected. Overall, even taking
into account variation across the mutants and improved methods, yield was still low and
inadequate for further functional investigation. This problem was addressed in Chapter 5.
Purification by protein G sepharose was effective after thorough optimisation of the
methods giving recombinant protein that was functional with relation to protein G binding.
However, fragments were seen by SDS-page and Western blotting, possibly due to poor
protein folding or proteolytic cleavage. Due to limitations in resolution it was not possible
to separate these fragments from the monomeric Fc-fusion by gel filtration, therefore
the calculations of protein concentration may not accurately reflect the concentrations
of intact monomers. This may have an effect on the ELISA data presented here as,
although equal concentrations of each mutant protein preparation was used, this might
not reflect equal concentrations of monomeric Fc-fusion. However, it was assumed that
each mutant would experience the same proteolytic cleavage and difficulties in folding and
thus comparable amounts of monomeric protein would be produced. The ELISA results
were subsequently disappointing, with high variations in repeat experiments. IgM binding
between mutants has been compared from ELISA results but any differences observed
needs further investigation.
The ELISAs showed comparable IgM binding for most DBL mutants, and three
mutants showed slight improvements in binding - 3.4 DBL mutant 87, and 3.8 DBL
mutants 44 and 65. Due to the high variation observed in repeat experiments these
results were not significant, however one of the mutants identified has an interesting
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mutation which is worth highlighting. 3.4 Mutant 87 contains an asparagine mutation
in helix 2a where it has been replaced with tyrosine. This region was also highlighted by
structural analysis of isolates, where four potential binding regions were identified (Figure
4.20), one of which was also identified by protein-protein interaction prediction tools and
corresponded to helix 2a. Improved binding might be surprising since the aromatic residue
tyrosine is located less commonly on protein-protein interfaces (Ma et al., 2003). However,
the conformation of tyrosine on the DBL surface is important. If improved binding is
observed, this suggests that the aromatic ring is buried under the surface, leaving the
hydroxyl group exposed. Thus tyrosine might act as a polar residue on the surface,
replacing the polar asparagine residue which may be involved in binding. A resulting
conformational change in the binding region may explain any improved binding. It has
been suggested that binding is not only dependent on polar hotspots but also on flexibility
of the binding site (Ma et al., 2003). Introducing tyrosine might improve binding by
introducing a favourable change in flexibility.
A recent study by Semblat et al. (2015) using an equivalent DBL-IgM homology model
from PfEMP1 tested the function of amino acids predicted to be involved in IgM binding.
The results suggested that the model needed revision as none of the residues had an
effect on binding. Data presented here are in agreement with this study. The predicted
involvement of helix 2a disagrees with the molecular simulation of binding, although the
region is highlighted by further structural analysis. Since the validity of the model is in
question, further investigation into the involvement of helix 2a in IgM-binding is worth
exploring.
Site-directed mutagenesis could be used to further investigate the role of helix 2a
and to identify the critical residues involved in IgM-binding, although protein yield and
folding difficulties need to be addressed. In Chapter 5, an extended IgG1 hinge region
was developed with this aim. The extended hinge allowed an increase in distance between
the Fc and the fused DBL domain and was designed with a degree of flexibility to allow
proper folding of both regions. The extended hinge was constructed from repeating the
IgG1 hinge region four times. The first region, which is proximal to the Fc, retains its
cysteine residues but these were replaced with alanine in the additional three hinge regions.
It was hypothesised that this would increase flexibility in the extended hinge as well as
increasing the distance from the Fc, allowing improved protein folding and homodimer
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formation.
Homodimer formation of the extended hinge DBL-Fc fusion proteins was observed.
However, protein fragments were still present suggesting that the constructs still had some
difficulty folding. Such fragments also suggest that there is proteolytic cleavage, which is
to be expected as the increased length of a hinge is known to increase susceptibility to
cleaving (Chen et al., 2013).
An extended DBL domain was also expressed with both the original and the extended
flexible hinge, but showed no improvement in IgM binding. When this work was started,
the DBL domain boundaries were unclear and therefore a short version of these DBL
domains was used, compared to the recently solved crystal structure (Hodder et al.,
2012). A minimal IgM-binding region has recently been identified in the DBL4ζ domain
of TM284var1 (Semblat et al., 2015). The short domains expressed here fall within
the equivalent minimal binding region, which might explain why there was no observed
improvement in binding using the full length DBL domains. The data presented therefore
support the minimal binding region of DBL4ζ and suggest that the minimal binding region
of the merozoite DBL domains is equivalent to that of PfEMP1 DBLs.
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6.2 Expression of merozoite DBL domains as Fc fusion proteins
Novel DBL Fc-fusion proteins have been produced, providing a framework for vaccine
or drug development using the DBL domains from merozoite surface proteins which are
known to be involved in erythrocyte invasion. These interesting and unique DBL domains
have been shown to bind the Fc of hIgM via the Cμ4 domain, a characteristic of eight other
DBL domains from PfEMP1 that are located on the erythrocyte surface (Crosnier et al.,
2016; Pleass et al., 2015). Fc-fusion proteins have shown clinical success and the addition
of the Fc from IgG1 allows improved half-life due to the interaction with the neonatal
Fc receptor (FcRn). Expression of the merozoite DBL domains as recombinant Fc-fusion
proteins allowed investigation into the region involved in IgM binding. The IgM-binding
property is thought to allow the parasite to evade immunity by masking itself in hIgM,
preventing recognition by specific and highly effective IgG Abs, but no critical residues
or binding motifs have previously been identified (Czajkowsky et al., 2010; Pleass et al.,
2015).
An Fc-fusion molecule typically consists of two IgG1-Fc chains attached to two
molecules of the fused protein, bound together by disulphide bonds. Recombinant protein
was initially expressed as monomeric DBL-Fc. The structure of the (∼35 kDa) DBL
domains and their size is thought to prevent homodimer formation, leading to the presence
of multiple fragments visible by Western blot. Protein yield was also low, typically
producing yields of 0.2 - 5 μg/ml of culture supernatant, in comparison to a yield of
5 - 10 μg/ml for unfused pFUSE-hIgG1-Fc2. Protein production needs to be improved in
order for the proteins to be further developed for clinical use. However, the monomeric
Fc-fusions were functional with respect to protein G and IgM binding. The Fc-fusion drug
Aloctate consists of a large proportion of monomeric protein, shown to be functionally
comparable to the homodimer form of the molecule. Monomeric DBL-Fc fusions therefore
allowed further analysis of the IgM binding region. Extensive method development gave
some improvement to the protein produced. Expression and purification methods were
optimised and limited amounts of homodimer were produced for some mutants, however
yield was still low and protein folding not optimal.
Due to the fragmented nature of these recombinant proteins, there were difficulties
obtaining accurate protein concentrations for functional investigations. FPLC peaks
gave an estimate of protein yield which was calculated using the Beer-Lambert
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equation. However, estimates were thought to be high by comparison to known protein
concentrations on a protein gel (data not shown). A BioRad colorimetric assay was
also used which is based on the Bradford method and calculates total protein quantity.
Both of these estimates were thought to be high as all protein fragments and improperly
folded proteins were quantified in the total amount. Functional analysis by ELISA was
comparable but not quantitative for this reason. SPR is frequently used for quantitative
binding analysis, but could not be used here due to the presence of protein fragments
which might interfere with affinity. For the same reason, circular dichroism analysis was
also not possible. This would have been useful to investigate the secondary structure of
the DBL mutants and identify mutations which significantly change the structure of the
mutants, as well as to confirm proper folding of the wild types.
The protein-folding problems were addressed by using an extended, flexible hinge based
on the IgG1 hinge. The aim was to improve protein folding by increasing the distance
between the Fc and the DBL and to allow a degree of flexibility. The current IgG1 hinge
was repeated three times and in these repeated regions, cysteine residues were mutated
to alanines to eliminate further disulphide bond formation and to give a higher degree of
flexibility. Improvements to homodimer formation were observed but improper folding was
still notable. Intermediate bands observed by Western blot may also be due to cleavage
which has previously been reported in the IgG1 hinge region of a recombinant human
IgG1 antibody expressed in CHO-KI cells (Yan et al., 2009). Extending the linker region
may also make the hinge more susceptible to cleavage as has been reported in other fusion
proteins Liu and May (2012); Zhang et al. (2009). Analysis of the four-hinge constructs
was difficult as resolution was not good enough above 97 kDa on the Western blot. It
is expected that the addition of the extended region adds a molecular weight of 10 kDa,
but this was not noticeable at ranges of 120 kDa. However, definite improvements to
folding were observed between protein containing the original hinge and the extended
hinge although protein yields still remained an issue.
This study is an important first step as improvements in protein production have
been observed, and the results highlight the potential that further development of the
hinge region may have on protein folding. Ongoing work in the laboratory on extended
hinge regions suggests that the flexible nature of the hinge may not be necessary and
that improved folding is observed in a similar construct where the IgG1 hinge has been
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repeated four times without mutating the cysteines. Therefore it may be the decreased
proximity which improves protein folding in the fusion proteins. In this study, the first
logical step was to develop the IgG1 hinge regions. An IgG3 hinge, at 62 amino acids in
length, is longer than the hinge regions in the other IgG1 subclasses and has a high degree
of flexibility. An IgG3-based hinge could be designed, or one based on the Cμ2 region of
IgM may also be worth investigating. IgM is a natural oligomer with no hinge region, but
it has an extra Cμ2 domain which could be used instead of the IgG1 hinge to decrease the
proximity of the Fc and the DBL domain. Further work is necessary but there is hope
that a sophisticated extended hinge region will provide optimal protein folding for the
successful development of DBL-Fc fusions as vaccine candidates.
CHO-K1 cell expression
CHO-K1 cells are well established in the production of therapeutics, and are the most
commonly used mammalian expression system for Fc-fusion proteins. Mammalian
expression was important in this study for proper disulphide bond formation, which is
critical for the stability of the DBL domain. Human HeK cells are used for the expression
of the Fc fusion protein Alprolix and were also tested in this study. Although HeK cells
are known to produce protein quickly, they were not successful for transfection in this case.
CHO-K1 cells were therefore used for production of the DBL-Fc fusion. Yield problems
were addressed by developing methods for selection of high-expressing clonal cell lines.
This facilitated protein production, and it was also found that the CHO-KI cells grow
better in Hams F-10 growth media instead of DMEM. However, a bacterial expression
system could be developed to further improve yield. E. coli expression systems are cost
effective and known to produce high protein yields. This is a commonly used system for
the expression of P. falciparum recombinant protein where glycosylation is not necessary.
However, care would be needed to ensure proper disulphide bond formation.
pFUSE-hIgG1-Fc2 plasmid
The pFUSE-hIgG1-Fc2 plasmid is a commercially available plasmid for the construction
of Fc-fusion proteins and has shown to be successful (Mekhaiel et al., 2011). This plasmid
is known to produce yields on the scale of micrograms per millilitre although typical
yields here were 0.1 - 0.5 μg/ml. pFUSE-hIgG1-Fc2 contains the hEF1-HTLV promoter, a
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strong promoter based on the Elongation Factor-1α core promoter 1. Protein yield is often
dependent on promoter strength, however it has been suggested that weaker promoters
are preferred in cases where proteins may be toxic.
Difficulties in bacterial growth may be related to the origin of replication on the pFUSE
plasmid. However, it is unclear which origin of replication is used in the plasmid, therefore
it is uncertain whether the plasmid is high or low copy number. Slow growth rates are
usually linked to low copy number plasmids. However, if the DNA is toxic to the cells a
low copy number plasmid is preferred. Therefore, it may be that the pFUSE plasmid is
high copy number and may not ultimately be the best vector for this work.
Commercially available plasmids for the expression of Fc-fusion proteins are limited.
Another plasmid used in the laboratory which produces a high yield of Fc fusion protein
has a low copy number. This plasmid is patent protected and therefore the promoter is
unknown. Further plasmid development is needed to optimise protein yield.
Protein purification
Protein was purified using the AKTA explorer FPLC system. This is a basic system that
is no longer in production. The newer, highly sophisticated AKTA pure machine has a
separate sample loop which prevents cell supernatant from being passed through the main
pumps and the mixing chamber. This mixing chamber contains a magnetic flea which
could be detrimental to protein and could explain some of the protein fragments observed.
A new machine is currently being installed in the laboratory and it will be interesting to
see whether improvements are seen in future protein purification.
Protein G sepharose columns were used to isolate the Fc-fusion proteins by affinity
purification. Protein A is commonly used for the purification of Fc-fusion proteins, however
the binding affinity of IgG is stronger to protein A than to protein G, and therefore a
lower elution pH is required. It was decided that low pH should be avoided in order to
prevent denaturing of the protein and to maintain the biological activity of the molecule,
therefore protein G sepharose was used. However, purification by protein A could be
further investigated.
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6.3 Accuracy of the molecular simulation of DBL-IgM binding
A model for IgM binding was constructed by developing homology models of IgM-binding
DBL domains based on known DBL structures and docking these to a model of IgM
(Czajkowsky et al., 2010). There were multiple possible binding conformations but these
were narrowed down by placing constraints on the termini of the IgM-binding domains
due to the central disposition of the IgM-binding DBL domains within the PfEMP1
(Czajkowsky et al., 2010). The accessibility of the domains within the PfEMP1 and
the localisation of ligand-binding residues in other DBL domains were also used to narrow
down the binding conformations (Czajkowsky et al., 2010). The model shows a striking
number of charged residues at immediate distances from oppositely charged residues on
the IgM surface (Czajkowsky et al., 2010). The model corresponds particularly well to the
DARC recognition site on P. knowlesi DBL (Singh et al., 2006).
A merozoite model of IgM binding was based on this PfEMP1 DBL-IgM docking
model. The DBL structures are homologous and therefore the binding sites are assumed
to be similar. However, due to the way that the potential conformations were narrowed
down in the PfEMP1 model, based on constraints due to the PfEMP1 protein structure, it
might be expected that the model is not accurate for the merozoite DBL domains. Protein
interface prediction suggests that the binding sites may even be different for MSPDBL1
compared to MSPDBL2.
A recent study of the minimal binding region for the DBL4ζ from TM284var1 using
the PfEMP1-IgM homology model provides further evidence that the model might not be
accurate (Semblat et al., 2015). Residues predicted to be critical for IgM binding were
mutated and shown not to affect binding and the authors have called for a revision of the
model. Data presented here highlight the need for further model development.
Although the homology model was used to select for mutants, a set of random
mutations was used rather than assuming the model to be correct and using it to
produce mutants by site-directed mutagenesis. The model was used to select mutants
for expression, but few mutations were actually in the regions predicted by the model.
Charged residues were therefore selected as well as those that had cysteine mutations.
Using improved recombinant proteins, future work might involve developing a larger
library of mutants in order to further investigate the IgM binding region. However,
constraints on available facilities may limit a large scale-study.
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6.4 The role of helix 2a in IgM binding
Despite the disappointing results from ELISA investigations of the mutant DBL Fc-fusion
proteins, regions of interest were identified following structural analysis of the IgM-binding
DBL domains. MSPDBL isolates were modelled, based on the crystal structure of 3D7,
and known IgM binders were superimposed on non-binders. This highlighted structural
differences in helices 1, h2a, h4 and h7 (Crosnier et al., 2016). Polymorphisms in h7 are
frequently observed in DBL domains, therefore any differences highlighted in this loop
were assumed to be unlikely due to changes in binding ability. Therefore the binding site
is more likely in one of the other three loops identified.
Analysis of surface residues predicted regions in MSPDBL1 and -2 likely to be involved
in protein-protein interactions. This analysis highlighted helix 2a as a binding interface
common to both MPSDBL1 and MPSDBL2 and is therefore likely to be involved in IgM
binding. Helix 2a is located on the surface of the DBL within subdomain 2 and is therefore
open to receptor interactions (Figure 6.1). However, MSPDBL1 and MPSDBL2 have also
been shown to bind the MSP1 complex on the erythrocyte surface (Lin et al., 2014).
This may occur through a common binding site. Competition studies would therefore be
interesting to investigate whether the merozoite DBLs are still able to bind IgM when in
complex.
Figure 6.1: Location of MPSDBL1 helix 2a which is highlighted in green.
Two studies of critical binding residues for the Duffy antigen showed that the binding
region lay in a central region spanning the fifth to the eight cysteine residues (C5 - C8)
of the PvRII and PkαRI DBL domains (Ranjan and Chitnis, 1999; Singh et al., 2003). A
191
6 DISCUSSION
further study by Mayor et al. (2005) aimed to identify receptor-binding regions of several
DBL domains from EBP and PfEMP1 protein families using deletion constructs. The
receptor-binding residues for DBL domains that bind sialic acid on glycophorin A for
erythrocyte invasion as well as complement receptor-1 and chondroitin sulphate A for
cytoadherence were mapped to central regions (Mayor et al., 2005). The region identified
spanned C5 to C8 except for the ICAM-1 binding region of the JDP8-DBLβ which also
required the C2 domain for ICAM-1 binding. However, it was shown that the region
spanning C1 - C4, as with the other DBLs investigated, was not required for binding.
Helix 2a of the merozoite DBL domains is located in this region which corresponds to
subdomain 1. This suggests that the IgM-binding region of the merozoite DBL may be a
unique binding site.
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6.5 Minimal IgM-binding region
Short versions of the merozoite DBL domains were originally expressed due to debate on
their exact location when this work first started. Since the crystal structure of MSPDBL2
has been resolved, the exact location of the DBL domain is clearer (Hodder et al., 2012).
Full-length DBL domains were expressed (Chapter 5) along with the shorter versions used
previously, in order to investigate whether there were any differences in protein folding or
binding between the DBLs of different lengths.
Figure 6.2: Minimal IgM binding region of DBLζ from TM284var1 compared
to the short merozoite DBL domain. The TM284var1 DBLζ minimal IgM binding
region (blue) lies within the short merozoite DBL (cream) and contains helix 2a (green).
No differences were observed, although the full length DBL domains produced higher
protein yields with the addition of the extended hinge. The minimal IgM-binding region
of DBLζ from TM284var1 has been identified as a central region consisting of subdomain
2 and flanking parts of subdomains 1 and 3 (Semblat et al., 2015). This region of the
DBL showed no loss of IgM binding affinity by SPR analysis (Semblat et al., 2015). The
short DBL domains produced here contain subdomain 2 with longer flanking regions of
subdomains 1 and 3 than the minimal binding region (Figure 6.2). Data presented here
are in agreement with the minimal IgM-binding region which lies within the short DBL
domains.
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6.6 Merozoite DBL-Fc fusion proteins as reagents for IgM purification
Currently, IgM purification is difficult due to it’s size, and current purification reagents
have limited efficacy. This is a problem for the manufacture of monoclonal IgM antibodies.
C1q and mannose-binding lectin (MBL) are susceptible to proteolysis and such affinity
ligands have IgM recovery rates of less than 95%. Merozoite Fc-fusion proteins may be
developed as novel IgM binding reagents for purification due to their high affinity for
IgM and their ability to be purified using protein G. However, IgM is sensitive to low pH
therefore the elution methods developed here would need optimisation.
6.7 Merozoite DBL-Fc fusion proteins as malaria vaccines
The clinical success of Fc-fusion proteins has focussed on their use for drug delivery. A
multimeric Fc fusion would be expected to enhance the interaction with the FcRn and
further increase the plasma half-life and vaccine activity of the fused protein (Czajkowsky
et al., 2015). In our laboratory, a single Fc has been engineered so that it can form
hexameric oligomers which bind to high-affinity Fc receptors (Mekhaiel et al., 2011;
Czajkowsky et al., 2015). The next step for malaria vaccine development, which is ongoing
in our laboratory, is to further develop this multimeric scaffold. This may facilitate the
production of a multimeric DBL-Fc fusion protein. A vaccine based on such a molecule
may show improved immunogenicity for inducing adhesion-blocking antibodies and would
have superior half-life. Further work is needed to identify binding motifs and critical
residues. The methods developed here may also be used to produce other malarial
Fc-fusion proteins which may have the ability to prime an immune response to malaria.
6.8 Merozoite DBL-Fc fusion proteins as therapeutics for the treatment
of IgM-related diseases
DBL-Fc fusion proteins may be used as therapeutics for IgM-mediated diseases due to
their high affinity for IgM. Cryoglobulinemia is a condition defined by the presence of
cryoglobulins in serum. Cryoglobulins are immunoglobulins or immune complexes which
precipitate from serum below temperatures of 37◦C (Oliver et al., 2005). Cryoglobulinemia
can be IgM-mediated by IgM cryoglobulins in type I cryoglobulinemia or by IgM-IgG
complexes in type II (Terrier et al., 2012). Symptoms include fatigue, skin ulcers,
neuropathy and kidney manifestations. Cryoglobulinemia may be present on its own or
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may be due to an underlying infection or diseases such as myeloma, macroglobulinemia or
B-cell non-Hodkgin’s lymphoma (Terrier et al., 2012). The reduction of IgM by DBL-Fc
fusion proteins could be used as therapeutics for these conditions. Complement activation
can lead to an intense inflammatory response in type II cryoglobulinemia where immune
complexes are deposited in blood vessel walls. These manifest clinically as purpuric skin
eruptions and ulcers (Schamberg and Lake-Bakaar, 2007). The reduction of IgM in serum
may also reduce complement activation and improve symptoms of vasculitis, which can
range from mild to severe.
IgM is the main underlying component of Schnitzler’s syndrome, a rare
auto-inflammatory disease which manifests as a rash and joint pain, as well as fever
and enlarged lymph nodes (Lipsker, 2010). Current treatments are ineffective and while
symptoms can be debilitating, patients are also prone to lymphoproliferative disorders such
as Waldenstro˝m’s macroglubulinemia (WM) and lymphoma (Lipsker, 2010). Treatment
of the underlying IgM monoclonal gammopathy by the DBL-Fc fusion proteins could be
investigated.
IgM reacts against myelin-associated glycoprotein (MAG) in anti-MAG demyelinating
neuropathy, resulting in nerve damage and peripheral neuropathy (Lunn and
Nobile-Orazio, 2012). Intravenous immunoglobulin treatment (IVIG) produces only
short-term benefits, and a small clinical trial of rituximab was of poor quality and is
awaiting a larger study (Lunn and Nobile-Orazio, 2012). Rituximab is currently the
main treatment for IgM gammopathy in Waldenstro˝m’s macroglobulinemia. However,
a common site effect is IgM flare which leads to the worsening of IgM-related symptoms
(Treon et al., 2004). Such an IgM flare has an occurrence rate of 40 - 50 % when rituximab
is used as a monotherapy for WM (Treon, 2009). It is possible that DBL-Fc fusion proteins
could be used in combination with rituximab to control IgM levels in serum.
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6.9 Concluding remarks
Novel merozoite DBL-Fc fusion proteins have been produced and used to investigate IgM
binding. The experimental results described here were limited by protein yield and lack of
homodimer formation. This was addressed by designing a flexible, extended hinge region
which led to improved homodimer formation of the Fc-fusion proteins. The hinge design,
however, is not optimal and could be further improved to make multimeric Fc-fusion
proteins for vaccine development.
While sequence analysis was unsuccessful, structural analysis identified a region which
is potentially involved in IgM binding. Helix 2a was predicted by structural modelling
of MSPDBL isolates known to bind IgM and identified from analysis of surface residues
as a protein-protein interaction interface. However, further experimental refinements are
required to investigate this result and to identify any critical residues in this region.
This study has provided a foundation to further develop the scaffold and identify the
IgM-binding site on the merozoite DBL domains. Binding to natural IgM is thought to
prevent detection of the parasite by the more effective IgG Ab. Thus, since DBL-Fc fusion
proteins may have immunogenicity for inducing anti-adhesion antibodies, a blood-stage
vaccine based on these proteins may have the potential to reduce parasitemia in the blood
(Fried and Duffy, 2015; Avril et al., 2011). The DBL-Fc fusion proteins have high affinity
for IgM and may also be developed for therapeutic use against IgM-mediated diseases or
as affinity ligands for IgM purification.
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Appendices
A Plasmid Maps
A.1 pCR2.1-TOPO
The commercially available PCR 2.1 TOPO vector from Life Technologies was used as
a parking vector to insert the DBL 3.4 and DBL 3.8 domains, forming the vectors PCR
2.1-TOPO 3.4 and PCR 2.1-TOPO 3.8. The cloned TOPO vectors were then used for
sub-cloning the DBL domains into the pFUSE vector. The TOPO vector was used as a
parking vector due to its cloning efficiency.
Comments for pCR®2.1-TOPO®
3931 nucleotides
LacZ! fragment: bases 1-547
M13 reverse priming site: bases 205-221
Multiple cloning site: bases 234-357
T7 promoter/priming site: bases 364-383
M13 Forward (-20) priming site: bases 391-406
f1 origin: bases 548-985
Kanamycin resistance ORF: bases 1319-2113
Ampicillin resistance ORF: bases 2131-2991
pUC origin: bases 3136-3809
CAG GAA ACA GCT ATG ACC ATG ATT ACG CCA AGC TTG GTA CCG AGC TCG GAT CCA CTA
GTC CTT TGT CGA TAC TGG TAC TAA TGC GGT TCG AAC CAT GGC TCG AGC CTA GGT GAT
T7 Promoter M13 Forward (-20) Primer
Not I Xho I Nsi I Xba I Apa I
lacZ!
f1 ori
+1
Plac
Ampicillin
pU
C
or
i
Kan
am
yc
in
pCR®2.1-TOPO®
3.9 kb
M13 Reverse Primer
lacZ! ATG Kpn I Sac I Spe IBamH IHind III
EcoR IEcoR IBstX I
BstX IEcoR V
AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG CCC TAT
TCT ATA GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC GGG ATA
AGT GAG TCG TAT TAC AAT TCA CTG GCC GTC GTT TTA CAA CGT CGT GAC TGG GAA AAC
TCA CTC AGC ATA ATG TTA AGT GAC CGG CAG CAA AAT GTT GCA GCA CTG ACC CTT TTG
PCR ProductGTA ACG GCC GCC AGT GTG CTG GAA TTC GCC CTT           AAG GGC GAA TTC TGCCAT TGC CGG CGG TCA CAC GAC CTT AAG CGG GAA           TTC CCG CTT AAG ACG
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AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCG
GGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTT
GTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGGTACCGAGCTCGGATCCA
CTAGTAACGGCCGCCAGTGTGCTGGAATTCGCCCTTAAGGGCGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCATGC
ATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG
GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCC
CAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTG
ACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCA
AGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTT
CACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAA
ACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGA
GCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATTCAGGGCGCAAGGGCTGCTAAAGGAAGCGGAACACGTAGAAAGCCAG
TCCGCAGAAACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTGGACAAGGGAAAACGCAAGCGCAAAGAGAAAGCAGG
TAGCTTGCAGTGGGCTTACATGGCGATAGCTAGACTGGGCGGTTTTATGGACAGCAAGCGAACCGGAATTGCCAGCTGGGGCGCCC
TCTGGTAAGGTTGGGAAGCCCTGCAAAGTAAACTGGATGGCTTTCTTGCCGCCAAGGATCTGATGGCGCAGGGGATCAAGATCTGA
TCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTAT
TCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTT
GTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTG
CGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCCC
ACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGAC
CACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCA
GGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCT
GCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGAC
ATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCC
CGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCG
TGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAG
ATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTT
CCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCAT
ACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCA
GTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTG
CACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCAC
GATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACT
GGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGT
GAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCA
GGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACT
CATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAA
ATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCG
CGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGA
AGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTA
GCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTC 
AAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACA
CCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGC
AGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTG
ACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGG
CCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCT
GATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG 
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A.2 pCR2.1-TOPO-DBL3.4-short
Plasmid map for the pCR2.1-TOPO-3.4 vector containing the DBL 3.4 insert from
MSPDBL1 (shown in purple). The 3.4 DBL domain has been inserted between NcoI
restriction site at 296 bases and the BglII restriction site at 1160 bases. The sequence
shows the DBL insert in purple with the flanking restriction sites in red. Neither NcoI
(CCATGG) not BglII (AGATCT) are present in the insert sequence, but are both present
in the TOPO plasmid, their positions being shown in yellow.
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AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCG
GGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTT
GTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGGTACCGAGCTCGGATCCA
CTAGTAACGGCCGCCAGTGTGCTGGAATTCGCCCTTCCATGGTTttctgcaagggcatcaagaacgtgctgagctgccctcccaag
aacagcgccggcagaaacggcgactggatcagcgtggccgtgaaagagagcagcaccaccaacaagggcgtgctggtgccccccag
acggaccaagctgtgcctgcggaacatcaacaaagtgtggcaccggatcaaggacgagaagaacttcaaagaggaattcgtcaagg
tcgcactgggcgagagcaacgccctgatgaagcactacaaagagaagaacctgaacgccctgaccgccattaagtacggcttcagc
gacatgggcgacatcatcaagggcaccgacctgatcgattaccagatcaccaagaacatcaaccgggccctggacaagatcctgag
aaacgaggccagcaacgacaagatcaagaaacgggtggactggtgggaggccaacaaggccgccttctgggacgccttcatgtgcg
gctacaaggtgcacatcggcaacaagccctgccccgagcacgacaacatggaccggatcccccagtacctgcggtggtttcgcgag
tggggcacctacgtgtgcagcgagtacaagaacaagttcgaggacgtgatcaagctgtgcaacatccagcagttcaccaaccagga
cgacagccagctgctggaaatcagcaagaaagacaagtgcaaagaggccctgaaacactacgaggaatgggtcaaccggcggaggc
ccgagtggaagggccagtgcgataagttcgagaaagagaagtctaagtacgaggacaccaagagcatcaccgccgagaagtacctg
aaagaaatctgcagcgagtgcgactgcaagtacaaggacctggacaacAGATCTAAGGGCGAATTCTGCAGATATCCATCACACTG
GCGGCCGCTCGAGCATGCATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTACAACGTC
GTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCC
CGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTG
GTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTT
CGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAAC
TTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAAT
AGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGC
CTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATTCAGGGCGCAAGGGCTGCTAAAGGAAGCG
GAACACGTAGAAAGCCAGTCCGCAGAAACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTGGACAAGGGAAAACGCAA
GCGCAAAGAGAAAGCAGGTAGCTTGCAGTGGGCTTACATGGCGATAGCTAGACTGGGCGGTTTTATGGACAGCAAGCGAACCGGAA
TTGCCAGCTGGGGCGCCCTCTGGTAAGGTTGGGAAGCCCTGCAAAGTAAACTGGATGGCTTTCTTGCCGCCAAGGATCTGATGGCG
CAGGGGATCAAGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCG
CTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAG
GGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGC
CACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGC
AGGATCTCCTGTCATCCCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCG
GCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGA
TCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCG
TGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTG
GCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCT
TTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAATTGAAAAAGGAAGAGTAT
GAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGA
AAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTT
CGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGA
GCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGA
CAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAG
GAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAA
CGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCC
GGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCT
GATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTAT
CTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAAC
TGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTT
GATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTG
AGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGC
TACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCAC
CACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTG
TCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCT
TGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGAC
AGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGT
CGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGG
CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATT
ACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG 
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A.3 pCR2.1-TOPO-DBL3.8-short
Plasmid map for the pCR2.1-TOPO-3.8 vector containing the DBL 3.8 insert from
MSPDBL2 (shown in maroon). The 3.8 DBL domain has been inserted between EcoRI
restriction site at 302 bases and the NcoI restriction site at 1163 bases. The sequence
shows the DBL insert in maroon with the flanking restriction sites in red. Neither EcoRI
(GAATTC) nor NcoI (CCATGG) are present in the insert sequence but both are present
within the TOPO plasmid, their positions being shown in yellow.
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pCR2.1-TOPO-DBL3.8 
 
 
AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCG
GGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTT
GTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGGTACCGAGCTCGGATCCA
CTAGTAACGGCCGCCAGTGTGCTGGAATTCGCCCTTGAATTCGATCTGCAAGGACTTCAGCAACCTGCCCCAGTGCCGGAAGAACG
TGCACGAGCGGAACAACTGGCTGGGCAGCAGCGTGAAGAACTTCGCCAGCGACAACAAGGGCGTGCTGGTGCCCCCCAGACGGCAG
AGCCTGTGCCTGAGAATCACCCTGCAGGACTTCCGGACCAAGAAGAAGAAAGAGGGCGACTTCGAGAAGTTCATCTACAGCTACGC
CAGCAGCGAGGCCCGGAAGCTGCGGACCATCCACAACAACAACCTGGAAAAGGCCCACCAGGCCATCCGGTACAGCTTCGCCGACA
TCGGCAACATCATCCGGGGCGACGACATGATGGACACCCCCACCAGCAAAGAGACAATCACCTATCTGGAAAAGGTGCTGAAGATC
TACAATGAGAACAACGACAAGCCCAAGGACGCCAAGAAGTGGTGGACCGAGAACCGGCACCACGTGTGGGAGGCCATGATGTGCGG
CTACCAGAGCGCCCAGAAAGACAACCAGTGCACCGGCTACGGCAACATCGACGATATCCCCCAGTTCCTGCGGTGGTTCCGCGAGT
GGGGCACCTACGTGTGCGAAGAGTCCGAGAAGAACATGAATACCCTGAAGGCCGTGTGCTTCCCCAAGCAGCCCAGAACCGAGGCC
AACCCTGCCCTGACCGTGCACGAGAACGAGATGTGCAGCAGCACCCTGAAGAAATACGAGGAATGGTACAACAAGCGCAAGACCGA
GTGGACCGAGCAGAGCATCAAGTATAACAACGATAAGATCAACTACGCCGACATCAAGACCCTGAGCCCCAGCGAGTACCTGATCG
AGAAGTGCCCCGAGTGCAAGTGCACCAAGAAAAACCTGCAGGACGCCATGGAAGGGCGAATTCTGCAGATATCCATCACACTGGCG
GCCGCTCGAGCATGCATCTAGAGGGCCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTG
ACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGC
ACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTG
GTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGC
CGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTG
ATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGT
GGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTA
TTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATTCAGGGCGCAAGGGCTGCTAAAGGAAGCGGAA
CACGTAGAAAGCCAGTCCGCAGAAACGGTGCTGACCCCGGATGAATGTCAGCTACTGGGCTATCTGGACAAGGGAAAACGCAAGCG
CAAAGAGAAAGCAGGTAGCTTGCAGTGGGCTTACATGGCGATAGCTAGACTGGGCGGTTTTATGGACAGCAAGCGAACCGGAATTG
CCAGCTGGGGCGCCCTCTGGTAAGGTTGGGAAGCCCTGCAAAGTAAACTGGATGGCTTTCTTGCCGCCAAGGATCTGATGGCGCAG
GGGATCAAGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTT
GGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGG
CGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCAC
GACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGG
ATCTCCTGTCATCCCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCT
ACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCT
GGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGA
CCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCG
GACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTA
CGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAATTGAAAAAGGAAGAGTATGAG
TATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAG
TAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGC
CCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCA
ACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAG
TAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAG
CTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGA
CGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGC
AACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGAT
AAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTA
CACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGT
CAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGAT
AATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGA
TCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTAC
CAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCAC
TTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCT
TACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGG
AGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGG
TATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGG
GTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCT
TTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACC
GCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG 
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A.4 pFUSE-hIgG1-Fc2
The commercially available pFUSE-hIgG1-Fc2 vector from Invivogen was used as an
expression vector.
110
pFUSE-hIgG1-Fc2
(4194 bp)
SV40 pAn
ßGlo pAn
Ori
Zeo
EM2KC
CMV enh
hFerL
hEF1-HTLV prom
hIgG1 Fc
IL2ss
SgfI (11)
PvuII (242)
HindIII (246)
EcoRI (626)
EcoRV (634)
NcoI (640)
BglII (648)
BspHI (745)
SmaI (1056)
XmnI (1257)
NheI (1340)
HpaI (1480)
XmnI (1578)
AseI (1577)
SwaI (1834)SmaI (2275)
AseI (2461)
PstI (2483)
HindIII (2587)
BspEI (2745)
SpeI (2852)
SdaI (3268)
PstI (3268)
PacI (3275)
BspLU11I (3281)
PacI (4015)
SwaI (4023)
NotI (4031)
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GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTA
GAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCC
GTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCC
GCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACC
GGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTT
TCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATGTACAGGATGCAACTCCTGTCTTGCA
TTGCACTAAGTCTTGCACTTGTCACGAATTCGATATCGGCCATGGTTAGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGG
GGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAA
GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGG
TCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCAT
CTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC
AAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCT
CCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTA
CACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGC
AGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCA
TTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCA
AAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTG
CAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCAC
ATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTC
ATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTG
CTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAG
GCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCT
GGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCA
GAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaaga
aggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccact
tttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGA
CCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCA
ATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGC
CTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAA
ATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGT
AGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGA
TGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACG
•••AspGl n
Gl uGl uAl aVa l PheHi sVa l CysAsnGl yA l aP roAspArgLeuAl aPheGl uArgGl yT rpP roGl nGl uGl y I l eGl uThr Me tAl aP roGl ySer A
l aAspArgPheAsnThr Ser Va l Va l Gl uSer T rpGl uAl aTy rLeuGl uAspLeuGl yA rgVa l T rpVa l T rpAl aLeuThrAsnAspP roVa l Va l Gl
nAspGl nVa l A l aSer I l ePheLeuThr Va l AspAspArgVa l Va l Gl yA l aPheAspAspGl uVa l PheAspArgSer PheGl yLeuArgAspThr T rp
PheGl uVa l A l aGl yA l aVa l AspArgAl aThr LeuVa l P roVa l A l aSer Thr LeuLysAl aMe t
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a l Ser Va l LeuThr Va l LeuHi sGl nAspT rpLeuAsnGl yLysGl uTy rLysCysLysVa l SerAsnLysAl aLeuP roAl aP ro I l eGl uLysThr I l
eSer LysAl aLysGl yGl nP roArgGl uP roGl nVa l Ty rThr LeuP roP roSer A rgGl uGl uMe tThr LysAsnGl nVa l Ser LeuThr CysLeuVa l
LysGl yPheTyrP roSerAsp I l eAl aVa l Gl uT rpGl uSerAsnGl yGl nP roGl uAsnAsnTyrLysThr Thr P roP roVa l LeuAspSerAspGl yS
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SgfI (11)
PvuII (242)
HindIII (246)
EcoRI (626)
EcoRV (634)
NcoI (640)
BglII (648)
BspHI (745)
SmaI (1056)
XmnI (1257)
NheI (1340)
HpaI (1480)
XmnI (1578)
AseI (1577)
SwaI (1834)
SmaI (2275)
AseI (2461) PstI (2483)
HindIII (2587)
BspEI (2745)
SpeI (2852)
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101
201
301
401
501
601
701
801
901
1001
1101
1201
1301
1401
1501
1601
1701
1801
1901
2001
2101
2201
2301
2401
2501
2601
2701
2801
2901
3001
3101
125
122
88
55
22
1
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TCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAG
CAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGT
GGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTC
CGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCAC
GAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTG
GTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTG
CGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAG
CAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGG
TCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACA
TACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA
SdaI (3268)
PstI (3268)
PacI (3275)
BspLU11I (3281)
PacI (4015) SwaI (4023) NotI (4031)
3201
3301
3401
3501
3601
3701
3801
3901
4001
4101
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A.5 pFUSE-hIgG1-Fc2-DBL3.4-short
Plasmid map for the pFUSE-hIgG1-Fc2-DBL3.4-short vector containing the DBL 3.4
insert from MSPDBL1 (shown in purple). The 3.4 DBL domain has been inserted within
the multiple cloning site between the NcoI restriction site at 640 bases and the BglII
restriction site at 1512 bases. The sequence shows the DBL insert in purple in the pFUSE
plasmid. The DBL is located before the start of the Fc sequence (which begins GACAAAA
in dark red).
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pFUSE-hIgG1-Fc2-3.4DBL-short
5058 bp
SgflI 11 PvuII 242
HindIII 246
EcoRI 626
EcoRV 632
NcoI 640
EcoRI 849
BglII 1512
BspHI 1609
SmaI 1920
XmnI 2121
NheI 2204
AseI 2441
XmnI 2442SwaI 2698
SmaI 3139
AseI 3325
PstI 3347
HindIII 3451
BspEI 3609
SpeI 3716
PstI 4132
SdaI 4132
PacI 4139
BspLU11I 4145
PacI 4879SwaI 4886
NotI 4895
hEF1-HTLV-prom
IL2ss
3.4-DBL-short
hIgG1-Fc2
SV40ßGlo
Zeo
EM2KC
hFerL
CMV-enh
Ori
234
APPENDICES
	
pFUSE-hIgG1-Fc2-3.4DBL-short 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGATATCGGCCATGGTTttctgcaagggcatcaagaacgtgctgagctgccctcccaaga
acagcgccggcagaaacggcgactggatcagcgtggccgtgaaagagagcagcaccaccaacaagggcgtgctggtgccccccagacggaccaagctgtgcctgcggaacatcaa
caaagtgtggcaccggatcaaggacgagaagaacttcaaagaggaattcgtcaaggtcgcactgggcgagagcaacgccctgatgaagcactacaaagagaagaacctgaacgcc
ctgaccgccattaagtacggcttcagcgacatgggcgacatcatcaagggcaccgacctgatcgattaccagatcaccaagaacatcaaccgggccctggacaagatcctgagaa
acgaggccagcaacgacaagatcaagaaacgggtggactggtgggaggccaacaaggccgccttctgggacgccttcatgtgcggctacaaggtgcacatcggcaacaagccctg
ccccgagcacgacaacatggaccggatcccccagtacctgcggtggtttcgcgagtggggcacctacgtgtgcagcgagtacaagaacaagttcgaggacgtgatcaagctgtgc
aacatccagcagttcaccaaccaggacgacagccagctgctggaaatcagcaagaaagacaagtgcaaagaggccctgaaacactacgaggaatgggtcaaccggcggaggcccg
agtggaagggccagtgcgataagttcgagaaagagaagtctaagtacgaggacaccaagagcatcaccgccgagaagtacctgaaagaaatctgcagcgagtgcgactgcaagta
caaggacctggacaacAGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTC
ATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAA
AGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCT
CCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACC
TGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT
TCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCT
GTCTCCGGGTAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATG
CTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTA
AAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCA
TCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTT
AAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCC
CTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCA
CAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGAC
CTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGG
ACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCA
ACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAA
ACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAG
AAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAA
TCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTG
TTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCC
ATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGC
CATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCC
CTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATT
AAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAA
GTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTT
TCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGAC
CGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG
CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATC
CGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCT
CAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTT
GTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA  	
MYRMQLLSCIALSLALVTNSISAMVFCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNI
NKVWHRIKDEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNINRALDKILR
NEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQYLRWFREWGTYVCSEYKNKFEDVIKLC
NIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVNRRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKY
KDLDNRSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
PGK*VLA 
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APPENDICES
A.6 pFUSE-hIgG1-Fc2-DBL3.8-short
Plasmid map for the pFUSE-hIgG1-Fc2-DBL3.8-short vector containing the DBL 3.8
insert from MSPDBL2 (shown in maroon). The 3.8 DBL domain has been inserted within
the multiple cloning site between the EcoRI restriction site at 626 bases and the NcoI
restriction site at 1487 bases. The sequence shows the DBL insert in maroon in the
pFUSE plasmid. The DBL is located before the start of the Fc sequence (which begins
GACAAA in dark red).
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pFUSE-hIgG1-Fc2-3.8DBL-short
5057 bp
SgflI 11 PvuII 242
HindIII 246
EcoRI 626
NcoI 1487
BglII 1511
BspHI 1608
SmaI 1919
XmnI 2120
NheI 2203
AseI 2440
XmnI 2441SwaI 2697
SmaI 3138
AseI 3324
PstI 3346
HindIII 3450
BspEI 3608
SpeI 3715
PstI 4131
SdaI 4131
PacI 4138
BspLU11I 4144
PacI 4878SwaI 4885
NotI 4894
hEF1-HTLV-prom
IL2ss
3.8-DBL-short
hIgG1-Fc2
SV40ßGlo
Zeo
EM2KC
hFerL
CMV-enh
Ori
236
APPENDICES
 
pFUSE-hIgG1-Fc2-38DBL-short 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGatctgcaaggacttcagcaacctgccccagtgccggaagaacgtgcacgagcggaaca
actggctgggcagcagcgtgaagaacttcgccagcgacaacaagggcgtgctggtgccccccagacggcagagcctgtgcctgagaatcaccctgcaggacttccggaccaagaa
gaagaaagagggcgacttcgagaagttcatctacagctacgccagcagcgaggcccggaagctgcggaccatccacaacaacaacctggaaaaggcccaccaggccatccggtac
agcttcgccgacatcggcaacatcatccggggcgacgacatgatggacacccccaccagcaaagagacaatcacctatctggaaaaggtgctgaagatctacaatgagaacaacg
acaagcccaaggacgccaagaagtggtggaccgagaaccggcaccacgtgtgggaggccatgatgtgcggctaccagagcgcccagaaagacaaccagtgcaccggctacggcaa
catcgacgatatcccccagttcctgcggtggttccgcgagtggggcacctacgtgtgcgaagagtccgagaagaacatgaataccctgaaggccgtgtgcttccccaagcagccc
agaaccgaggccaaccctgccctgaccgtgcacgagaacgagatgtgcagcagcaccctgaagaaatacgaggaatggtacaacaagcgcaagaccgagtggaccgagcagagca
tcaagtataacaacgataagatcaactacgccgacatcaagaccctgagccccagcgagtacctgatcgagaagtgccccgagtgcaagtgcaccaagaaaaacctgcaggacgC
CATGGTTAGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGG
AGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCC
CATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC
AAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACA
GCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGG
TAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTT
TATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTA
CAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCT
GTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACT
GACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAAT
ATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCA
CGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCA
CTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCG
GCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCA
TGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCT
GCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAG
ACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTG
GCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAAT
GGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTA
CTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCG
TCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCG
TTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATG
TGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGT
GGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTC
GGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCC
TTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGT
TCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACA
AACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAAC
GAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATC
GTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA  
 
 
 	
MYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRITLQDFR
TKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIY
NENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAV
CFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEKCPECKC 
TKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE
VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
NHYTQKSLSLSPGK*VLA 
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A.7 pFMCS
24/05/2016, 22:06
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pFMCS
3517 bp
SgflI 11
PvuII 242
HindIII 246
NheI 661
HpaI 801
AseI 898
XmnI 899
SwaI 1155
SmaI 1596
AseI 1782
PstI 1804HindIII 1908
BspEI 2066
SpeI 2173
PstI 2592BspLU11I 2605
PacI 3336
SwaI 3344
NotI 3352
EcoRI
EcoRV
NcoI
BamHI
XhoI
BglII
hEF1-HTLV-prom
IL2ss
SV40
ßGlo
Zeo
EM2KC
hFerL
CMV-enh
Ori
238
APPENDICES
pFMCS 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCGATATCCCATGGGGATCCCTCGAGAGATCTGCTAGCTGGCCAGACATGATAAGATACA
TTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAA
CAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATA
GCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTT
CTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAA
ATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGG
AACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCG
CCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACC
CAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGA
GCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaag
gttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgcccca
tctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTG
GCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCC
GGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAA
CAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACT
AATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGAT
ACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGG
GCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAA
AGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTT
TCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGG
TATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAA
GACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAG
AACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAG
CAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTT
AATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAA
CAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA 
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APPENDICES
A.8 pFMCS-3.4DBL-FL
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pFMCS-3.4DBL-FL
4420 bp
SgflI 11 PvuII 242
HindIII 246
EcoRI 626
EcoRV 632
NcoI 640
EcoRI 858
EcoRI 1530
BglII 1560
NheI 1566
AseI 1803
XmnI 1804
SwaI 2060
SmaI 2626
AseI 2716
PstI 2738
HindIII 2842
BspEI 3000
SpeI 3107
PstI 3523
SdaI 3523
PacI 3530
BspLU11I 3536
PacI 4270SwaI 4227
NotI 4286
hEF1-HTLV-prom
IL2ss
3.4-DBL-FL
SV40
ßGloZeo
EM2KC
hFerL
CMV-enh
Ori
240
APPENDICES
pFMCS-34DBL-FL 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCGATATCaagtgccccgacgagaacttctgcaagggcatcaagaacgtgctgagctgcc
ctcccaagaacagcgccggcagaaacggcgactggatcagcgtggccgtgaaagagagcagcaccaccaacaagggcgtgctggtgccccccagacggaccaagctgtgcctgcg
gaacatcaacaaagtgtggcaccggatcaaggacgagaagaacttcaaagaggaattcgtcaaggtcgcactgggcgagagcaacgccctgatgaagcactacaaagagaagaac
ctgaacgccctgaccgccattaagtacggcttcagcgacatgggcgacatcatcaagggcaccgacctgatcgattaccagatcaccaagaacatcaaccgggccctggacaaga
tcctgagaaacgaggccagcaacgacaagatcaagaaacgggtggactggtgggaggccaacaaggccgccttctgggacgccttcatgtgcggctacaaggtgcacatcggcaa
caagccctgccccgagcacgacaacatggaccggatcccccagtacctgcggtggtttcgcgagtggggcacctacgtgtgcagcgagtacaagaacaagttcgaggacgtgatc
aagctgtgcaacatccagcagttcaccaaccaggacgacagccagctgctggaaatcagcaagaaagacaagtgcaaagaggccctgaaacactacgaggaatgggtcaaccggc
ggaggcccgagtggaagggccagtgcgataagttcgagaaagagaagtctaagtacgaggacaccaagagcatcaccgccgagaagtacctgaaagaaatctgcagcgagtgcga
ctgcaagtacaaggacctggacaacaccttcaaagaattcaaggacCCATGGGGATCCCTCGAGAGATCTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAA
ACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTC
ATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCC
AAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAG
ATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCA
TTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATT
GGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGC
CGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTC
CGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAAC
TCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTAT
AGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccacccttt
cccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTT
TATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCT
CAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGT
CAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTG
CCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCC
AAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCG
GTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCG
TTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCC
TCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTA
GGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCA
CTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCT
GCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAG
AAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCA
GCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAA
ATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA 
MYRMQLLSCIALSLALVTEFDIKCPDENFCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKL
CLRNINKVWHRIKDEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNINR
ALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQYLRWFREWGTYVCSEYKN
KFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVNRRRPEWKGQCDKFEKEKSKYEDTKSITAEKYL
KEICSECDCKYKDLDNTFKEFKDPWGSLERSASW 
241
APPENDICES
A.9 pFMCS-3.8DBL-FL
24/05/2016, 20:39
Page 1 of 1http://www.bioinformatics.org/savvy/cgi-bin/savvy.cgi
pFMCS-3.8DBL-FL
4411 bp
SgflI 11 PvuII 242
HindIII 246
EcoRI 627
EcoRV 633
NcoI 1533
BamHI 1539
XhoI 1545
BglII 1551
NheI 1558
AseI 1795
XmnI 1796
SwaI 2052
SmaI 2493
AseI 2679
PstI 2698
HindIII 2805
BspEI 2933
SpeI 3079
PstI 3586Sda 4 7
PacI 3493
BspLU11I 3499
PacI 4233SwaI 4241
NotI 4249
hEF1-HTLV-prom
IL2ss
3.8-DBL-FL
SV40 ßGloZeo
EM2KC
hFerL
CMV-enh
Ori
242
APPENDICES
pFMCS-38DBL-FL 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCaagtgccccaccgaggaaatctgcaaggacttcagcaacctgccccagtgccggaaga
acgtgcacgagcggaacaactggctgggcagcagcgtgaagaacttcgccagcgacaacaagggcgtgctggtgccccccagacggcagagcctgtgcctgagaatcaccctgca
ggacttccggaccaagaagaagaaagagggcgacttcgagaagttcatctacagctacgccagcagcgaggcccggaagctgcggaccatccacaacaacaacctggaaaaggcc
caccaggccatccggtacagcttcgccgacatcggcaacatcatccggggcgacgacatgatggacacccccaccagcaaagagacaatcacctatctggaaaaggtgctgaaga
tctacaatgagaacaacgacaagcccaaggacgccaagaagtggtggaccgagaaccggcaccacgtgtgggaggccatgatgtgcggctaccagagcgcccagaaagacaacca
gtgcaccggctacggcaacatcgacgatatcccccagttcctgcggtggttccgcgagtggggcacctacgtgtgcgaagagtccgagaagaacatgaataccctgaaggccgtg
tgcttccccaagcagcccagaaccgaggccaaccctgccctgaccgtgcacgagaacgagatgtgcagcagcaccctgaagaaatacgaggaatggtacaacaagcgcaagaccg
agtggaccgagcagagcatcaagtataacaacgataagatcaactacgccgacatcaagaccctgagccccagcgagtacctgatcgagaagtgccccgagtgcaagtgcaccaa
gaaaaacctgcaggacgtgttcgagctgaccttcgacCCATGGGGATCCCTCGAGAGATCTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACT
AGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGT
TTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGC
CTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGT
ATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGA
AAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAA
GAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGG
TCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCAC
CTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCT
CCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTG
TATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcat
agacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCG
CCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCC
GCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGT
GGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGG
AAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCA
GTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAG
GCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCAT
AGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCT
CTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCG
CTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCA
GCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGC
TGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGG
ATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCA
ATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGT
CCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA 
MYRMQLLSCIALSLALVTEFKCPTEEICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRI
TLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETITYLE
KVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNM
NTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEK 
CPECKCTKKNLQDVFELTFDPWGSLERSASW 
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pFMCS-3.4DBL-short
4381 bp
SgflI 11 PvuII 242
HindIII 246
EcoRI 626
EcoRV 632
NcoI 640
EcoRI 840
EcoRI 1530
BglII 1560
NheI 1566
AseI 1803
XmnI 1804
SwaI 2060
SmaI 2626
AseI 2716
PstI 2738
HindIII 2842
BspEI 3000
SpeI 3107
PstI 3523
SdaI 3523
PacI 3530
BspLU11I 3536
PacI 4270SwaI 4227
NotI 4286
hEF1-HTLV-prom
IL2ss
3.4-DBL-short
SV40
ßGloZeo
EM2KC
hFerL
CMV-enh
Ori
244
APPENDICES
pFMCS-34DBL-short 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCGATATCttctgcaagggcatcaagaacgtgctgagctgccctcccaagaacagcgccg
gcagaaacggcgactggatcagcgtggccgtgaaagagagcagcaccaccaacaagggcgtgctggtgccccccagacggaccaagctgtgcctgcggaacatcaacaaagtgtg
gcaccggatcaaggacgagaagaacttcaaagaggaattcgtcaaggtcgcactgggcgagagcaacgccctgatgaagcactacaaagagaagaacctgaacgccctgaccgcc
attaagtacggcttcagcgacatgggcgacatcatcaagggcaccgacctgatcgattaccagatcaccaagaacatcaaccgggccctggacaagatcctgagaaacgaggcca
gcaacgacaagatcaagaaacgggtggactggtgggaggccaacaaggccgccttctgggacgccttcatgtgcggctacaaggtgcacatcggcaacaagccctgccccgagca
cgacaacatggaccggatcccccagtacctgcggtggtttcgcgagtggggcacctacgtgtgcagcgagtacaagaacaagttcgaggacgtgatcaagctgtgcaacatccag
cagttcaccaaccaggacgacagccagctgctggaaatcagcaagaaagacaagtgcaaagaggccctgaaacactacgaggaatgggtcaaccggcggaggcccgagtggaagg
gccagtgcgataagttcgagaaagagaagtctaagtacgaggacaccaagagcatcaccgccgagaagtacctgaaagaaatctgcagcgagtgcgactgcaagtacaaggacct
ggacaacCCATGGGGATCCCTCGAGAGATCTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGT
GAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTT
TTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAA
TAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCAT
TTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCA
GATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCC
TGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGT
TCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGT
CACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGA
ACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAAT
GATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGG
AGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAG
GCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTG
TAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACC
GCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATA
ATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGT
CAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGC
CTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAA
AATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGAT
ACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCC
CGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGG
TATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTG
GTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTAC
GGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGT
GTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATT
TCTCTATCGAA 
MYRMQLLSCIALSLALVTEFDIFCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNIN
KVWHRIKDEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNINRALDKIL
RNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQYLRWFREWGTYVCSEYKNKFEDVI
KLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVNRRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSE 
CDCKYKDLDNPWGSLERSASW 
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A.11 pFMCS-3.8DBL-short
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pFMCS-3.8DBL-short
4372 bp
SgflI 11 PvuII 242
HindIII 246
EcoRI 627
EcoRV 633
NcoI 1494
BamHI 1500
XhoI 1506
BglII 1512
NheI 1519
AseI 1756
XmnI 1757
SwaI 2013
SmaI 2454
AseI 2640
PstI 2659
HindIII 2766
BspEI 2894
SpeI 3040
PstI 3547Sda 4 8
PacI 3454
BspLU11I 3460
PacI 4194SwaI 4202
NotI 4210
hEF1-HTLV-prom
IL2ss
3.8-DBL-short
SV40
ßGloZeo
EM2KC
hFerL
CMV-enh
Ori
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APPENDICES
pFMCS-38DBL-short 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCatctgcaaggacttcagcaacctgccccagtgccggaagaacgtgcacgagcggaaca
actggctgggcagcagcgtgaagaacttcgccagcgacaacaagggcgtgctggtgccccccagacggcagagcctgtgcctgagaatcaccctgcaggacttccggaccaagaa
gaagaaagagggcgacttcgagaagttcatctacagctacgccagcagcgaggcccggaagctgcggaccatccacaacaacaacctggaaaaggcccaccaggccatccggtac
agcttcgccgacatcggcaacatcatccggggcgacgacatgatggacacccccaccagcaaagagacaatcacctatctggaaaaggtgctgaagatctacaatgagaacaacg
acaagcccaaggacgccaagaagtggtggaccgagaaccggcaccacgtgtgggaggccatgatgtgcggctaccagagcgcccagaaagacaaccagtgcaccggctacggcaa
catcgacgatatcccccagttcctgcggtggttccgcgagtggggcacctacgtgtgcgaagagtccgagaagaacatgaataccctgaaggccgtgtgcttccccaagcagccc
agaaccgaggccaaccctgccctgaccgtgcacgagaacgagatgtgcagcagcaccctgaagaaatacgaggaatggtacaacaagcgcaagaccgagtggaccgagcagagca
tcaagtataacaacgataagatcaactacgccgacatcaagaccctgagccccagcgagtacctgatcgagaagtgccccgagtgcaagtgcaccaagaaaaacctgcaggacCC
ATGGGGATCCCTCGAGAGATCTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGT
GATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCA
AGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATA
GGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATG
TTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAA
GGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCT
GCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACA
CGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTC
CCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTG
GTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTG
TCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAG
GCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGG
CCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAG
CGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCAC
GCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGC
GGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAA
GTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTT
AATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGC
TCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCG
CCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCC
CGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGC
GGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTT
GATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGA
CGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTT
TTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCG
AA 
MYRMQLLSCIALSLALVTEFICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRITLQDFR
TKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIY
NENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAV
CFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEKCPECKC 
TKKNLQDPWGSLERSASW	
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pFMCS-IgG1 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCGATATCCCATGGGGATCCCTCGAGAGATCTGACAAAACTCACACATGCCCACCGTGCC
CAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCA
CGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTC
ACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAG
AACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAG
CAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAAC
GTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGA
TGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAAC
AACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCA 
AAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTT
TCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATA
ATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAAC
CTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCC
CCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAG
GCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCC
GGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggtt
agtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatct
cctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCT
AGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGA
GCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAA
ACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAAT
ACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACA
CTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCG
GGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGG
CCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCC
CCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTAT
CTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGAC
ACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAAC
AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAG 
CAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAAT
TAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAA
AACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA 
MYRMQLLSCIALSLALVTEFDIPWGSLERSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR
EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK*VLA 
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pFMCS-hIgG1-Fc2-34DBL-FL 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCGATATCaagtgccccgacgagaacttctgcaagggcatcaagaacgtgctgagctgcc
ctcccaagaacagcgccggcagaaacggcgactggatcagcgtggccgtgaaagagagcagcaccaccaacaagggcgtgctggtgccccccagacggaccaagctgtgcctgcg
gaacatcaacaaagtgtggcaccggatcaaggacgagaagaacttcaaagaggaattcgtcaaggtcgcactgggcgagagcaacgccctgatgaagcactacaaagagaagaac
ctgaacgccctgaccgccattaagtacggcttcagcgacatgggcgacatcatcaagggcaccgacctgatcgattaccagatcaccaagaacatcaaccgggccctggacaaga
tcctgagaaacgaggccagcaacgacaagatcaagaaacgggtggactggtgggaggccaacaaggccgccttctgggacgccttcatgtgcggctacaaggtgcacatcggcaa
caagccctgccccgagcacgacaacatggaccggatcccccagtacctgcggtggtttcgcgagtggggcacctacgtgtgcagcgagtacaagaacaagttcgaggacgtgatc
aagctgtgcaacatccagcagttcaccaaccaggacgacagccagctgctggaaatcagcaagaaagacaagtgcaaagaggccctgaaacactacgaggaatgggtcaaccggc
ggaggcccgagtggaagggccagtgcgataagttcgagaaagagaagtctaagtacgaggacaccaagagcatcaccgccgagaagtacctgaaagaaatctgcagcgagtgcga
ctgcaagtacaaggacctggacaacaccttcaaagaattcaaggacCCATGGGGATCCCTCGAGAGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTG
GGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCA
AGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGA
CTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACC
CTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGA
ACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGT
GATGCACGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCA
CAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTT
TATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAAT
CAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATAT
AGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGC
AATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGAC
AGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGAT
CTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGC
ACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGA
CCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTG
AGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttccca
ggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATG
GTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGC
CCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAAT
GGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAA
GTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGT
GGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCA
GCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTT
TCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGT
GCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTC
GTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGG
CAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGC
TCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAA
AAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGG
CCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAG
GCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA 
MYRMQLLSCIALSLALVTEFDIKCPDENFCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKL
CLRNINKVWHRIKDEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNINR
ALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQYLRWFREWGTYVCSEYKN
KFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVNRRRPEWKGQCDKFEKEKSKYEDTKSITAEKYL 
KEICSECDCKYKDLDNTFKEFKDPWGSLERSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*VLA 
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pFMCS-hIgG1-Fc2-38DBL-FL 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCaagtgccccaccgaggaaatctgcaaggacttcagcaacctgccccagtgccggaaga
acgtgcacgagcggaacaactggctgggcagcagcgtgaagaacttcgccagcgacaacaagggcgtgctggtgccccccagacggcagagcctgtgcctgagaatcaccctgca
ggacttccggaccaagaagaagaaagagggcgacttcgagaagttcatctacagctacgccagcagcgaggcccggaagctgcggaccatccacaacaacaacctggaaaaggcc
caccaggccatccggtacagcttcgccgacatcggcaacatcatccggggcgacgacatgatggacacccccaccagcaaagagacaatcacctatctggaaaaggtgctgaaga
tctacaatgagaacaacgacaagcccaaggacgccaagaagtggtggaccgagaaccggcaccacgtgtgggaggccatgatgtgcggctaccagagcgcccagaaagacaacca
gtgcaccggctacggcaacatcgacgatatcccccagttcctgcggtggttccgcgagtggggcacctacgtgtgcgaagagtccgagaagaacatgaataccctgaaggccgtg
tgcttccccaagcagcccagaaccgaggccaaccctgccctgaccgtgcacgagaacgagatgtgcagcagcaccctgaagaaatacgaggaatggtacaacaagcgcaagaccg
agtggaccgagcagagcatcaagtataacaacgataagatcaactacgccgacatcaagaccctgagccccagcgagtacctgatcgagaagtgccccgagtgcaagtgcaccaa
gaaaaacctgcaggacgtgttcgagctgaccttcgacCCATGGGGATCCCTCGAGAGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCG
TCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACT
GGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAA
TGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCA
TCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACA
AGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGA
GGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAA
TGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCA
GGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCT
ACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTT
TCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAAT
AAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAA
GCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCAT
GGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGG
TCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGG
CGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATT
ATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcatagac
agtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGG
CCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCC
CAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAG
ACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAG
TCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTT
ACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGG
GCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGC
TCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCC
TGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCC
AAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA
CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAA
GCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCT
CAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAA
AATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCC
AGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA 
MYRMQLLSCIALSLALVTEFKCPTEEICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRI
TLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETITYLE
KVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNM
NTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEK 
CPECKCTKKNLQDVFELTFDPWGSLERSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK*VLA 
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GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCGATATCCCATGGGACAAAACTCACACAGCCCCACCGGCCCCATCTAGAGACAAAACTC
ACACAGCCCCACCGGCCCCAGTCGACGACAAAACTCACACAGCCCCACCGGCCCCAAGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACC
GTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAAC
TGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGA
ATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCC
ATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACG
AGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGA
ATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTC
AGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTC
TACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATT
TTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAA
TAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAA
AGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCA
TGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTG
GTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCG
GCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTAT
TATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcataga
cagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCG
GCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCC
CCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGA
GACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAA
GTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTT
TACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCG
GGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGG
CTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTC
CTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTC
CAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCC
ACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGA
AGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATC
TCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATA
AAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCC
CAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA 
MYRMQLLSCIALSLALVTEFDIPWDKTHTAPPAPSRDKTHTAPPAPVDDKTHTAPPAPRSDKTHTCPPCPAPELL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG
QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*VLA 
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GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCGATATCttctgcaagggcatcaagaacgtgctgagctgccctcccaagaacagcgccg
gcagaaacggcgactggatcagcgtggccgtgaaagagagcagcaccaccaacaagggcgtgctggtgccccccagacggaccaagctgtgcctgcggaacatcaacaaagtgtg
gcaccggatcaaggacgagaagaacttcaaagaggaattcgtcaaggtcgcactgggcgagagcaacgccctgatgaagcactacaaagagaagaacctgaacgccctgaccgcc
attaagtacggcttcagcgacatgggcgacatcatcaagggcaccgacctgatcgattaccagatcaccaagaacatcaaccgggccctggacaagatcctgagaaacgaggcca
gcaacgacaagatcaagaaacgggtggactggtgggaggccaacaaggccgccttctgggacgccttcatgtgcggctacaaggtgcacatcggcaacaagccctgccccgagca
cgacaacatggaccggatcccccagtacctgcggtggtttcgcgagtggggcacctacgtgtgcagcgagtacaagaacaagttcgaggacgtgatcaagctgtgcaacatccag
cagttcaccaaccaggacgacagccagctgctggaaatcagcaagaaagacaagtgcaaagaggccctgaaacactacgaggaatgggtcaaccggcggaggcccgagtggaagg
gccagtgcgataagttcgagaaagagaagtctaagtacgaggacaccaagagcatcaccgccgagaagtacctgaaagaaatctgcagcgagtgcgactgcaagtacaaggacct
ggacaacCCATGGGACAAAACTCACACAGCCCCACCGGCCCCATCTAGAGACAAAACTCACACAGCCCCACCGGCCCCAGTCGACGACAAAACTCACACAGCCCCACCGGCCCCA
AGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCC
CTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAG
AAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCT
TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCT
CACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA
GTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGT
AACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGT
GGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCA
ATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCC
CACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCC
AGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTT
GCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCG
TACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGT
CGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGC
TCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggt
tcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACC
CGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAG
GCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCT
TGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAA
AACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGA
CGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTAT
GGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAA
AAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAA
CCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGC
GTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCG
GTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAA
GTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACC
GCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACT
CACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTA
ACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA 
MYRMQLLSCIALSLALVTEFDIFCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNIN
KVWHRIKDEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNINRALDKIL
RNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQYLRWFREWGTYVCSEYKNKFEDVI
KLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVNRRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSE 
CDCKYKDLDNPWDKTHTAPPAPSRDKTHTAPPAPVDDKTHTAPPAPRSDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK
VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*VLA 
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A.17 pFMCS-4HF-hIgG1-Fc2-3.8DBL-short
04/05/2016, 22:37
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pFMCS-4HF-hIgG1-Fc2-3.8DBL-short
5148 bp
SgflI 11 PvuII 242
HindIII 246
EcoRI 627
Xba 1530SalI 1566
BglII 1603
BspHI 1699
SmaI 2010
XmnI 2172
NheI 2295
AseI 2532
XmnI 2533SwaI 2789
SmaI 3230
AseI 3416
PstI 3435
HindIII 3543
BspEI 3670
SpeI 3807
PstI 4243
SdaI 4244
PacI 4230
BspLU11I 4236
PacI 4970SwaI 4978
NotI 4986
NcoI
hEF1-HTLV-prom
IL2ss
3.8-DBL-FL
4HF
hIgG1-Fc2
SV40ßGlo
Zeo
EM2KC
hFerL
CMV-enh
Ori
258
APPENDICES
pFMCS-4HF-hIgG1-Fc2-38DBL-short 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCatctgcaaggacttcagcaacctgccccagtgccggaagaacgtgcacgagcggaaca
actggctgggcagcagcgtgaagaacttcgccagcgacaacaagggcgtgctggtgccccccagacggcagagcctgtgcctgagaatcaccctgcaggacttccggaccaagaa
gaagaaagagggcgacttcgagaagttcatctacagctacgccagcagcgaggcccggaagctgcggaccatccacaacaacaacctggaaaaggcccaccaggccatccggtac
agcttcgccgacatcggcaacatcatccggggcgacgacatgatggacacccccaccagcaaagagacaatcacctatctggaaaaggtgctgaagatctacaatgagaacaacg
acaagcccaaggacgccaagaagtggtggaccgagaaccggcaccacgtgtgggaggccatgatgtgcggctaccagagcgcccagaaagacaaccagtgcaccggctacggcaa
catcgacgatatcccccagttcctgcggtggttccgcgagtggggcacctacgtgtgcgaagagtccgagaagaacatgaataccctgaaggccgtgtgcttccccaagcagccc
agaaccgaggccaaccctgccctgaccgtgcacgagaacgagatgtgcagcagcaccctgaagaaatacgaggaatggtacaacaagcgcaagaccgagtggaccgagcagagca
tcaagtataacaacgataagatcaactacgccgacatcaagaccctgagccccagcgagtacctgatcgagaagtgccccgagtgcaagtgcaccaagaaaaacctgcaggacCC
ATGGGACAAAACTCACACAGCCCCACCGGCCCCATCTAGAGACAAAACTCACACAGCCCCACCGGCCCCAGTCGACGACAAAACTCACACAGCCCCACCGGCCCCAAGATCTGAC
AAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCA
CATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAG
CACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATC
TCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCA
GCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGA
CAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCTAGCT
GGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTAT
AAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAA
TTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATT
AGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCC
TTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTA
GTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGG
GTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCG
TCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCA
CGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgt
caggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgc
cacttttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACC
GCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCG
AAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGT
TGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATC
ATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAG
GGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATA
CGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAG 
CAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAG
GACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCT
TTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTAT
CGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGC
CTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAG
CGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAA
GGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGC
TCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA 
MYRMQLLSCIALSLALVTEFICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRITLQDFRTK
KKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENN
DKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP
RTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEKCPECKCTKKNLQDP
WDKTHTAPPAPSRDKTHTAPPAPVDDKTHTAPPAPRSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*VLA 
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A.18 pFMCS-4HF-hIgG1-Fc2-3.4DBL-FL
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pFMCS-4HF-hIgG1-Fc2-3.4DBL-FL
5196 bp
SgflI 11 PvuII 242
HindIII 246
EcoRI 627
EcoRV 633
EcoRI 858
XbaI 1578SalI 1614
BglII 1650
BspHI 1747
SmaI 2058
XmnI 2220
NheI 2343
AseI 2584
XmnI 2584
SwaI 2840
SmaI 3281
AseI 3467
PstI 3486
HindIII 3593
BspEI 3721
SpeI 3858
PstI 4274
SdaI 4275
PacI 4281
BspLU11I 4287
PacI 5021SwaI 5029
NotI 5037
EcoRI;NcoI
hEF1-HTLV-prom
IL2ss
3.4-DBL-FL
4HF
hIgG1-Fc2
SV40ßGlo
Zeo
EM2KC
hFerL
CMV-enh
Ori
260
APPENDICES
pFMCS-4HF-hIgG1-Fc2-34DBL-FL 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCGATATCaagtgccccgacgagaacttctgcaagggcatcaagaacgtgctgagctgcc
ctcccaagaacagcgccggcagaaacggcgactggatcagcgtggccgtgaaagagagcagcaccaccaacaagggcgtgctggtgccccccagacggaccaagctgtgcctgcg
gaacatcaacaaagtgtggcaccggatcaaggacgagaagaacttcaaagaggaattcgtcaaggtcgcactgggcgagagcaacgccctgatgaagcactacaaagagaagaac
ctgaacgccctgaccgccattaagtacggcttcagcgacatgggcgacatcatcaagggcaccgacctgatcgattaccagatcaccaagaacatcaaccgggccctggacaaga
tcctgagaaacgaggccagcaacgacaagatcaagaaacgggtggactggtgggaggccaacaaggccgccttctgggacgccttcatgtgcggctacaaggtgcacatcggcaa
caagccctgccccgagcacgacaacatggaccggatcccccagtacctgcggtggtttcgcgagtggggcacctacgtgtgcagcgagtacaagaacaagttcgaggacgtgatc
aagctgtgcaacatccagcagttcaccaaccaggacgacagccagctgctggaaatcagcaagaaagacaagtgcaaagaggccctgaaacactacgaggaatgggtcaaccggc
ggaggcccgagtggaagggccagtgcgataagttcgagaaagagaagtctaagtacgaggacaccaagagcatcaccgccgagaagtacctgaaagaaatctgcagcgagtgcga
ctgcaagtacaaggacctggacaacaccttcaaagaattcaaggacCCATGGGACAAAACTCACACAGCCCCACCGGCCCCATCTAGAGACAAAACTCACACAGCCCCACCGGCC
CCAGTCGACGACAAAACTCACACAGCCCCACCGGCCCCAAGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCC
CCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG
TGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGA
CCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGT
GCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCAC
TACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATG
CTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTG
TGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCT
GAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACT
AGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAG
GCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTA
TCCTCAGTCCTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCG
TCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGA
TGAACAGGGTCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGT
GAGCACCGGAACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATA
CTATGCCAATGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCA
AACTCACAGGAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGC
GCTCGGGGAGGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGT
CACGCGCCTGTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGT
GAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGT
ACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCAC
CCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGT
TATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGA
GCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCG
CTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGC
ACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAG
CAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGA
AAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGA
TCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCA
TTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTG
CCAGAACATTTCTCTATCGAA 
MYRMQLLSCIALSLALVTEFDIKCPDENFCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCL
RNINKVWHRIKDEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNINRALDK
ILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQYLRWFREWGTYVCSEYKNKFEDVI
KLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVNRRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECD
CKYKDLDNTFKEFKDPWDKTHTAPPAPSRDKTHTAPPAPVDDKTHTAPPAPRSDKTHTCPPCPAPELLGGPSVFLFP
PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*VLA 
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A.19 pFMCS-4HF-hIgG1-Fc2-3.8DBL-FL
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pFMCS-4HF-hIgG1-Fc2-3.8DBL-FL
5187 bp
SgflI 11 PvuII 242
HindIII 246
EcoRI 627
Xba 1569SalI 1605
BglII 1641
BspHI 1738
SmaI 2049
XmnI 2211
NheI 2334
AseI 2574
XmnI 2575
SwaI 2831
SmaI 3272
AseI 3458
PstI 3477
HindIII 3584
BspEI 3712
SpeI 3849
PstI 4265
SdaI 4266
PacI 4272
BspLU11I 4277
PacI 5012SwaI 5020
NotI 5028
NcoI
hEF1-HTLV-prom
IL2ss
3.8-DBL-FL
4HF
hIgG1-Fc2
SV40ßGlo
Zeo
EM2KC
hFerL
CMV-enh
Ori
262
APPENDICES
pFMCS-4HF-hIgG1-Fc2-38DBL-FL 
 
GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG
GGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC
GCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTG
GTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG
CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCAccggcGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACTGAATTCaagtgccccaccgaggaaatctgcaaggacttcagcaacctgccccagtgccggaaga
acgtgcacgagcggaacaactggctgggcagcagcgtgaagaacttcgccagcgacaacaagggcgtgctggtgccccccagacggcagagcctgtgcctgagaatcaccctgca
ggacttccggaccaagaagaagaaagagggcgacttcgagaagttcatctacagctacgccagcagcgaggcccggaagctgcggaccatccacaacaacaacctggaaaaggcc
caccaggccatccggtacagcttcgccgacatcggcaacatcatccggggcgacgacatgatggacacccccaccagcaaagagacaatcacctatctggaaaaggtgctgaaga
tctacaatgagaacaacgacaagcccaaggacgccaagaagtggtggaccgagaaccggcaccacgtgtgggaggccatgatgtgcggctaccagagcgcccagaaagacaacca
gtgcaccggctacggcaacatcgacgatatcccccagttcctgcggtggttccgcgagtggggcacctacgtgtgcgaagagtccgagaagaacatgaataccctgaaggccgtg
tgcttccccaagcagcccagaaccgaggccaaccctgccctgaccgtgcacgagaacgagatgtgcagcagcaccctgaagaaatacgaggaatggtacaacaagcgcaagaccg
agtggaccgagcagagcatcaagtataacaacgataagatcaactacgccgacatcaagaccctgagccccagcgagtacctgatcgagaagtgccccgagtgcaagtgcaccaa
gaaaaacctgcaggacgtgttcgagctgaccttcgacCCATGGGACAAAACTCACACAGCCCCACCGGCCCCATCTAGAGACAAAACTCACACAGCCCCACCGGCCCCAGTCGAC
GACAAAACTCACACAGCCCCACCGGCCCCAAGATCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAAC
CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCA
TAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTC
TCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACC
AGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTC
CGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCACGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTG
TGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTT
TTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATTCTAAAATACAGCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGA
ATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCA
TTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCC
AGATGCTCAAGGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTC
CTGCTCCTCTGCCACAAAGTGCACGCAGTTGCCGGCCGGGTCGCGCAGGGCGAACTCCCGCCCCCACGGCTGCTCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAG
TTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTTGTCCGGCACCACCTGGTCCTGGACCGCGCTGATGAACAGGG
TCACGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGGAGAACCCGAGCCGGTCGGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGCGGTGAGCACCGG
AACGGCACTGGTCAACTTGGCCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAA
TGATTAATTGTCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccaccctttcccaggcatagacagtcagtgacttacCAAACTCACAG
GAGGGAGAAGGCAGAAGCTTGAGACAGACCCGCGGGACCGCCGAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTTATGGTGCGCCGGCCCTCGGAGGCAGGGCGCTCGGGGA
GGCCTAGCGGCCAATCTGCGGTGGCAGGAGGCGGGGCCGAAGGCCGTGCCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCCGCCCCAAAGCAAGGGGAAGTCACGCGCCT
GTAGCGCCAGCGTGTTGTGAAATGGGGGCTTGGGGGGGTTGGGGCCCTGACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAAC
CGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCAT
AATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACG
TCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACG
CCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAA
AAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGA
TACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCC
CCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAG
GTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTT
GGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTA
CGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTG
TGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACAT
TTCTCTATCGAA 
	
MYRMQLLSCIALSLALVTEFKCPTEEICKDFSNLPQCRKNVHERNNWLGSSVKNFASDNKGVLVPPRRQSLCLRI
TLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKETITYLE
KVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNM
NTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYLIEK 
CPECKCTKKNLQDVFELTFDPWDKTHTAPPAPSRDKTHTAPPAPVDDKTHTAPPAPRSDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*VLA 
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B IgM-binding of the IgG-Fc was not detected by sandwich ELISA
Figure .1: IgG Fc IgM-binding control ELISA. IgG Fc does not bind IgM. IgM was
captured by αhIgM (Sigma I2386) which was coated on the plate, IgG-Fc was then added
and allowed to bind, and the IgG Fc was detected with αIgG-Fc-AP (Sigma A9544).
Nothing was detected, therefore the IgG Fc does not bind IgM. This shows that any
binding detected in the DBL-Fc fusion proteins is due to the DBL itself and not the
IgG-Fc tag.
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C Summary of all MSPDBL1 and MSPDBL2 mutant DBL domains
Table .1: 3.8 DBL mutants created. Mutants selected for protein expression are
highlighted in red.
DBL mutant Mutation Change in charge Position
3.8 #4
S210G h1
S395C h6
3.8 #12
L203V loop (h1a-h1)
R423L Y h5
T396A h7
N424K Y h7
3.8 #13
K294R loop h4
G324S h5
N366S h6
3.8 #17
V202M loop (h1a-h1)
P205S loop (h1a-h1)
L211P loop (h1-h2a)
K255R h3
T335S loop (h5-h6)
3.8 #23
K200N Y loop (h1a-h1)
D229G Y h2
Y235H Y h2
3.8 #24
K232E Y h3
M277L loop (h3-h4)
K440E Y loop (+h7)
3.8 #27
K225E Y loop (h2-h3)
E401K Y h7
3.8 #31
A242T h3
K363M Y h6
3.8 #33
K255R Y h4
W310R Y h5
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M321V h5
3.8 #34
G228D Y loop (h2a-h2)
K330E Y loop (h5-h6)
3.8 #37
W309R Y h5
M321L h5
D421V Y h7
3.8 #38
N300K Y loop (h4-h5)
K304E Y loop (h4-h5)
3.8 #39
K200E Y loop (h1a-h1)
W349R Y h6
3.8 #42 E443G Y loop (+h7)
3.8 #44
N185S loop (h1a-h1)
N339D Y loop (h5-h6)
3.8 #46 T430I loop (+h7)
3.8 #47 K283I Y h5
3.8 #50
I270T h3
S432N loop (+h7)
3.8 #51 H388Y Y loop (h6-h7)
3.8 #52 T379I loop (h60h7)
3.8 #53
C177W loop (h1a-h1)
L204V loop (h1a-h1)
3.8 #60
S190G loop (h1a-h1)
R207I Y h1
C334Y loop (h5-h6)
A387V loop (h6-h7)
S394R Y h7
K448E Y loop (+h7)
3.8 #65
H257Q Y h3
T396A h7
3.8 #70
N199Y loop (h1a-h1)
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Q376H Y loop (h6-h7)
3.8 #72
S210G loop (h1a-h1)
I248T h3
H316L h5
3.8 #75
M276I loop (h3-h4)
N313S h5
D341V Y loop (h5-h6)
3.8 #78 S240G h3
3.8 #80
N186K Y loop (h1a-1)
N419S h7
The mutations in each of the thirty 3.8 DBL mutants are shown in Table C and the
eighteen 3.4 DBL mutants are shown in Table .2. Mutants often contained multiple amino
acid substitutions, and the table shows whether a mutation changes the charged amino
acid or introduces a charge. The location of the mutation on the DBL structure is shown
in the final column. Mutants selected for protein expression are highlighted in red.
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Table .2: 3.4 DBL mutants created. Mutants selected for protein expression are
highlighted in red.
DBL mutant Mutation Change in charge Position
3.4 #10
G169S h1
K194N Y h1
N278D Y h4
C427R Y h7
3.4 #22 T360S h6
3.4 #26
K194T Y h1
Q265H h4
E279G Y h4
I285F loop (h4-h5)
N388S h7
3.4 #31
F213S loop (h1-h2a)
R270P Y h4
3.4 # 36
D323V Y loop (h5-h6)
3.4 # 47
I266N h4
3.4 # 48
S281G loop (h4-h5)
A294V h5
W300R Y h5
3.4 #51 R391K h7
3.4 # 56
I243V h3
3.4 # 66
I200V loop (h1-h2a)
H310R Y h5
E318V Y loop (h5-h6)
3.4 #69 D283N Y loop (h4-h5)
3.4 # 74
D170E h1
L228P h2
N321Y loop (h5-h6)
3.4 # 77
A175T loop (h1-h2a)
N269D Y h4
C340S h6
K407M Y h7
3.4 # 87
N201Y h2a
3.4 #89
K266R h4
E318D loop (h5-h6)
3.4 #90
G214R Y h5
K287R loop (h4-h5)
I325T loop (h5-h6)
D439Y/V350E Y h7
3.4 #102 D273Y Y h4
3.4 #104 K430R h7
268
APPENDICES
D Structural analysis of MSPDBL1 and MSPDBL2 mutant DBL
domains
3.4 DBL mutant 66 (E318V)
Mutation shown in dark blue (Fig .2) and docking to (light blue) IgM model shown (Fig
.3).
Figure .2: 3.4 DBL mutant 66. E318V mutation is located in the loop between h5 and h6.
Figure .3: 3.4 DBL mutant 66 E318V mutation (blue) in relation to IgM docking.
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3.4 DBL mutant 74 (N321Y)
Mutation shown in blue (Fig .4) and docking to IgM model shown (Fig .5).
Figure .4: 3.4 DBL mutant 74. N321Y mutation is located in the loop between h5 and h6.
Figure .5: 3.4 DBL mutant 74 321Y mutation in relation to IgM docking.
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3.8 DBL mutant 17 (T335S)
Mutation shown in blue (Fig .6) and docking to IgM model shown (Fig .7).
Figure .6: 3.8 DBL mutant 17. T335S mutation is located in the loop between h5 and h6.
Figure .7: 3.8 DBL mutant 17 T335S mutation in relation to IgM docking.
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3.8 DBL mutant 34 (K330E)
Mutation shown in blue (Fig .8) and docking to IgM model shown (Fig .9).
Figure .8: 3.8 DBL mutant 34. K330E mutation is located in the loop between h5 and h6.
Figure .9: 3.8 DBL mutant 34 K330E mutation in relation to IgM docking.
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3.8 DBL mutant 44 (N339D)
Mutation shown in blue (Fig .10) and docking to IgM model shown (Fig .11).
Figure .10: 3.8 DBL mutant 44. N339D mutation is located in the loop between h5 and
h6.
Figure .11: 3.8 DBL mutant 44 N339D mutation in relation to IgM docking.
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E Sequence analysis of MSPDBL1 and MSPDBL2 mutant DBL domains
MSPDBL1         FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
Mutant56        FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
Mutant47        FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
Mutant36        FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
Mutant74        FCKGIKNVLSCPPKNSAGRNGEWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
Mutant31        FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
Mutant48        FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
Mutant77        FCKGIKNVLSCPPKNSAGRNGDWISVTVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
Mutant22        ----------------AGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 44 
Mutant69        FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
Mutant26        FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTTLCLRNINKVWHRIK 60 
Mutant10        FCKGIKNVLSCPPKNSAGRNSDWISVAVKESSTTNKGVLVPPRRTNLCLRNINKVWHRIK 60 
Mutant66        FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNVNKVWHRIK 60 
Mutant51        FCKGIKNVLSCPPKNSAGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVWHRIK 60 
                                ****.:****:******************.*****:******** 
 
MSPDBL1         DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant56        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAVKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant47        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQNTKNI 120 
Mutant36        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant74        DEKNFKEEFVKVALGESNAPMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant31        DEKNSKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant48        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant77        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant22        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 104 
Mutant69        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant26        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYHITKNI 120 
Mutant10        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant66        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
Mutant51        DEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 120 
                **** ************** **************:*******************: **** 
 
MSPDBL1   NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant56        NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant47        NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant36        NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMVRIPQY 180 
Mutant74        NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant31        NPALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant48        NRALDKILRNEAGNDKIKKRVDWWEVNKAAFRDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant77        DRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant22        NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 164 
Mutant69        NRALDKILRNEASNNKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant26        NRALDKILRNGASNDKFKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant10        NRALDKILRDEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
Mutant66        NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVRIGNKPCPVHDNMDRIPQY 180 
Mutant51        NRALDKILRNEASNDKIKKRVDWWEANKAAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQY 180 
                : *******: *.*:*:********.***** *********:******* **** ***** 
 
MSPDBL1   LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant56        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant47        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant36        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant74        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant31        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant48        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant77        LRWFREWGTYVSSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant22        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFSNQDDSQLLEISKKDKCKEALKHYEEWVN 224 
Mutant69        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant26        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVS 240 
Mutant10        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant66        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
Mutant51        LRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVN 240 
                ***********.*******************:***************************. 
 
MSPDBL1   RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDN------------ 288 
Mutant56        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
Mutant47        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
Mutant36        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
Mutant74        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
Mutant31        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
Mutant48        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
Mutant77        RRRPEWKGQCDKFEKEKSMYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
Mutant22        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDN------------ 272 
Mutant69        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
Mutant26        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPC- 299 
Mutant10        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSERDCKYKDLDNRSDKTHTCPPCP 300 
Mutant66        RRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
Mutant51        RRKPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNRSDKTHTCPPCP 300 
                **:*************** ******************* *********             
Figure .12: MSPDBL1 mutant DBL sequence alignment.
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Mutant17       -XXXXXXATMYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
Mutant12       -XXXXXXXPMYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
Mutant37       --XXXXXGPHVRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
Mutant23       --XXXXXXXMYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
Mutant70       -XXXXXXXXXXXMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
Mutant65       -XXXXXXXTMYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
Mutant48       -XXXXXRATMYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
Mutant38       --XXXXXXXXYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
Mutant34       XXXXXXXXXMYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
Mutant4        --XXXERATMYRMQLLSCIALSLALVTNSICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
MSPDBL2        -----------------------------ICKDFSNLPQCRKNVHERNNWLGSSVKNFAS 
 
 
Mutant17       DNKGMLVSPRRQSPCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLERAH 
Mutant12       DNKGVVVPPRRQSLCLRITLQDFRTKKKKEGDFEKFIYSYASSEALKLRTIHNNNLEKAH 
Mutant37       DNKGVLVPPRRQSLCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAH 
Mutant23       DNNGVLVPPRRQSLCLRITLQDFRTKKKKEGGFEKFIHSYASSEARKLRTIHNNNLEKAH 
Mutant70       DYKGVLVPPRRQSLCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAH 
Mutant65       DNKGVLVPPRRQSLCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAQ 
Mutant48       DNKGVLVPPRRQSLCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTNHNNNLEKAH 
Mutant38       DNKGVLVPPRRQSLCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAH 
Mutant34       DNKGVLVPPRRQSLCLRITLQDFRTKKKKEDDFEKFIYSYASSEARKLRTIHNNNLEKAH 
Mutant4        DNKGVLVPPRRQGLCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAH 
MSPDBL2  DNKGVLVPPRRQSLCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAH 
 
 
Mutant17       QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHV 
Mutant12       QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHV 
Mutant37       QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKRWTENRHHV 
Mutant23       QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHV 
Mutant70       QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHV 
Mutant65       QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHV 
Mutant48       QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHV 
Mutant38       QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENKDKPEDAKKWWTENRHHV 
Mutant34       QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHV 
Mutant4        QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHV 
MSPDBL2  QAIRYSFADIGNIIRGDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHV 
 
 
Mutant17       WEAMMCGYQSAQKDNQCSGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
Mutant12       WEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
Mutant37       WEAMLCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
Mutant23       WEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
Mutant70       WEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKHP 
Mutant65       WEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
Mutant48       WEALMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
Mutant38       WEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
Mutant34       WEAMMCGYQSAQEDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
Mutant4        WEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
MSPDBL2        WEAMMCGYQSAQKDNQCTGYGNIDDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQP 
 
 
Mutant17       RTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYL 
Mutant12       RTEANPALTVHENEMCSSALKKYEEWYNKRKTEWTEQSIKYNNDKIKYADIKTLSPSEYL 
Mutant37       RTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNVKINYADIKTLSPSEYL 
Mutant23       RTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYL 
Mutant70       RTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYL 
Mutant65       RTEANPALTVHENEMCSSALKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYL 
Mutant48       RTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYL 
Mutant38       RTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYL 
Mutant34       RTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYL 
Mutant4        RTEANPALTVHENEMCSCTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYL 
MSPDBL2  RTEANPALTVHENEMCSSTLKKYEEWYNKRKTEWTEQSIKYNNDKINYADIKTLSPSEYL 
 
 
Mutant17       IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVFLSPQN-PRHPXDLXXPE- 
Mutant12       IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVFPLPPKTQGHPHDLPDP*G 
Mutant37       IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVFLSPQN-PRTPS*SPGPLR 
Mutant23       IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVFLSPQN-PRTPS*SPGP*G 
Mutant70       IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVSS-PPK-PKTPS*SPGPLR 
Mutant65       IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVFLFPPN-PRTPS*SPGPLR 
Mutant48       IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVFLFPPK-PKDTLMISRTPE 
Mutant38       IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVFLFPPK-PKDTLMISRTPE 
Mutant34       IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVSSPPKT-QGHPHDLPDP*G 
Mutant4        IEKCPECKCTKKNLQDAMVRSDKTHTCPPCPAPELLGGPSVFLSPQN-PRHPHDLPDP*G 
MSPDBL2  IEKCPECKCTKKNLQD-------------------------------------------- 
Figure .13: MSPDBL2 mutant DBL sequence alignment.
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F Stability analysis of MSPDBL1 and MSPDBL2 mutant DBL domains
The effect of each mutation on protein stability was analysed using the SDM server. The
free energy difference between the wild-type and mutant protein gave a stability score
for each mutation. This predicts whether the mutation will have an impact on protein
structure (Worth et al., 2011). It was predicted that 3.4 DBL mutants 48 and 77 and 3.8
DBL mutant 34 consist entirely destabilising mutations. It was predicted that 3.4 mutant
66 contains two neutral mutations, however mutation H310R is predicted to have a highly
destabilising effect. It should also be noted that the mutation I243V in 3.4 mutant 56 has
been predicted to have a slightly destabilising effect.
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Table .3: Summary of 3.4 DBL mutants expressed. Mutants expressed and their
corresponding amino acid mutations. Each mutation was analysed for its stabilising effect
using the SDM server and given a stability score based on the free energy difference
between the wild-type and mutant. A positive stability score was classed as stabilising
and a negative destabilising. Scores between -0.5 and 0.5 was classed as having a neutral
effect. Scores between 0.5 and 1 (-0.5 and -1) were classed as slightly stabilising (slightly
destabilising). Scores between 1 and 2 (-1 and -2) were classed as stabilising (destabilising).
Scores above 2 (below -2) were classed as highly stabilising (highly destabilising).
DBL
mutant
Mutation Change in
charge
Position Stability
score
Stabilising
Effect
3.4 #10
G169S h1 2.11 + + +
K194N Y h1 -0.67 −
N278D Y h4 0.89 +
C427R Y h9 -0.30 0
3.4 #26
K194T Y h1 1.88 ++
Q265H Y h4 -0.91 −
E279G Y h4 -3.59 −−−
I285F loop (h4-h5) 0.72 +
N388S h7 -0.02 0
3.4 # 36 D323V Y loop (h5-h6) 3.72 + + +
3.4 # 47 I266N h4 -2.76 −−−
3.4 # 48
S281G loop (h4-h5) -2.53 −−−
A294V h5 -1.57 −−
W300R Y h5 -3.31 −−−
3.4 # 56 I243V h3 -0.98 −
3.4 # 66
I200V loop (h1-h2a) -0.44 0
H310R h5 -2.02 −−−
E318V Y loop (h5-h6) 0.13 0
3.4 # 74
D170E h1 0.01 0
L228P h2 -4.85 −−−
N321Y loop (h5-h6) -0.4 0
3.4 # 77
A175T loop (h1-h2a) -2.05 −−−
N269D Y h4 -1.17 −−
C340S h6 -5.18 −−−
K407M Y h7 0.52 −
3.4 # 87 N201Y h4 0.96 +
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Table .4: Summary of 3.8 DBL mutants expressed. Mutants expressed and their
corresponding amino acid mutations. Each mutation was analysed for its stabilising effect
using the SDM server and given a stability score based on the free energy difference
between the wild-type and mutant. A positive stability score was classed as stabilising
and a negative destabilising. Scores between -0.5 and 0.5 was classed as having a neutral
effect. Scores between 0.5 and 1 (-0.5 and -1) were classed as slightly stabilising (slightly
destabilising). Scores between 1 and 2 (-1 and -2) were classed as stabilising (destabilising).
Scores above 2 (below -2) were classed as highly stabilising (highly destabilising).
DBL
mutant
Mutation Change in
charge
Position Stability
score
Stabilising
Effect
3.8 #4
S210G h1 -1.31 −−
S395G h6 3.51 + + +
3.8 #12
L203V loop (h1a-h1) 0.19 0
R243L Y h5 0.26 0
T396A h7 2.29 + + +
N424K Y h7 1.57 ++
3.8 #17
V202M loop (h1a-h1) -0.51 −
P205S loop (h1a-h1) -1.12 −−
L211P loop (h1-h2a) -1.95 −−
K255R h3 0.83 +
T335S loop (h5-h6) -0.32 0
3.8 #23
K200N Y loop (h1a-h1) 0.26 0
D229G Y h2 -1.15 −−
Y235H Y h2 -0.09 0
3.8 #34
G228D Y loop (h2a-h2) -2.53 −−−
K330E Y loop (h5-h6) -0.72 −
3.8 #37
W309R Y h5 -3.62 −−−
M321L h5 -0.01 0
D421V Y h7 2.93 + + +
3.8 #38
N300K Y loop (h4-h5) -1.11 −−
K304E Y loop (h4-h5) 0.94 +
3.8 #44
N184S loop (h1a-h1) -0.67 −
N339D Y loop (h5-h6) 0.6 +
3.8 #65
H257Q Y h3 -1.5 −−
T396A h7 2.29 + + +
3.8 #70
N199Y loop (h1a-h1) 1.35 ++
Q376H Y loop (h6-h7) 0.79 +
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G Protein-protein interaction prediction (PPIP)
Protein-protein interface prediction was undertaken using meta-PPISP tool.
 
Prediction by meta-PPISP : metamethod for Protein-Protein Interaction Site 
Prediction 
Column 1: AA (Amino Acid code) 
Column 2: Ch (Chain ID) 
Column 3: AA# (Amino Acid number) 
Column 4-7: Prediction scores of cons-PPISP, PINUP, Promate, and meta-PPISP 
           Note: PINUP and Promate scores are scaled by 100 
Column 8: Prediction of whether the residue is in an interface 
  (P = Positive; N = Negative; - = Burried and not predicted) 
         (Note: P corresponds to a score > 0.34 in 7th column; user may set a 
          different threshold for positive prediction.) 
************************************************************************* 
R      50    0.003   0.830   0.393   0.463       P 
N      51    0.000   0.990   0.396   0.000       - 
I      52    0.050   0.990   0.404   0.509       P 
N      53    0.005   0.990   0.435   0.568       P 
K      54    0.031   0.990   0.400   0.554       P 
V      55    0.008   0.660   0.407   0.432       P 
W      56    0.006   0.990   0.472   0.586       P 
H      57    0.002   0.830   0.386   0.397       P 
R      58    0.002   0.990   0.363   0.423       P 
I      59    0.002   0.490   0.369   0.382       P 
K      60    0.002   0.490   0.407   0.369       P 
 
 
 
Y     114    0.039   0.660   0.462   0.361       P 
Q     115    0.003   0.660   0.368   0.326       N 
I     116    0.002   0.830   0.428   0.455       P 
T     117    0.000   0.000   0.380   0.000       - 
K     118    0.002   0.330   0.333   0.211       N 
N     119    0.002   0.490   0.295   0.375       P 
I     120    0.000   0.000   0.408   0.000       - 
N     121    0.002   0.830   0.312   0.433       P 
R     122    0.002   0.660   0.300   0.296       N 
A     123    0.002   0.990   0.376   0.517       P 
	
Figure .14: Meta-PPISP protein interface prediction results for MSPDBL1.
Region in h2a and h4 predicted to be protein-protein interface.
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Prediction by meta-PPISP : metamethod for Protein-Protein Interaction Site 
Prediction 
Column 1: AA (Amino Acid code) 
Column 2: Ch (Chain ID) 
Column 3: AA# (Amino Acid number) 
Column 4-7: Prediction scores of cons-PPISP, PINUP, Promate, and meta-PPISP 
           Note: PINUP and Promate scores are scaled by 100 
Column 8: Prediction of whether the residue is in an interface 
  (P = Positive; N = Negative; - = Burried and not predicted) 
         (Note: P corresponds to a score > 0.34 in 7th column; user may set a 
          different threshold for positive prediction.) 
************************************************************************* 
K      13    0.033   0.550   0.321   0.370       P 
N      14    0.007   0.660   0.366   0.352       P 
V      15    0.082   0.880   0.379   0.488       P 
H      16    0.006   0.770   0.350   0.428       P 
E      17    0.006   0.660   0.399   0.501       P 
R      18    0.011   0.880   0.425   0.567       P 
N      19    0.012   0.880   0.375   0.554       P 
N      20    0.808   0.880   0.378   0.491       P 
W      21    0.928   0.990   0.466   0.710      P 
L      22    0.669   0.880   0.435   0.580       P 
G      23    0.049   0.880   0.458   0.519      P 
S      24    0.039   0.550   0.452   0.364       P 
S      25    0.017   0.440   0.410   0.361       P 
 
 
 
 
L      37    0.854   0.550   0.360   0.345       P 
V      38    0.959   0.770   0.415   0.493       P 
P      39    0.000   0.990   0.440   0.000       - 
P      40    0.775   0.660   0.435   0.430       P 
R      41    0.000   0.660   0.421   0.000       - 
R      42    0.000   0.660   0.329   0.000       - 
Q      43    0.865   0.990   0.419   0.592       P 
S      44    0.715   0.660   0.387   0.514       P 
 
 
 
 
 
 
 
 
 
 
3.4 
Figure .15: Meta-PPISP protein interface prediction results for MSPDBL2.
Region in loop h1a-h1 and loop h1-h2a predicted to be protein-protein interface.
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H Homology block analysis
Table .5: Homology blocks commonly found in IgM-binding DBL domains.
Homology block % occurrence in
binders
% occurrence in
non-binders
% occurrence in
VarDom server
97 50 7 4
108 30 7 3
160 30 7 1
222 20 0 0.9
318 20 0 0.6
Table .6: Homology blocks commonly found in non-binding DBL domains.
Homology block % occurrence in
binders
% occurrence in
non-binders
% occurrence in
VarDom server
45 10 53 12
48 20 40 10
260 0 20 0.9
304 0 13 0.5
305 0 13 0.5
311 0 13 0.5
326 0 13 0.5
327 0 13 0.5
353 0 13 0.5
380 0 13 0.5
393 0 13 0.5
403 0 13 0.5
Homology blocks (HBs) contained in ten IgM-binding DBL domains and fifteen
non-binding DBL domains described by Pleass et al. (2015), were analysed. Homology
blocks which frequently occur in either IgM-binding (Table .5) or non-binding DBL
domains (Table .6) were identified. These were compared to how often they occur in
the VarDom server. HBs are numbered according to their frequency in the database, with
lower numbers more common (Rask et al., 2010). Homology blocks 260, 304, 305, 311, 326,
237, 280, 293 and 403 appear only in non-binding DBL domains, and not in IgM-binding
DBL domains. Homology blocks 222 and 318 appear in only IgM-binding DBL domains,
and not in non-binding domains. These are rare homology blocks in the VarDom server,
occurring in less than 1% of the DBLs analysed across seven genomes. When a HB occurs
multiple times, it occurs in DBL domains belonging to the same DBL class (e.g. HB 304
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is found in two DBL4ε domains and HB 403 is found in two DBLζ domains). These would
therefore be expected to have sequence homology.
Using the open source SPMF data-mining library (available at http://
www.philippe-fournier-viger.com/spmf/index.php), four homology block motifs
occurring in multiple IgM-binding DBL domains were identified by the Apriori algorithm
(Fournier-Viger et al., 2014). These were (97 108), (76 160), (76 97) and (76 126).
However, three of these motifs were also observed in non-binding DBL domains. The
motif (76 97) was not observed in a non-binding DBL domain and may therefore be
unique to IgM-binding domains. However, 76 is a common HB at the N terminal of both
IgM-binding and non-binding DBL domains. The C terminal HB 97, while more common
in IgM-binding DBL domains has been observed in the non-binding MAL6P1.4 DBL7ε
domain. Further analysis awaits a larger dataset to identify whether the HB motif (76 97)
is unique to IgM-binding DBL domains.
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I Structural analysis of known IgM-binding and non-binding DBL
domains
Figure .16: Structural conservation of all known IgM-binding vs. non-binding
DBL domains. Known IgM-binding DBL domains (red) superimposed on non-binding
isolates (cream). Homology models of any DBL domains with unknown structure were
produced using the Phyre2 software based on the crystal structure of their most closely
related known DBL structure (Kelley et al., 2015) and superimposed to highlight structural
differences.
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Figure .17: Structural conservation of all known IgM-binding vs. non-binding
DBLε domains. Known IgM-binding DBLε domains (red) superimposed on non-binding
DBLε domains (cream). Homology models of any DBL domains with unknown structure
were produced using the Phyre2 software based on the crystal structure of their most
closely related known DBL structure (Kelley et al., 2015) and superimposed to highlight
structural differences.
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Figure .18: Structural conservation of all known IgM-binding vs. non-binding
DBLζ domains. Known IgM-binding DBLζ domains (red) superimposed on non-binding
DBLζ domains (cream). Homology models of any DBL domains with unknown structure
were produced using the Phyre2 software based on the crystal structure of their most
closely related known DBL structure (Kelley et al., 2015) and superimposed to highlight
structural differences.
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J FPLC profiles
Merozoite DBL mutant Fc-fusion proteins
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Figure .19: 3.4 DBL mutant purification FPLC profiles. Expression conditions were
kept the same for each mutant, and the purification peaks compared to the wild-type 3.4
DBL domain.
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Figure .20: 3.8 DBL mutant purification FPLC profiles. Expression conditions were
kept the same for each mutant, and the purification peaks compared to the wild-type 3.8
DBL domain.
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Extended-hinge DBL-Fc fusion proteins
(a) Original 3.4 DBL-Fc fusion (b) Original 3.8 DBL-Fc fusion
(c) Full-length 3.4 DBL-Fc fusion (d) Full-length 3.8 DBL-Fc fusion
Figure .21: FPLC purification profiles for the original DBL-Fc fusion proteins
vs. the new full-length DBL-Fc fusions with the original IgG1 hinge. Expression
conditions were the same for each recombinant protein produced. Purification peaks of
the full-length DBL-Fc fusion proteins show no improvement on the original short DBL-Fc
fusion proteins.
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(a) Original 3.4 DBL-Fc fusion (b) Original 3.8 DBL-Fc fusion
(c) Original 3.4 DBL with extended hinge (d) Original 3.8 DBL with extended hinge
Figure .22: FPLC purification profiles for the original DBL-Fc fusion proteins
vs. the new extended hinge DBL-Fc fusions with the original short DBL
domains. Expression conditions were the same for each recombinant protein produced.
Purification peaks of the extended hinge DBL-Fc fusion proteins show no improvement
on the original short DBL-Fc fusion proteins.
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(a) Full-length DBL-Fc fusion with IgG1 hinge (b) Full-length 3.8 DBL-Fc fusion with IgG1 hinge
(c) Full-length 3.4 DBL-Fc fusion with extended
hinge
(d) Full-length 3.8 DBL-Fc fusion with extended
hinge
Figure .23: FPLC purification profiles for the full-length DBL-Fc fusion proteins
containing the original IgG1 hinge vs. the new extended hinge. Expression
conditions were the same for each recombinant protein produced. The purification peak for
the extended hinge version of 3.4 FL DBL-Fc is much bigger than for the same full-length
3.4 DBL produced as an Fc fusion with only the original IgG1 hinge. There is no difference
in the purification peaks for the similar FL 3.8 DBL-Fc fusion proteins.
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